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ABSTRACT
Toxoplasma gondii is an obligate intracellular parasite that can cause lifethreatening disease in immunocompromised individuals. Host cell invasion is therefore
central to the pathology of the disease and parasite survival. Unlike many intracellular
pathogens, T. gondii does not enter cells by manipulating the host’s phagocytic
machinery; instead, the parasite enters the cell by a process of active penetration.
Gliding motility and active penetration are driven by a complex of proteins termed the
glideosome. The glideosome consists of four major proteins: TgMyoA, an
unconventional myosin XIV, myosin light chain (TgMLC1) and glideosome-associated
proteins 45 and 50 (TgGAP45, TgGAP50).
TgMyoA has been shown to be essential for parasite motility, but the role of
TgMLC1 in regulating myosin function remains unknown. Our lab has identified an
inhibitor of T. gondii motility and invasion that results in a post-translational
modification (PTM) to TgMLC1. Using molecular genetic and mass spectrometry
methods we have shown cysteine 53 and cysteine 58 of TgMLC1 are essential for the
modification to occur.
To determine if the TgMLC1 PTM alters TgMyoA activity, glideosomes were
isolated from DMSO- and 115556-treated parasites. Using an in vitro motility assay we
have shown that the TgMyoA actin filament displacement velocities are decreased after
115556 treatment. This is the first evidence that TgMLC1 plays a role in regulating
TgMyoA activity. The TgMLC1 PTM is responsible, at least in part, for the invasion
and motility defects seen in the parasite after compound treatment.
During the course of our investigations we have shown that TgMLC1 is
dimethylated on lysine 95. This is an unusual modification for cytosolic proteins and
has not been previously described for MLCs. Experiments using parasites expressing a
non-methylatable form of TgMLC1 (TgMLC1-K95A) show that dimethylation is not
necessary for TgMLC1 peripheral localization, TgMLC1 protein-protein interactions
and is not required for TgMyoA activity in vitro. However, TgMLC1-K95A does not
appear to be phosphoryalted indicating that TgMLC1 dimethylation is necessary for
efficient phosphorylation of TgMLC1.
These experiments will provide new insight into the ways in which TgMLC1
regulates this unconventional myosin motor complex.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

1

1.1. Apicomplexan Parasites
Toxoplasma gondii was first described one hundred years ago in 1908 by
Nicolle and Manceaux (Weiss, 2007). Its name is derived from the Greek word “Toxo”,
meaning bow shaped, and its species name from Ctenodactylus gondii, the rodent from
which it was isolated (Black and Boothroyd, 2000). T. gondii belongs to the phylum
Apicomplexa that contains over 5,000 members including many medically important
parasites such as Plasmodium species, the causative agents of malaria and
Cryptosporidium

species,

the

causative

agents

of

the

diarrheal

disease

cryptosporidiosis. A number of other apicomplexan parasites such as Eimeria and
Neospora cause disease of great agricultural importance. Although apicomplexan
parasites vary greatly in size and host range the phylum is so named because these
parasites have a number of unique structures at their apical end. Many basic biological
processes are conserved throughout the phylum.
T. gondii is an attractive model organism for studying apicomplexan biology
since it is easily maintained in tissue culture, easily transfected and its biology can be
studied both in vitro and in a variety of animal models.

1.2. Toxoplasmosis and the T. gondii life cycle
T. gondii is the causative agent of toxoplasmosis. Infection of individuals with
an intact immune system is usually asymptomatic. However, infection of
immunocompromised individuals results in a potentially fatal encephalitis (Luft et al.,
1993). An acute infection in a pregnant woman can result in fetal hydrocephaly, mental
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retardation, blindness or stillbirth (Tamma, 2007). Chronic infection rates of T. gondii
vary greatly with geographic area, ranging from 15%-80% (Dubey, 1998)
The population structure of T. gondii comprises 3 clonal lineages, types I, II and
III. Type I and III strains were produced from just one or two matings between the
ancestral type II strain. All 3 types have been isolated from humans and a wide variety
of animals (Grigg et al., 2001). Type I strains are acutely virulent in mice with an LD100
of a single tachyzoite. Type I strains can cause ocular toxoplasmosis in
immunocompetent individuals and are most often associated with congenital
toxoplasmosis (Howe et al., 1997). Type II and III strains have a median lethal dose
(LD50) of 102 to 105 tachyzoites in mice although type II strains are responsible for the
majority of toxoplasmosis cases in adults (Howe and Sibley, 1995; Howe et al., 1997).
Crosses between type II and type III strains resulted in a small percentage of progeny
with increased virulence compared with either of the parental strains (Grigg et al.,
2001). Characterization of the factors that are responsible for conferring virulence has
recently begun. Increased virulence was conferred by rhoptry proteins 16 and 18 (Saeij
et al., 2007). Both ROP16 and ROP18 are serine/threonine protein kinases that are
injected into the host cell before or during invasion. ROP16 localizes to the host cell
nucleus and alters the phosphorylation of STAT3. This results in increased secretion of
IL-12p40 from macrophages infected with type II strain parasites compared with type
III strain parasites (Saeij et al., 2007). ROP18 localizes to the parasitophorous vacuole
membrane (PVM) and vesicles in the host cell cytoplasm soon after invasion (El Hajj et
al., 2007; Taylor et al., 2006). Expression of the ROP18 allele from type I strain in type
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III strain parasites increased the growth rate and virulence (Taylor et al., 2006). By
sequence analysis, ROP18 is thought to be an active kinase although its host cell
substrates have not yet been identified.
The T. gondii life cycle contains both sexual and asexual stages (Figure 1).
Felines are the definitive host for T. gondii and although T. gondii can invade a very
wide vary of animals it is not understood why the parasites can only reproduce sexually
within the gut of the cat. The asexual stage begins when an animal ingests either an
oocyst or tissues contaminated with a bradyzoite tissue cyst. As the cyst passes through
the stomach it is ruptured and bradyzoites invade the epithelial cells of the small
intestine (Weiss, 2007). The bradyzoites then convert to the fast-growing tachyzoite
stage and disseminate quickly throughout the body. After oral infection in mice,
parasites are detected in the enterocytes and goblet cells of the small intestine 2 hours
post infection, the lamina propria 8 hours post infection and the mesenteric lymph
nodes and other distal tissues 18-24 hours post infection (Dubey, 1997). Dissemination
of the parasites throughout the body is aided by parasite invasion of immune cells.
Invasion of murine dendritic cells results in increased dendritic cell motility and
increased parasite dissemination to various organs of the mouse (Lambert et al., 2006).
Approximately 7-10 days post-infection, tachyzoites convert back to the slow-growing
bradyzoite form and will persist as cysts, mainly in the muscles and nervous system, for
the life of the host (Weiss, 2007). Tissue cysts do not cause disease if the infected
individual has a competent immune system. Reactivation of cysts can occur in
immunocompromised individuals that can result in reoccurrence of an acute infection.
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Disease pathology is caused by tissue destruction resulting from both the lytic
cycle of T. gondii and inflammation produced by the immune response (Nguyen et al.,
2003). The lytic cycle of T. gondii involves repeated cycles of host cell invasion,
parasite replication within the cell and then active host cell egress (Figure 2). Invasion
of T. gondii occurs quickly, taking approximately 15 seconds from the time of host cell
attachment (Hoff and Carruthers, 2002). Soon after parasite invasion the
parasitophorous vacuole (PV) associates with a number of host organelles including the
nucleus, mitochondria and Golgi (Coppens et al., 2006; Hoff and Carruthers, 2002).
The host cell cytoskeleton is reorganized to surround the PV and the host cell
microtubule-organizing center (MTOC) is moved adjacent to the PV. The host cell’s
endocytic trafficking pathways are diverted to the PV (Coppens et al., 2006)
Soon after invasion, parasites begin to divide by a process termed endodyogeny
where two daughter parasites are formed within the mother parasite (Hu et al., 2002a).
Each replication cycle takes approximately 7-10 hours. Cell division by T. gondii
contrasts with that of other apicomplexan parasites where multiple daughters are
produced within the mother by processes termed schizogony or endopolygeny
(Morrissette and Sibley, 2002). Parasites cultured in vitro egress from host cells after
approximately 6 rounds of parasite division when there are between 64 and 128
parasites per vacuole. Host cell egress is an active process and is not simply due to host
cell lysis. The PVM is permeable to molecules of 1300Da or less so the PV ionic
composition is similar to that of the host cell cytoplasm (Schwab et al., 1994). It seems
the parasites sense a decrease in host cell potassium levels resulting from host cell
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plasma membrane permeabilisation (Moudy et al., 2001). Subsequently calcium levels
are increased in the parasite and the parasites become motile and exit the cell at discrete
sites (Hoff and Carruthers, 2002; Moudy et al., 2001).

1.3. Structural features of T. gondii
1.3.1. The T. gondii pellicle. The pellicle comprises the parasite plasma
membrane (PPM), the inner membrane complex (IMC) and the subpellicular network.
The PPM is decorated with a large number of GPI-anchored surface antigens (SAGs)
that play roles in cell adhesion and immune response. SAG1 alone makes up 3-5% of
total parasite protein (Kasper, 1987). Although antibodies against SAG1 block
invasion, SAG1-deficient parasites are still invasive, suggesting that the SAGs may
have redundant function or attachment to host cells can be mediated by numerous
receptor ligand interactions (Mineo and Kasper, 1994). Due to the abundance of GPIanchored SAG proteins it has been difficult to identify transmembrane proteins of the
PPM (Gilk et al., 2006).
The IMC is a series of flattened vesicles that are sutured together and run along
the length of the parasite underneath the PPM (Figure 3, inset II). There are three
breaks in the IMC, at the extreme apical and basal ends of the parasite (Morrissette and
Sibley, 2002) and at the micropore. The subpellicular network has a mesh-like structure
that extends the length of the parasite and is thought to be important for maintenance of
cell shape and connecting the IMC with the subpellicular microtubules. Single rows of
intramembranous particles in the IMC are interspersed with 22 double particle rows
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that overlay the 22 subpellicular microtubules of the parasite (see section 1.3.2 below).
The subpellicular network displays remarkable mechanical strength, is resistant to
harsh homogenization and extraction conditions and cannot be disrupted with either
cytochalasin D or oryzalin implying that it is not actin- or tublin-based (Mann and
Beckers, 2001). Two components of the subpellicular network, IMC1 and IMC2, have
homology to articulins of ciliate protozoa between amino acids 50 and 450 and
similarity to other cytoskeletal components in their presumptive coiled-coil domains
(Mann and Beckers, 2001). The proteins involved in linking the IMC with the
underlying cytoskeletal structures are unknown.
1.3.2. Tublin-based structures in T. gondii. Apicomplexan parasites contain 3
microtubule organizing centers (MTOCs), namely the apical polar rings located at the
extreme end of the parasite (Russell and Burns, 1984), the centrioles and the spindle
pole plaques that are located near the parasite nucleus.

T. gondii contains 22

subpellicular microtubules that lie beneath the IMC and radiate approximately twothirds the length of the parasite. (Morrissette et al., 1997; Nichols and Chiappino,
1987). Disruption of the subpellicular microtubules affects parasite motility, invasion
and cell polarity (Morrissette and Sibley, 2002). The microtubles are connected to the
apical polar rings at their negative ends and do not appear to be capped at their positive
ends (Russell and Burns, 1984). Some apicomplexan parasites, including T. gondii,
contain an unusual tubulin-based structure called the conoid. The conoid, a truncated
cone of 280nm in length and 380nm in diameter (Hu et al., 2002b), is located
underneath the lower apical polar ring in intracellular parasites. During parasite
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motility, the conoid and the upper apical polar ring extend and retract (Hu et al., 2002b)
(Mondragon and Frixione, 1996). The molecular mechanisms involved in conoid
extension and retraction have not been elucidated. Treatment with ionomycin induces
conoid extension, suggesting calcium signaling plays a role. Treating parasites with
cytochalasin D partially prevents ionomycin-induced extension suggesting myosin
motors may also be involved (Mondragon and Frixione, 1996). Running through the
conoid and apical polar rings are two short intraconoid microtubules. It has been
hypothesized that these microtubules may serve as tracks for microtuble-based motors
to drive extension. The function of the conoid is unknown.
T. gondii contains three α-tubulin and three β-tubulin genes. The expression of
these genes varies across the stages of the T. gondii life cycle and each isoform appears
to be specifically incorportated into different tublin structures (Hu et al., 2004).
1.3.3. T. gondii secretory organelles. Apicomplexan parasites contain three
unique secretory organelles, the micronemes, the rhoptries and the dense granules. The
micronemes are small organelles located at the apical end of the parasites. The contents
of the micronemes are constitutively released from the parasite after contact with the
host cell and secretion of the micronemes can be artificially induced by calcium
ionophores, indicating that calcium signaling is important for secretion (Carruthers and
Sibley, 1999). Micronemal proteins are involved in host cell adhesion and most of these
proteins contain conserved adhesive domains including: thrombospondin-like repeats
found in MIC1 (Saouros et al., 2005); epidermal growth factor-like domains found in
MIC3 and MIC6 (Garcia-Reguet et al., 2000; Reiss et al., 2001); and lectin-like
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domains found in MIC3 and MIC8 (Cerede et al., 2005). MIC1 is capable of binding
sialyated oligosaccharides (Blumenschein et al., 2007) and deletion of MIC1 results in
a 50% decrease in invasion efficiency (Cerede et al., 2005). The MIC2 homolog in
Plasmodium, TRAP, binds heparin (Tossavainen et al., 2006) and host cells that are
deficient in proteoglycans are less susceptible to T. gondii infection indicating that
proteoglycans also play a role in T. gondii invasion although an interaction between
MIC2 and heparin has not been shown. Attempts to create MIC2 deficient parasites
have been unsuccessful and analysis of parasites expressing MIC2 under the control of
a conditional promoter show that decreasing levels of MIC2 to 2% of wildtype levels
results in a 80% decrease in invasion, showing that MIC2 is essential for invasion
(Huynh and Carruthers, 2006). MIC2 is vital for connecting the host cell to the parasite
cytoskeleton (Figure 6, section 1.8).
The rhoptries are large club-shaped organelles located at the apical end of the
parasite. Secretion of proteins from the rhoptries is tightly regulated and does not seem
to occur unless the parasites are intimately associated with the host cell (Mital et al.,
2005). It is currently not known what intracellular signals control rhoptry secretion.
Rhoptry proteins play numerous roles in the parasite’s biology, including adhesion to
the host cell, modification of the parasitophorous vacuole and virulence (review by
Dubremetz, 2007).
The dense granules of apicomplexan parasites are approximately 200nm in
diameter (Mercier et al., 2005), electron dense and located throughout the body of the
parasites. Secretion of the dense granules occurs constitutively in a calcium
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independent manner and via a burst of secretion approximately one hour after invasion
(Carruthers and Sibley, 1997). Like the rhoptries, the signals that induce dense granule
secretion are not known. Secretion of dense granules occurs sub-apically from the PPM
although how this secretion occurs and how the dense granules traverse the two
membranes of the IMC is not understood. Dense granule proteins are found in the PVM
and the PV space (reviewed by Mercier et al., 2005).
The molecular motors involved in secretion of these organelles have not been
studied. Treatment with cytochalasin D does not prevent microneme or rhoptry
secretion, suggesting myosin motors are not essential. It is thought that the microtubule
motor dynein is involved in secretion since mironemes are often found lining up along
the parasites microtubules (Carruthers and Sibley, 1999).

1.4. T. gondii host cell invasion
1.4.1. Parasite invasion. Since T. gondii is an obligate intracellular parasite, host
cell invasion is necessary for survival. Unlike many other intracellular pathogens,
apicomplexan parasites do not enter cells by manipulation of the cell’s endocytic or
phagocytic apparatus. T. gondii enters cells by a process of active penetration that does
not depend on rearrangement of the host cell actin cytoskeleton (Dobrowolski and
Sibley, 1996). Invasion is a complex multistep process (Mital, 2006, Figure 4) and
begins with the parasite gliding along the surface of the host cell. During motility the
parasite extends and retracts its conoid and secretes proteins from the micronemes.
Micronemal proteins are important for host cell adhesion (section 1.3.3) and mediate an
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initial distal attachment with the host cell (Mital et al., 2005). Since T. gondii is capable
of invading almost every nucleated cell in a wide variety of animals it is likely that
many receptor-ligand interactions can mediate attachment.
After the initial attachment occurs between the parasite and the host cell,
rhoptry neck proteins must be released from the parasite before a tighter interaction can
occur (Mital et al., 2005). Micronemal protein AMA1 mediates this tight interaction
and along with rhoptry neck proteins RON2 and RON4 forms the moving junction. The
moving junction is a tight association that exists between the host cell PM and PPM as
the parasites penetrate the host cell (Alexander et al., 2005). By live video microscopy
and electron microscopy the parasite is seen to constrict at the moving junction as it
moves past the host PM and enters the cells. As the parasite enters the cell, a PVM is
formed from the host cell PM (Suss-Toby et al., 1996). Host cell proteins are excluded
from the membrane based on their membrane anchor as they pass the moving junction
(Mordue et al., 1999). It is likely that removal of proteins from the PVM helps prevent
trafficking of the PV to the lysosomes once the parasite has fully entered the cell.
During host cell penetration, rhoptry bulb proteins are secreted that modify the PVM.
Microneme proteins involved in adhesion are capped to the posterior end of the parasite
as the parasites moves further inside the cell. Once these proteins reach the basal end of
the parasites they are cleaved within their transmembrane domain (Carruthers and
Blackman, 2005) and released into the extracellular environment.
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1.5. T. gondii motility
1.5.1. Parasite motility. Apicomplexan parasites lack the cilia and flagella often
present on other motile cells and display a form of substrate-dependent gliding motility
that occurs without a change in cell shape (Hakansson et al., 1999). Parasites display
three forms of motility. Circular gliding involves parasites lying on their sides and
gliding in a counterclockwise direction at speeds of approximately 1.5µm/s. Upright
twirling involves parasites “standing” with their posterior ends attached to the
substratum and spinning in a clockwise direction. Helical rotation occurs in two distinct
steps. Step 1 involves the parasite lying on a side and moving forward one body length
in a cork-screw motion through 180 degrees. In step 2 the parasite “resets” itself by
flipping from one side to the other. This allows the parasite to repeat the first corkscrew motion again. All three forms of motility are inhibited by cytochalasin D and
butanedione monoxime, suggesting that all forms are driven by an actin myosin motor
(Hakansson et al., 1999).
T. gondii motility is directional, with the parasite moving its apical end first, and
results in the deposition of parasite surface antigens onto the host cell or solid substrate.
Visualization of these deposited trails is possible with antibodies directed against the
surface antigens (Dobrowolski et al., 1997). Increased motility is correlated with
increased virulence in T. gondii. Type I strains have increased motility in vitro and
increased ability to traverse biological membranes compared with type II and III strains
(Barragan and Sibley, 2002).
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In motile parasites, intracellular calcium levels are dynamic, displaying cyclical
increases and decreases (Lovett and Sibley, 2003). During the early steps of invasion
calcium levels are diminished and they are low in intracellular parasites for at least five
minutes after invasion presumably allowing the parasite to shut off calcium-mediated
signaling pathways involved in motility and invasion (Lovett and Sibley, 2003). In this
study the levels of calcium in replicating parasites was not assessed. Intracellular
parasites become motile and egress from host cells after treatment with calcium
ionophores. Abscisic acid (ABA) plays an important role in the calcium signal
transduction pathway in the parasites. Increases in levels of ABA in the parasite
increase the production of the second messenger cyclic adenosine diphosphoribose
(cADPR) resulting in calcium release from intracellular stores. Preventing ABA
synthesis with fluridone prevents parasite egress showing that calcium plays a vital role
in parasite motility (Nagamune et al., 2007).

1.6. Myosin motors: An overview
In the broadest terms, proteins in the myosin superfamily are molecular motors
that use energy generated from ATP hydrolysis to displace actin filaments. These
proteins are involved in a wide variety of cellular functions including muscle
contraction, cell motility, intracellular trafficking of organelles and cytokinesis. Myosin
motors from muscle were the first to be identified and are considered “conventional”.
They are a part of myosin class II, a class currently made up of a large number of
muscle and non-muscle myosins. Class I myosin motors were the next to be described
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and all other classes are named in the order in which they were identified; these
myosins are considered “unconventional” (Sellers, 2000). To date, 24 myosin classes
have been described that display a huge variation in step size, velocity, force
production and subcellular localization (Foth et al 2007, Sellers, 2000).
Myosin motors comprise three distinct regions: a conserved head which
contains the ATPase and actin binding domains; a neck of variable length that interacts
with myosin light chains (MLC); and a variable tail domain.
The myosin head domain is itself built of 4 subdomains: an N-terminal domain;
an upper 50kDa domain; a lower 50kDa domain; and the converter domain. The
domains are connected by flexible loops (Sellers, 2000, Figure 5a). Actin binding
occurs at a cleft between the upper 50kDa and lower 50kDa domains and this region
displays small changes in conformation when ATP and actin bind to myosin. A loop in
the upper 50kDa domain is necessary for correct enzymatic activity of the protein.
Mutations in this region can lead to either increased or decreased enzymatic functioning
of the protein (Brzeska and Korn, 1996; Debold et al., 2007) and are responsible for
diseases such as hypertrophic cardiomyopathy (HCM) so this loop is often referred to
as the HCM loop. In most myosin proteins this loop contains either a negatively
charged (D or E) or phosphorylatable (S or T) residue that is important for the
enzymatic function of the myosin. This is known as the TEDS rule (Bement and
Mooseker, 1995). Extending from the converter region is the long helical neck or “lever
arm” of the protein. In most cases essential or regulatory light chains (ECLs/RCLs) or
calmodulin bind to and stabilize the neck (Tyska and Warshaw, 2002).
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The amino-terminal domain and the upper and lower 50kDa domains are
relatively rigid and allow only small changes in conformation upon actin and ATP
binding. The converter domain is more flexible and small changes that occur in the
head are amplified by the converter domain resulting in large structural changes in the
lever arm (Sellers, 2000).
The tail domains of myosins are highly divergent. A number of myosin motors
function as dimers and the coiled-coiled domains in the tail usually mediate this
interaction. Tail domains also mediate other protein-protein interactions such as the
interaction of myosin V with its cargo and interaction of myosin X with microtubules
(Sousa and Cheney, 2005). Tail domains can also be important for regulating myosin
activity. For example myosin V has a folded, inactive confirmation when no cargo is
bound to its tail (Trybus, 2008).
Myosin motors interact only weakly with actin when ATP is bound to the
nucleotide-binding domain of the protein. When ATP is hydrolyzed to ADP and
inorganic phosphate (Pi), a large conformational change occurs within the protein
where the angle of the lever arm is altered in relation to the head domain. Subsequently
Pi release results in the myosin head interacting tightly with actin and undergoing the
powerstroke, during which myosin returns to its original confirmation. At the end of the
powerstroke ADP is released and is replaced by ATP. The speed at which myosin can
move actin filaments depends on two parameters: the displacement of the actin filament
generated by the power-stroke (d) and the length of time myosin spends strongly bound
to actin, termed the duty-ratio (τon). For muscle myosin II d is approximately 5-10nm,
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whereas myosin class V proteins move approximately 36nm along the actin filament.
Skeletal muscle myosins spend approximately 5% of their cycle time strongly bound to
actin and therefore are considered low duty ratio motors (Tyska and Warshaw, 2002;
Yanagida et al., 2000). Myosin V spends a much longer time (~70%) strongly bound to
actin and is a high duty ratio motor (De La Cruz et al., 1999).

1.7. Regulation of myosin motors by myosin light chains
The role of ELCs and RLCs in regulating myosin function has been well studied
for conventional myosins. ELCs and RLCs bind to and stabilize the extended α-helical
neck region of the protein with RLCs binding farthest and ELCs binding closest to the
head (Rayment et al., 1993). Both light chains are calmodulin-like proteins and bind a
conserved sequence in the α-helix termed the IQ-motif, with consensus sequence
IQX3RGX3R.
Myosin motors are regulated in a number of ways depending on the organism
and tissue type in question. More is known about the regulation of myosin II activity
than the myosins from other classes. The ATPase activity of smooth muscle myosin is
regulated by RLC phosphorylation. Muscle contraction is initiated when calmodulin is
activated by an increase in intracellular calcium. This leads to activation of MLC kinase
(MLCK) that phosphorylates RLC on serine 19 and activates myosin. RLC
phosphorylation on serine 1 and 2 can negatively regulate muscle function by reducing
subsequent serine 19 phosphorylation. If serine 19 is already phosphorylated, serine 1/2
phosphorylation inhibits the actin-activated ATPase of myosin and decreases myosin’s
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affinity for actin (Satterwhite et al., 1992). Removal of RLC from myosin causes a
decrease in the myosin’s ATPase activity and the velocity at which smooth muscle
myosin can move actin filaments in the in vitro motility assay from 0.8µm/s to 0.1µm/s
(Lowey and Trybus, 1995). Expression of smooth muscle heavy meromyosin in the
absence of ELC but in the presence of phosphorylated RLC caused a significant
decrease in myosin activity (Lowey and Trybus, 1995) showing that both light chains
are important for correct myosin function.
The actin-activated ATPase activity of skeletal muscle myosins is regulated by
troponin and tropomyosin (Timson, 2003). ELCs and RLCs of skeletal muscle appear
to affect the mechanical properties of the protein. Removal of the ELC or RLC from
skeletal muscle myosin leads to a significant decrease in the velocity with which
myosin can move actin filaments (Lowey et al., 1993b) and removal of both light
chains decreases filament velocities from 8.8 to 0.8µm/second without affecting
myosin ATPase activity. However removal of ELCs decreased myosin’s ability to
produce force by 50% while removal of RLC did not alter myosins force producing
capacity (VanBuren et al., 1994).
Fast skeletal muscle myosin contains two essential light chain isoforms. Myosin
with ELC1 moves actin filaments more slowly in an in vitro motility assay than myosin
with ELC3 (Lowey et al., 1993a).

ELC1 contains an N-terminal 40 amino acid

extension compared to ELC3, the first 10 amino acids of which are lysine rich and are
followed by a 30 amino acid proline-rich region. This N-terminal region binds to the
negatively charged C-terminus of actin as demonstrated by cross-linking and electron
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microscopy (Timson, 2003). In cardiac muscle two ELC forms are present, ELC
ventricular (ELCv) and ELC atrial (ELCa). Both of these proteins contain N-terminal
extensions that bind actin. Deletion of amino acids from this N-terminal region
decrease isometric force production of isolated cardiac tissue without affecting
unloaded shortening velocities (Miller et al., 2005).
Motor activity of non-muscle myosin II from Dictyostelium is upregulated by
RLC phosphorylation on serine 13. Expression of RLC in which serine 13 has been
mutated to alanine in Dictyostelium RLC null cells rescues the mutant phenotype
indicating that MLC phosphorylation is not essential for myosin function but does play
a role in regulating myosin activity (Ostrow et al., 1994; Zhang et al., 2002).
Class I myosin from lower eukaryotes are activated by phosphorylation at the
TEDS rule site while vertebrate myosin I are regulated by their associated light chains.
Myosin I proteins use calmodulin (CaM) as a light chain and activity is modulated by
calcium binding (Stoffler and Bahler, 1998; Wolenski et al., 1993; Zhu et al., 1996).
Myosin V contains six IQ motifs that bind either calmodulin or ELC. The extent to
which calcium can modulate myosin V activity depends on which IQ motifs are
occupied by calmodulin since calmodulin binds calcium with high affinity while ELC
does not contain functional calcium-binding sites (Trybus 2008). Myosin V activity can
be regulated by calcium due to conformational changes in CaM upon calcium binding
and dissociation of calmodulin from myosin in the presence of calcium (Trybus et al.,
2007).
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1.8. Myosin motor proteins in Apicomplexan parasites
1.8.1. Myosin motor proteins in Apicomplexan parasites. 11 myosin genes have
been identified in the T. gondii genome (namely MyoA-K, Table 1) while only six
myosin genes have been identified in the Plasmodium species genome (MyoA, B, E, F,
J and K [MyoF, J and K were previously named C, D and F respectively]) despite the
more complex life cycle of Plasmodium parasites (Chaparro-Olaya et al., 2005; Frenal
et al., 2007). Cryptosporidium parasites contain six myosin genes and Theileria
annulata contains only three (Pain et al., 2005).
1.8.2. Class XIV myosins. Myosin class XIV consist of myosins from
apicomplexa and the closely related ciliate Tetrahymena thermophila. These myosin
proteins contain a polymorphism in the highly conserved sequence HYAG (position
584 of chicken skeletal muscle). 220 of the 230 (95.7%) non-class XIV myosins have a
tyrosine or a phenylalanine at position 2 in this sequence and 5 (2.2%) have an
isoleucine at this position. However all class XIV myosin contain the phosphorylatable
residue serine or a threonine at this position (Frenal et al., 2007).
Myosins A, D, B, C, E and H all fall into myosin class XIV although they are
divided into subclasses a-c (Table 1, (Foth et al., 2006; Heintzelman and Schwartzman,
1997). Apicomplexan MyoA is the best characterized of the myosin genes and is
present in all apicomplexan parasites investigated to date. TgMyoA and PfMyoA play
an essential role in parasite motility and invasion and the function of TgMyoA will be
described in greater detail in subsequent sections. TgMyoD is most closely related to
TgMyoA with 55.7% identity and is thought to have arisen from MyoA gene

19

duplication (Hettmann et al., 2000). MyoD genes are only found in T. gondii and
Eimeria tenella and TgMyoD is the smallest T. gondii myosin weighing in at only
91kDa. It localizes to the parasite periphery in both tachyzoites and bradyzoites,
although it is expressed at higher levels in bradyzoites. TgMyoD is not essential for
parasite gliding motility or invasion and TgMyoD knock-out parasites do not show
decreased virulence in mice (Herm-Gotz et al., 2006). The exact role of TgMyoD is not
known.
MyoB, MyoC and MyoE are members of the Class XIV subclass b and are
found in T. gondii, E. tenella and Gregarina polymorpha. Notably MyoB and E from
Plasmodium are not orthologues to MyoB and MyoE in Toxoplasma and their
phylogenetic classification has not yet been determined. TgMyoB and TgMyoC are
encoded from a single gene and differ only at their C-terminus due to alternative
splicing of the last intron. Both MyoB and MyoC have been implicated in parasite cell
division (Delbac et al., 2001). MyoC is the bigger of the two genes with 118 unique
amino acids compared to MyoB. It is predominately localized at the apical and
posterior polar rings of extracellular parasites. It also localizes to the IMC in growing
daughter parasites and may play a role of assembly and elongation of the IMC during
daughter cell development (Delbac et al., 2001). MyoB has 21 unique amino acids
compared to MyoC and shows a non-uniform cytoplasmic distribution. Parasites
overexpressing MyoB are delayed in replication and the formation of parasite rosettes
within the PV is disturbed. TgMyoE is expressed in bradyzoites only and the function
of this protein is unknown.
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MyoH is a member of the class XIVc and is found in all apicomplexan parasites
analyzed thus far except P. falciparum and G. polymorpha. The function of myosins in
this class has not been examined experimentally although analysis of conserved
functional domains present in these proteins may provide some clues as to their
function. The TgMyoH tail contains a domain with homology to the α-tubulin
suppressor (ATS1) and regulator of chromosome condensation 1 (RCC1). These
proteins are implicated in coordinating microtubule structures during the cell cycle
(Foth et al., 2006; Kirkpatrick and Solomon, 1994) suggesting MyoH may function
during mitosis or cytokinesis. This is the first example of an ATS1 domain being
present on a myosin tail.
1.8.3. Non-class XIV myosins in apicomplexa. MyoF, MyoG and MyoI are in
newly designated myosin classes XXII, XXIII and XXIV respectively (Foth et al.,
2006). MyoF is present in all apicomplexan parasites analyzed to date. It has an
extended neck that contains numerous IQ motifs and between four and six WD40
repeats. Proteins containing WD40 motifs have been implicated in many diverse cell
processes. The WD40 motifs form a beta propeller structure (Foth et al., 2006) that
serves

as

a

platform

for

multiple

protein-protein

interactions

(http://www.ebi.ac.uk/interpro). Specificity of protein binding is imparted by sequences
outside the WD40 domains.
MyoG from T. gondii and E. tenella are found in class XXIII and contain a TH4
microtubule binding domain. TH4 domains are found in a number of other myosins
(Sellers, 2000) and have been shown to be important for proper myosin function
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(Weber et al., 2004). Binding of MyoG to microtubules has not been demonstrated
experimentally.
T. gondii and C. parvum contain a MyoI gene found in the class XXIV. These
proteins contain an extended neck and CpMyoI contains a Src-homology 3 domain at
its N-terminus and coiled-coiled domains in its tail suggesting CpMyoI forms a dimer
(Frenal et al 2007). Again, neither the function nor the cellular localization of these
proteins is known.
MyoJ and MyoK are class VI myosins. Class VI myosins are the only myosin
known to move towards the minus end of actin filaments, although the directionality of
MyoJ and MyoK has not been verified. The function and localization of MyoJ and
MyoK are unknown.
1.8.4. Myosin light chains in T. gondii. To date only a single myosin light chain,
TgMLC1, has been cloned in T. gondii. TgMLC1 binds to the single degenerate IQ
motif in the TgMyoA tail although the role of this protein in regulating myosin function
is not understood. Blast searches of T. gondii genome database (toxodb.org) reveal
seven myosin light chain-like or calmodulin-like genes (accession numbers
113.m00782,

583.m05420,

50.m03285,

59.m03455,

83.m01266,

541.m01151,

583.m05709). The functions of these proteins and their associated myosins have not
been characterized. Proteomic analysis of the parasite conoid reveals that TgMLC2
(113.m00782) is present in the conoid (Hu et al., 2006) and along with its associated
myosin heavy chain may play a role in driving conoid extension and retraction.
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Interestingly, there is an inconsistency between the number of myosins in the T.
gondii genome compared to MLCs. It is possible that myosin light chains may be
shared by two or more myosins. The MLC binding sequence is conserved between
MyoD and MyoA and it has been hypothesized that these myosin motors may share a
light chain (Herm-Gotz et al., 2006) although there is currently no experimental
evidence to support this idea. A second possibility is that some myosin motors may not
have an associated light chain although this possibility is less likely since all T. gondii
myosins contain at least one IQ motif. A third possibility is that some myosin proteins
may bind MLCs that have very little sequence homology to known MLCs and so these
proteins are not identifiable through bioinformatic analysis.

1.9 An actomyosin motor drives motility and host cell invasion
1.9.1. The T. gondii “glideosome”. Gliding motility in T. gondii is driven by
TgMyoA, its associated light chain TgMLC1 and two glideosome associated proteins
TgGAP45 and TgGAP50. Collectively these proteins are termed the glideosome.
TgMyoA is a 93kDa protein that was originally identified using degenerate
primers against the conserved head domain of myosin motors (Heintzelman and
Schwartzman, 1997). The head domain contains only 23-34% identity to other myosins
and is distinct from the majority of other myosins in that it does not adhere to the
“TEDS rule” (Foth et al., 2006; Heintzelman and Schwartzman, 1997). TgMyoA and
PfMyoA share 67% amino acid identity although PfMyoA does adhere to the TEDS
rule suggesting the TgMyoA and PfMyoA may be regulated by different mechanisms.
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TgMyoA was originally described as having no neck and a short tail of only 57 amino
acids (Heintzelman and Schwartzman, 1997). However subsequent analysis of
apicomplexan MyoA sequence and the crystal structure of PfMyoA “tail” shows that
this region forms a alpha helical structure reminiscent of the necks of other myosins
(Bosch et al., 2006). Additionally, this region contains a degenerate IQ motif that binds
apicomplexan MLC1 and is similar in length to the neck domains of the S1 skeletal
muscle myosin (Herm-Gotz et al., 2002). Although this region has a highly basic
charge of pI 10.8, reminiscent of the tail regions of myosin class I proteins, it seems
more appropriate to consider this region as the neck of the MyoA and it is likely that it
acts as the myosin’s lever-arm. Although MyoA is of similar size to skeletal muscle
myosin S1 it is likely that these proteins function with different mechanisms since the
converter region of MyoA is divergent compared to other myosins. Most myosin
motors contain two reactive cysteines in the converter domain (Cys 697 and Cys 707 in
chicken skeletal myosin) that undergo large rearrangements during the powerstroke
(Tyska and Warshaw, 2002) and a number of conserved glycine residues, one of which
acts as the ‘pivot-point’ for the lever arm. These cysteine residues and pivot point
glycine are not conserved in apicomplexan MyoA proteins (Herm-Gotz et al., 2002).
Despite its small step size of 5.3nm, TgMyoA moves towards the plus end of
actin filaments at velocities of approximately 5.2µm/s, a speed comparable to skeletal
muscle myosin (Herm-Gotz et al., 2002). PfMyoA filament velocity is slightly slower
at 3.5µm/s and PfMyoA function is calcium independent (Green et al., 2006).
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It is not possible to generate parasites lacking TgMyoA. Expression of TgMyoA
under the control of a conditional promoter allowed comprehensive characterization of
TgMyoA function (Meissner et al., 2001; Meissner et al., 2002). Parasites, in which the
expression of TgMyoA has been turned off are immotile, show an 80% decrease in the
levels of invasion and were unable to egress from host cells (Meissner et al., 2002).
Depletion of TgMyoA did not decrease intracellular parasite growth or calcium
ionophore-stimulated microneme secretion.
The TgMyoA neck contain a truncated light chain binding IQ motif consisting
of only IQX3RR/K whereas the IQ consensus sequence from other myosins is
IQX3RGX3R (Sellers, 2000) and binds a single light chain TgMLC1. TgMLC1 has a
predicted molecular weight of 24kDa although it resolves on SDS PAGE gels with an
apparent molecular weight of 30kDa. TgMLC1 is a calmodulin-like protein and
contains 2 degenerate EF hand domains that are not thought to bind calcium (HermGotz et al., 2002). TgMLC1 and its homologs in other apicomplexa contain a 79 amino
acid N-terminal extension compared to other calmodulin-like myosin light chains. The
role of this N-terminal extension is unknown. Characterization of the TgMLC1
homolog in Plasmodium, MTIP (Myosin tail interacting protein), reveals that the Nterminal extension is unnecessary for binding to the PfMyoA tail. Amino acids (aa) 80204 of PfMTIP are required for MyoA binding (Bergman et al., 2003) and deletion of
either aa80-94 or the last 15aa of PfMTIP abrogates PfMyoA interaction (Bergman et
al., 2003; Jones et al., 2006). Many IQ-motif interacting proteins contain a conserved
Q-loop that is involved with direct binding to the IQ motif. Mutation of the MTIP Q-
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loop inhibits PfMTIP-PfMyoA tail interaction (Jones et al., 2006). The crystal structure
for PfMTIP aa 60-204 interacting with PfMyoA tail has been resolved (Bosch et al.,
2006; Jones et al., 2006, Figure 5b). The closed conformation of PfMTIP is reminiscent
of other essential light chain/myosin heavy chain interactions. The conformation is
stabilized by two salt bridges, one between PfMTIP D137 and PfMTIP K71 and the
second between PfMyoA R806 and PfMTIP D139. Arginine R806 is part of the
PfMyoA tail IQ motif and mutation of this residue and the adjacent R/K residue in both
TgMyoA and PfMyoA disrupt light chain binding (Herm-Gotz et al., 2002; Jones et al.,
2006).
The glideosome is assembled in two stages. TgMyoA, TgMLC1 and TgGAP45
are soluble proteins synthesized and assembled in the cytosol into a complex called the
proto-glideosome. They are subsequently trafficked to the membrane where they
interact with TgGAP50. TgGAP50 is a transmembrane protein located in the outer
membrane of the IMC and functions to anchor the complex to the membrane (Gaskins
et al., 2004). Deletion of the TgMyoA tail abrogates both TgMLC1 and TgGAP45
interaction and TgMyoA peripheral localization (Herm-Gotz et al., 2002). TgGAP45 is
a multiply phosphorylated protein of unknown function (Gilk, 2004). PfGAP45 has
been shown to be myristylated and palmitoylated suggesting it may function in
signaling the proto-glideosome to the IMC (Rees-Channer et al., 2006).
1.9.2. Actin in Apicomplexan parasites. T. gondii encodes one actin gene,
TgACT1, which contains 83% identity to vertebrate actin and 93% homology to the
PfACT1 gene in P. falciparum. Treating parasites with cytochalasin D inhibits all
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forms of motility and host cell invasion (Dobrowolski et al., 1997). In contrast,
treatment with the actin polymerizing agent jasplakinolide (JAS) causes increased
parasite motility; however this movement is unproductive and JAS-treated parasites
cannot invade host cells (Shaw and Tilney, 1999; Wetzel et al., 2003).
Actin co-sedimentation assays in both T. gondii and P. falciparum have shown
that 97% of actin in the cell is the globular form (Dobrowolski et al., 1997; Pinder et
al., 1998). Visualization of actin filaments in the parasites using fluorescent derivatives
of phalloidin or by transmission electron microscopy (TEM) has not been possible
(Wetzel et al., 2003), although short, unbranched, cytochalasin D-sensitive actin
filaments were visualized in T. gondii using freeze-etch electron microscopy (Wetzel et
al., 2003). Analysis of recombinantly expressed TgACT1 and PfACT1 has shown that
these proteins form short actin filaments with an average length of only 100nm
compared with an average length of 3.5µm for rabbit actin (Sahoo et al., 2006; Schmitz
et al., 2005). This unusually short length is due to intrinsic properties of the actin
monomer. In skeletal muscle actin filaments, a strong ionic interaction occurs between
R39 of one monomer and E276 on the adjacent actin monomer. Sequence analysis of
the TgACT1 reveal that residue 277 (equivalent to 276 in skeletal muscle actin) is an
arginine which prevents this strong interaction occurring between adjacent monomers
in apicomplexan actin filaments.
A number of actin-binding proteins are absent from the genomes of
apicomplexan parasites such as gelsolin, Arp2/3 complex, α-actinin and fimbrin. Until
recently the proteins involved in regulating actin filament dynamics were
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uncharacterized. It has recently been shown that PfFormin1 can nucleate actin filaments
in vitro and is present at the moving junction of the parasite during invasion implicating
this protein in regulating actin filament polymerization during invasion (Baum et al.,
2008). T. gondii contains one profilin (TgPRF) gene that is essential for parasite
invasion and egress. TgPRF interacts directly with parasite actin and supports assembly
and stabilization of skeletal muscle actin filaments in vitro and is likely important for
regulating actin filament formation in the parasite (Plattner et al., 2008).
1.9.3. How does TgMyoA drive parasite motility? At the moving junction of
invading parasites, short actin filaments located between the PM and the IMC are
connected to the parasite surface and underlying host cell by a number of bridging
proteins including MIC2, M2AP and aldolase (Figure 6). MIC2 is a transmembrane
domain-containing protein that is found in the PPM following secretion from the
micronemes. The cytosolic tail of MIC2 binds the glycolytic enzyme aldolase that
binds directly to actin (Jewett and Sibley, 2004). Since the actin filaments are stably
attached to the host cell surface and TgMyoA is thought to be stably anchored in the
IMC membrane, TgMyoA can propel the parasite forward into the host cell when it
undergoes the powerstroke (Figure 6). Interestingly, MIC2-deficient parasites are still
capable of circular gliding but have a decreased ability for helical gliding and twirling
indicating that other adhesins (presumably other microneme proteins) have the
capability to connect the host cell surface to the parasite cytoskeleton during circular
gliding (Huynh and Carruthers, 2006). Fluorescence recovery after photobleaching
(FRAP) experiments with TgGAP50-YFP have shown that this protein does not
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recover fluorescence after photobleaching indicating that this protein is stably anchored
in the membranes of the IMC and holds the glideosome in place during motility
(Johnson et al., 2007). However it is not known how this anchoring occurs. To date it
has not been possible to identify proteins that connect the cytoskeleton of the parasite
with the glideosome. The IMC is a cholesterol-rich membrane and it has been
suggested that cholesterol may contribute to the immobilization of the glideosome in
the IMC membrane, although it is likely that other factors also play a role (Johnson et
al., 2007).

1.10. Identification of small molecule effectors of T. gondii invasion
It is difficult to study T. gondii invasion using classical forward genetic
techniques since invasion is an essential process and parasites that lack genes essential
for invasion will not be viable. Our lab has chosen to use a “chemical genetics”
approach to studying the process of T. gondii invasion. A high throughput fluorescencebased screen was performed to identify small molecule inhibitors of T. gondii invasion
(Carey et al., 2004).
The screen was performed using a dual-fluorescence invasion assay. Parasites
expressing YFP were added to host cells and treated with DMSO or a small molecule
of interest for 15 minutes at room temperature (RT). At this temperature parasites
cannot invade and incubation allows the small molecule to interact with its target.
Parasites are subsequently incubated at 37°C for 60 minutes. Cells are fixed and
extracellular parasites are labeled using an anti-SAG1 antibody conjugated to Alexa-
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546. Therefore intracellular parasites fluoresce green, while extracellular parasites
fluoresce red and green appearing yellow in a merged image. The level of parasite
invasion can then be determined using fluorescence microscopy.
12,160 small molecules from the Chembridge DiversetE collection were
screened in the assay and 65 inhibitors of invasion and 8 enhancers were identified.
False positives, cytotoxic and chemically impure compounds were eliminated from the
collection of hit molecules and were not studied further. The remaining 24 inhibitors
and 6 enhancers of invasion were characterized in a number of secondary assays,
summarized in Figure 7 (Carey et al., 2004). 21 out of 24 inhibitors of invasion also
inhibited parasite motility and all of the enhancers of invasion enhanced motility.
Target identification is the most challenging aspect of any small molecule
screen and can be approached in one of two general ways. Assumption-free approaches
require no prior knowledge of the process being studied and usually involve making
“tagged” versions of the small molecules of interest. For example, producing a small
molecule derivative linked to biotin would make it possible to identify the proteins
interacting with the small molecule by streptavidin pull-down or western blot. Likewise, producing a small molecule derivative containing a fluorescent tag may make it
possible to identify the cellular location where the small molecule exerts its effects and
allow identification of tagged proteins following gel electrophoresis.
Hypothesis-driven approaches involve making educated guesses about how the
compounds might be acting based on the biological effects of the molecules. For
example, we have hypothesized that some of the invasion inhibitors and enhancers may
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act by altering the parasite’s motility apparatus since many of the compounds affect
parasite motility. These experiments will be discussed in more detail in chapter 3.
Once a number of candidate targets have been identified, it is necessary to
validate which protein is the biologically relevant target. Target validation can be
approached in a number of ways and each approach will have benefits and drawbacks
depending on the small molecule and target in question (Ward et al., 2002). It is hoped
that by identifying the targets of the small molecule inhibitors and enhancers identified
in our screen, valuable insight can be gained about the proteins involved in T. gondii
invasion.
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Figure 1. The T. gondii life cycle.
The sexual cycle of T. gondii occurs in the gut of the cat after the cat ingests
tissue contaminated with bradyzoite cysts. The oocysts are passed from the gut with the
feces. The asexual cycle can occur when an animal ingests either oocysts or food
contaminated with a bradyzoite tissue cysts. Soon after the bradyzoite cysts are
ruptured in the stomach of the animal, the bradyzoites convert back to tachyzoites that
disseminate throughout the body of the animal. In the presence of a competent immune
system, the tachyzoites convert back to bradyzoites and encyst in the tissues of the
infected animal for long periods of time.
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Figure 2. The lytic cycle of T. gondii
The lytic cycle of T. gondii begins with parasites gliding along and invading into a host
cell. During invasion, proteins are secreted into the host cell that modulate a number of
host cell processes. The nucleus, mitochondria and host cytoskeletal structures are
reorganized in the host cell to surround the PV. The Golgi is “disassembled” and can be
visualized by small punctate structures adjacent to the PV. Parasite replication begins
by endodyogeny soon after invasion, with each round of division taking 7-10 hours. A
decrease in host cell potassium causes intracellular parasites to become motile and
egress from host cells at discrete sites.
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Figure 3. Structural features of T. gondii tachyzoites.
Unique cytoskeletal structures include the conoid, a truncated cone that extends
and retracts during parasite motility, and two apical polar rings (APR). The parasite
contains 22 subpellicular microtubles that travel two-thirds the length of the parasite.
Between the microtubules and the parasite plasma membrane (PPM) lies the IMC, a
series of flattened vesicles that are sutured together and run along the length of the
parasite. T. gondii contains three distinct secretory organelles, the micronemes, the
rhoptries and the dense granules. Line drawing from (Nichols and Chiappino, 1987).
Insert 1 from (Hu et al., 2002b). Insert 2 from (Johnson et al., 2007).
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Figure 4. T. gondii invasion
Adapted from Mital 2006. See text for details.
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Figure 5. Crystal structure of skeletal muscle myosin S1 (A) and PfMyoA tail with
PfMTIP and PkMTIP (B).
(A) Image taken from Rayment et al 1993. (B) Image taken from Bosch et al
2007. PfMTIP amino acids 63-204 (yellow/orange) and PkMTIP amino acids 79 to
203 (blue/purple) co-crystalized with PfMyoA tail (red).
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Figure 6. The T. gondii glideosome
Glideosome proteins TgMyoA, TgMLC1 and TgGAP45 are anchored to the
IMC via transmembrane protein TgGAP50. Short actin filaments located between the
plasma membrane and the IMC. These actin filaments are stably attached to the host
cell via bridging proteins MIC2 and aldolase. Adapted from Gilk, 2004.
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Figure 7. Effects of small molecule inhibitors and enhancers in secondary assays.
Red = inhibitor, Green = enhancer, Yellow = Altered motility compared to WT, White =
No effect. Adapted from Carey et al., 2004.
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D
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E
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F

XXII
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G

XXIII

Tg, Et

H

XIVc

I

XXIV

All except Ps,
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J
K

VI
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All
All

Unusual Characteristics
Contains a short tail of
57aa

Function
Drives motility
and invasion

B and C are products of
alternative splicing of a
single gene
Smallest myosin in Tg

Cell division
Cell division

Contains numerous IQ
and WD40 motifs
Tail contains TH4 MT
binding domain
Tails contains
ATS1/RCC1 domain
CpMyoI contains SH2 Nterminal domain

Unknown
Unknown –
expressed in
bradys only
Unknown

Reference
Herm-Gotz et
al 2002
Messiner et al
2002?
Delbac et al
Delbac et al
Herm-Gotz et
al 2006
Foth et al 2007
Foth et al 2007

Unknown

Foth et al 2007

Unknown

Foth et al 2007

Unknown

Foth et al 2007

Unknown
Unknown

Foth et al 2007
Foth et al 2007

Table 1. Myosin motors in Apicomplexan parasites.
Abbreviations: Tg Toxoplasma gondii; Et, Eimeria tenella; Gp, Gregarina polymorpha;
Ps, Plasmodium species.
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CHAPTER 2: MATERIALS AND METHODS
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2.1. General Methods
2.1.1. Materials. Unless otherwise noted all chemicals were bought from Sigma
(St. Louis, MO). Protease inhibitor cocktail (Sigma catalog #P8340) contains 4-(2aminoethyl) benzenesulfonyl fluoride (AEBSF), pepstatinA, E-64, bestatin, leupeptin,
and aprotinin.
2.1.2. Parasite culture and strains. Parasites were maintained by continuous
passage in human foreskin fibroblasts (HFFs) in Dulbecco’s Modified Eagle’s Media
(DMEM) containing 1% (v/v) heat inactivated fetal calf serum (FCS), 1% (v/v)
penicillin/streptomycin mix (Invitrogen, St. Louis, MO) and 1% (v/v) 10mM HEPES
pH 7.0 (Invitrogen) as previously described (Roos et al., 1994). Parasite lines were
archived frozen in liquid nitrogen in DMEM containing 10% (v/v) fetal calf serum and
7.5% (v/v) high quality DMSO. Parasite lines used are summarized in Table 2. Parasite
transfections, drug selections and isolation of clones were performed as previously
described (Kim et al., 1993; Messina et al., 1995; Roos et al., 1994).
2.1.3 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. Protein
samples were boiled in 1X SDS PAGE sample buffer in either the presence or absence
of 1.25% (v/v) β-mercaptoethanol (β-ME) for 5 minutes. Proteins were visualized
directly by silver (Carey et al., 2000) or Coomassie blue staining or transferred to
nitrocellulose or PVDF (Wichroski et al., 2002). For western blot analysis, membranes
were blocked with 5% (w/v) dry milk in Tris-buffered saline containing 0.1% (v/v)
Tween (TBS-T) for one hour to overnight. Blots were incubated with primary antibody
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for 1 hour and secondary antibody conjugated to horseradish peroxidase for 30 minutes,
agitating at RT. Antibodies used for western blotting are summarized in Table 5.
2.1.4 2D gel electrophoresis. Proteins were solubilised in one of two ways.
(1) Octylglucoside Method: Protein pellets were resuspended in lysis buffer
(10mM tris pH 7.4 containing 0.5% (v/v) protease inhibitor mix and 50ug/ml
RNase/DNase), followed by four freeze/thaw cycles in liquid nitrogen. SDS buffer
(0.3% (w/v) SDS and 200mM DTT) was added to samples which were then water bath
sonicated (Branson, Danbury, CT) for 20 minutes at RT, incubated at 55°C for 10
minutes and incubated at RT for 2 hours. Octyl buffer (9.9M urea, 4% (w/v)
octylglucoside, 100mM DTT) was added to samples and incubated at RT for 1 hour.
Ampholytes (GE Healthcare, Piscataway, NJ) and bromophenol blue was added to a
final concentration of 0.5% (v/v) and 0.01% (v/v) respectively. Insoluble proteins were
pelleted at 15,000xg for 30 minutes at RT. Buffer volumes used for 11 and 18cm strips
are summarized in Table 4.
(2) ASB14 Method: Protein pellets were resuspended in ASB14 solubilisation
buffer (7M urea, 2M thiourea, 2% amidosulfobetaine-14 (Calbiochem, San Diego, CA),
0.5% (v/v) TX-100 (Pierce, Rockford, IL), 20mM DTT and 0.5% (v/v) ampholytes)
and incubated at RT for at least 2 hours. Bromophenol blue was added to a
concentration of 0.01% (v/v). Proteins were spun at 15,000xg for 30 minutes at RT to
remove any insoluble material.
IPG strips were rehydrated in the solubilized protein extracts for 15 to 20 hours
at 50V. Programs used to resolve proteins are summarized in Table 3.
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2.1.5. Immunoprecipitation. Parasite proteins were extracted in IP lysis buffer
(1% (v/v) TX-100, 50mM Tris-Cl pH 8, 150mM NaCl, 5mM EDTA) with 1:100
protease inhibitors on ice for 10 minutes. Extracts were clarified at 13,000xg for 30
minutes at 4°C. Protein extracts were incubated with antibody for 60 minutes at 4°C,
followed by an additional 60 minute incubation with protein A or G conjugated to
Sepharose (Zymed, San Francisco, CA). The beads were washed with 60 volumes of IP
lysis buffer. Proteins were eluted from the beads for 1D gel electrophoresis by boiling
for five minutes in 1X sample buffer with or without reducing agent. Proteins were
eluted for 2D gel electrophoresis in either octylglucoside or ASB14 buffer by
incubating for 15 minutes at RT. Antibody dilutions used for immunoprecipitation are
listed in
2.1.6. Immunofluoresence. Intracellular parasites were grown on confluent HFF
monolayers for approximately 24 hours. Fresh extracellular parasites were filtered
through a 3µm filter, and allowed to settle on Cell-tak (BD Biosciences, San Jose, CA)
treated coverslips for 30 minutes. Cells were fixed with 2% (v/v) formaldehyde diluted
in Hanks balanced salt solution (Invitrogen) for 15 minutes at RT. Cells were
permeabilised with 0.25% (v/v) TX-100 diluted in Hanks buffer for 10 minutes at RT.
Primary and secondary antibodies were diluted into Hanks buffer containing 0.5%
(w/v) BSA, filtered through a 0.22µm filter and incubated with cells for 15 minutes at
RT. Primary antibody dilutions are listed in Table 5. Secondary antibodies conjugated
to either Alexa 488 or 546 were diluted 1:500.
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2.1.7.

35

S-metabolic labeling of parasites. T75 flasks containing confluent HFF

monolayers were inoculated with approximately 2x107 parasites and grown for
approximately 16 hours at 37°C in 5% CO2. The 1% (v/v) DMEM was replaced with
cysteine/methionine free DMEM containing 1% (v/v) dialysed FCS and 500µCi
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Easy tag protein labeling mix (Perkin Elmer, Waltham, MA) and incubated for 24
hours until parasite egress.
2.1.8. Compound storage and use. All small molecule inhibitors were bought
from ChemBridge Corporation or synthesized by Federica Catti (where indicated) and
stored at - 20°C. Compound stocks were dissolved to a concentration of 40mM in high
quality DMSO and stored in the dark at -20C. Unless otherwise noted, compounds were
diluted to 100µM concentration in Hanks buffered salt solution before use.

2.2. Chapter 3 Methods
2.2.1. Effect of small molecule inhibitors on TgGAP45 phosphorylation.
Parasites were treated with 100µM small molecule for 15 minutes at RT followed by
protein solubilisation using the octylglucoside method. Proteins were resolved by 2D
gel electrophoresis on 18cm strips, pH 4.5-5.5, and TgGAP45 phosphorylation trains
were visualized by anti-TgGAP45 western blot.
2.2.2. Isolation of myosin for in vitro motility assay. A protein preparation
enriched for the glideosome was isolated by actin co-sedimentation. Parasite proteins
were extracted in actin buffer (0.5% (v/v) TX-100, 25mM KCl, 1mM EGTA, 10mM
DTT, 25mM Imidazole pH7.4, 4mM MgCl2) on ice for ten minutes. Insoluble proteins
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were removed by centrifugation at 100,000xg for 20 minutes at 4°C. To enrich for
myosin A, soluble proteins were incubated with approximately 0.2mg rabbit actin
filaments (Cytoskeleton Inc, Denver CO) at RT for 10 minutes and centrifuged at
100,000xg for 20 minutes at 4°C. Soluble proteins were discarded and actin filaments
were incubated in actin buffer containing 1mM ATP for 10 minutes at RT to release
functional myosin from actin filaments. Actin filaments were removed by
centrifugation at 100,000xg for 20 minutes at 4°C.
2.2.3. Actin filament polymerization. 1mg of G-actin (Cytoskeleton) was
reconstituted in 100µl ultra pure water and then diluted in 1.9mls of actin resuspension
buffer (5mM Tris pH 8, 0.2mM CaCl2, 0.2mM ATP, 0.5mM DTT). Actin was
incubated on ice for 30 minutes and centrifuged at 100,000xg for 60 minutes to remove
any insoluble actin. Actin was polymerized with the addition of 80µl of actin
polymerization buffer (2.5M KCl, 100mM MgCl2, 50mM ATP) and incubated on ice
for 60 minutes. Actin filaments were stabilized with phalloidin at a final concentration
of 100µM.
2.2.4. In vitro motility assays. Protein extracts enriched for the glideosome were
added to flow cells (Warshaw et al., 1990) and incubated for 2 minutes to allow protein
to adhere to nitrocellulose-coated coverslips. Flow cells were washed with actin buffer
containing 0.5mg/ml BSA. Actin buffer containing 1µM actin was added to the flow
cell and incubated for 1 minute at 30°C to allow myosin heads time to bind actin. Flow
cells were washed 3 times in actin buffer containing 1mM ATP to release actin
filaments from functional myosin. Flow cells were washed with actin buffer 3 times.
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Flow cells were twice infused with TRITC-labeled actin filaments and incubated for 30
seconds. Finally, flow cells were washed with actin buffer containing 0.5% (v/v)
methylcellulose and 1mM ATP. Myosin activity was monitored by video microscopy
and actin filament velocities were determined as previously described (Work and
Warshaw, 1992).
2.2.5. Expression of TgMyoA in baculovirus. MyoA full length (FL) or MyoA
motor domain (MD) (amino acids 1-777) were cloned into a modified pVL vector
(Invitrogen) in frame with a C-terminal Flag tag using NcoI and BamHI restriction
sites. Full length TgMLC1 was cloned into a pAcSG2 vector (BD Biosciences) using
EcoRI and BglII restriction sites. Recombinant baculovirus encoding TgMyoA and
TgMLC1 constructs were isolated by as previously described (O'Reilly, 1992). Sf9
cells in suspension culture were infected with recombinant virus coding for TgMyoA
+/- TgMLC1 and harvested 3 days later. Sf9 cells were lysed by sonication in lysis
buffer (10mM imidizole pH 7.2, 300mM NaCl, 2mM EGTA, 5mM MgCl2, 7% (w/v)
sucrose, 3mM NaN3). Extracts were clarified by centrifugation and TgMyoA was
purified using a Flag affinity resin as previously described (Krementsov et al., 2004).
2.2.6. Visualization of MyoA localization in Sf9 cells by immunofluoresence
assay. Sf9 cells were allowed to settle on Cell-tak-treated coverslips for 30 minutes in
PBS. Cells were fixed in 70% (v/v) acetone, 30% (v/v) methanol for 10 minutes. Cells
were washed 3 times in PBS and incubated for 60 minutes at RT with 1µg/ml of antiFlag Ab (Sigma) diluted in 1XPBS containing 0.5% (w/v) BSA. Cells were washed 3
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times with PBS followed by incubation in goat anti-mouse Alexa 488 (Invitrogen)
diluted 1:500 in PBS containing 0.5% (w/v) BSA.
2.2.7. Fractionation of proteins from Sf9 cells. 5x106 Sf9 cells were extracted in
200ul of lysis buffer (50mM Tris pH 8, 150mM NaCl and 5mM EDTA, 1:100 protease
inhibitors) containing 2% (w/v) Chaps, 0.5% (v/v) NP-40 and 1% (w/v) Octylglucoside
on ice for 30 minutes, or by sonication (Fisher Scientific, Sonic dismembranator Model
100) with a fine probe, using 4 x 20 second 10 watt bursts with 1 minute incubation on
ice between bursts. Soluble and insoluble proteins were separated by centrifugation at
100,000xg for 20 minutes. 3x105 cell equivalents were resolved on 12% SDS PAGE
gels. MyoA was visualized by anti-Flag western blot and TgMLC1 was visualized by
anti-TgMLC1 western blot.
2.2.8. Effect of small molecules on the composition of the glideosome.
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labeled parasites were treated with 100µM compound for 15 minutes at RT and the
glideosome was isolated by anti-GAP45 immunoprecipitation as described above
(section 2.1.5). Proteins were resolved by SDS PAGE and visualized by
autoradiography (Carey, 2004).
2.2.9. Time course assay. 2x107 parasites were treated with DMSO or 100µM
115556 for various times as indicated. Parasites were pelleted at 6500xg for 4 minutes
and boiled in 1xSB with 1.25% (v/v) βME. Proteins were resolved on 12% SDS PAGE
gels, transferred to Protran (GE Healthcare) nitrocellulose membranes and visualized
by anti-TgMLC1 western blotting.
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2.2.10 Reversibility assay. 2x107 extracellular parasites were treated with
DMSO or 100µM 115556 for 15 minute at RT. Parasites were pelleted at 6500xg for 4
minutes and resuspended in compound-free Hanks buffer for varying times as
indicated. Parasites were pelleted at 6500xg for 4 minutes and boiled in 1xSB
containing 1.25% (v/v) βME. Intracellular parasites were grown in confluent HFF
monolayers for 24 hours. 1% DMEM was removed from flasks and replaced with 1%
DMEM containing DMSO or 100µM 115556 and incubated for 15 minutes. The media
was removed and replaced with compound-free DMEM for the times indicated. All
incubations with intracellular parasites were done at 37°C in 5% CO2. Infected cells
were harvested by scraping, pelleted at 6500xg and resuspended in 1xSB containing
1.25% (v/v) βME. Proteins were resolved on 12% SDS PAGE gels, transferred to
nitrocellulose and TgMLC1 was visualized by anti-TgMLC1 western blot.
2.2.11. Effect of 115556 on isolated glideosomes.
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S-labeled parasites were

treated with DMSO or 115556 and glideosomes isolated by anti-TgGAP45 IP as
described above in section 2.2.4.
Glideosome proteins attached to the protein A beads were treated with DMSO
or 100µM 115556 for 15 minutes at RT. Proteins were eluted from beads by boiling in
1xSB containing 1.25% (v/v) βME; proteins were resolved by SDS PAGE and
visualized by autoradiography.
2.2.12. Effect of DTT on the resolution of the modified form of TgMLC1.
Parasites were treated with DMSO or 100µM 115556 as described above. Parasites
were lysed by boiling in 1xSB in either the presence or absence of 50mM DTT.
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Proteins were resolved on 12% SDS PAGE gels, transferred to nitrocellulose and
visualized by anti-TgMLC1 western blot.
2.2.13. Effect of SDS and DTT on glideosome composition.
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parasites were extracted 150mM NaCl, 50mM Tris pH8 containing 0.5% (v/v) SDS or
2% (v/v) SDS or 0.5% (v/v) SDS/100mM DTT. Samples were boiled for 5 minutes and
diluted with 10 volumes of IP lysis buffer. Glideosomes were isolated by anti-GAP45
IP. Proteins were resolved on 12% SDS PAGE gels, transferred to PVDF membranes
and visualized by autoradiography.
2.2.14. Effect of 115556 on glideosome oligomerization. Glideosomes were
isolated from
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S-labeled parasites expressing myc- TgMLC1 by either anti-GAP45 or

anti-myc IP. Proteins were resolved by 2D gel electrophoresis on 18cm strips, pH 4-7
and transferred to PVDF following resolution on second dimension 12% SDS PAGE
gels. Proteins visualized by autoradiography.
2.2.15. Bradyzoite induction. Freshly lysed RH ΔHXGPRT ΔUPRT (deleted
at both HXGPRT and UPRT loci; (Bohne and Roos, 1997)) tachyzoites were grown on
confluent HFF monolayers in either T25 tissue culture flasks or coverslips in a 6-well
tissue culture plate in minimal essential medium without NaHCO3 (Invitrogen) but
containing 25 mm HEPES pH7 (Invitogen) (Matrajt et al., 2004).

Flasks were

incubated in 0.03% CO2 for 2-5 days. Parasites were fixed with 2% (v/v) formaldehyde
and permeabilized with 0.25% (v/v) TX-100 (Pierce). Expression of TgMLC1 was
detected by immunofluoresence microscopy using rabbit anti-TgMLC1 antibody and
goat

anti-rabbit

secondary

antibody

conjugated
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to

Alexa-488

(Invitrogen).

Differentiation of tachyzoites to bradyzoites was determined by visualization of the
bradyzoite cyst wall using tetramethyl rhodamine isothiocyanate (TRITC)-labeled
Dolichos biflorus lectin (Boothroyd et al., 1997).

2.3. Chapter 4 Methods
2.3.1. Effect of alkaline phosphatase on electrophoretic migration of TgMLC1.
To determine if alkaline phosphatase (AP) can replicate the electrophoretic mobility
shift of TgMLC1 the glideosome was immunoprecipitated from 35S-labeled parasites.
Protein A beads were incubated in 300ul AP buffer (10mM Tris pH 7.4, 1mM MgCl2,
0.1mM ZnCl2) in the presence or absence of 150U of bovine alkaline phosphatase
(Sigma) at 37°C for 30 minutes. Proteins were resolved by 2D gel electrophoresis on
18cm, pH 4.5-5.5 strips. Proteins were transferred to PVDF membranes following
resolution on 12% SDS PAGE gels and visualized by autoradiography.
2.3.2. RNA Isolation and cDNA synthesis. 8x107 parasites were extracted in
1ml of Trizol Reagent (USB, Cleveland, OH) for 5 minutes at RT. 1/5 volume of
chloroform was added and samples were incubated at RT for 2-3 minutes. Samples
were centrifuged at 12,000xg for 15 minutes at 4°C. The upper aqueous phase was
removed into a clean tube and incubated with 500µl of isopropanol at RT for 10
minutes. Samples were centrifuged at 12,000xg for 10 minutes at 4°C. The supernatant
was removing and RNA pellets were washed in 1ml of 75% (v/v) ethanol and
centrifuged at 7,500xg for 5 minutes at 4°C. The ethanol was removed and RNA pellets
were dryed before resuspended in 200µl of double distilled H2O.
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cDNA was synthesized using the first strand cDNA synthesis kit (Invitrogen).
5µg of RNA was incubated with 10mM dNTP, Oligo dT Primer, 10x reverse
transcriptase reaction buffer, 25mM MgCl2, 0.1mM DTT and RNase out. Samples were
incubated at 42°C for 2 minutes, 1µl Superscript reverse transcriptase II enzyme was
added to the samples and incubated at 42°C for 50 minutes. The reaction was stopped
by incubating samples at 70°C for 15 minutes.
2.3.3. Cloning of N- and C-terminally tagged myc-TgMLC1 into the TgTUB
vector. TgMLC1 was amplified from total parasite cDNA using primer sets mycTgMLC1 5’/ TgMLC1 3’A and TgMLC1 5’ B/ TgMLC1-myc 3’. TgMLC1 PCR
products were cloned in Topo TA vector (Sigma) as per manufacturers instructions.
TgMLC1 was subsequently subcloned from the Topo TA vector into a T. gondii
expression vector pTgTUB with BglII and AvriII restriction sites (Figure 8). From this
vector proteins are expressed under the control of a tubulin promter. The 3’UTR of the
SAG1 gene is present on the plasmid downstream of the NotI restriction site. Parasites
were selected with chloramphenicol after 24 hours of growth in drug-free media.
2.3.4. Determination of TgMLC1 mRNA sequence from DMSO- and 115556treated parasites. Parasites were treated with DMSO or 100µM 115556 for 15 minutes
at RT. Total RNA was isolated as described above in section 2.4.2. TgMLC1 cDNA
was produced using TgMLC1 UTR 5’ and TgMLC1 UTR 3’ primers. The sequences of
the TgMyoA cDNA from DMSO- and 115556- treated parasites were compared to the
predicted mRNA sequence from ToxoDB using Sequencher software (Gene Codes
Corp, Ann Arbor, MI).
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2.3.5. Isolation of TgMLC1 for mass spectrometry analysis by differential
detergent fractionation. 2x109 freshly egressed tachyzoites were treated with 100µM
115556 for 20 minutes at RT. Parasites were extracted in 1% (v/v) TX-100 in PBS on
ice for 10 minutes. Proteins were layered over a cushion of PBS containing 15% (v/v)
glycerol. Insoluble proteins were pelleted for 10 minutes at 16,300xg in a Sorvall HB-6
swinging bucket rotor at 4°C. Soluble proteins were discarded and insoluble proteins
were resuspended in PBS containing 1% (v/v) deoxycholate (DOC) for 10 minutes on
ice and centrifuged as above. Soluble proteins were acetone precipitated overnight at 20°C. Protein pellets were solubilised for 2D gel electrophoresis using the
octylglucoside method. Gels were stained with Coomassie brilliant blue and TgMLC1
spots were cut from the gel in preparation for in-gel digestion with trypsin or
chymotrypsin. A schematic diagram of this extraction procedure is shown in Figure 24.
2.3.6. Cloning of TgMLC1 truncation mutants into the pTgTUB vector.
(i) Cloning myc-TgMLC180-213 and myc-TgMLC11-196 expression constructs.
Using myc-TgMLC1 Topo plasmid as a template, ΔC and ΔN constructs were made by
amplifying truncated TgMLC1 PCR products with primers myc-TgMLC1 5’/
TgMLC1aa193 3’ and myc- TgMLC1 aa80 5’/ TgMLC1 3’ respectively. PCR products
were cloned in the Topo TA vector and subcloned using BglII and AvrII restriction
sites into pTgTUB (ii) Cloning TgMLC11-79YFP. Using myc- TgMLC1 Topo as a
template, aa1-79 of TgMLC1 were amplified using primers TgMLC1 5’B/ TgMLC179
3’. PCR products were cloned in the Topo TA vector and subcloned using BglII and
AvrII restriction sites into pTgTUB (iii) To create TgMLC120-79YFP, TgMLC140-79YFP
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and TgMLC160-79YFP the TgMLC11-79YFP expression vector was used a template for
PCR. PCR products were amplified using TgMLC1aa20 5’, TgMLC1aa40 5’ or
TgMLC1aa60 5’ as a forward primer and YFP DHFR 3’ as a reverse primer. PCR
products were cloned in the Topo TA vector and subcloned using BglII and NcoI
restriction sites into pTgTUB.
2.3.7. Cloning TgMLC1 point mutants into the pTgTUB vector. All sitedirected mutagenesis experiments were carried out using the Quick-change
mutagenesis kit (Stratagene, La Jolla, CA) as per manufacturers instructions. Briefly,
expression vectors with the desired mutation were amplified using the myc- TgMLC1
expression vector as a template and the high fidelity enzyme Pfu and primer sets
indicated. Parental methylated DNA was digested for 2 hours at 37°C using the enzyme
DpnI. 5µl of a 50µl reaction was transformed in chemically competent DH5α E. coli
cells and grown overnight on LB-ampicillin plates. Plasmids were isolated from clonal
populations of bacterial cells grown in 3ml liquid cultures. The plasmids containing the
desired mutation were identified by restriction digestion and DNA sequencing.
2.3.8. Fatty Acyl Exchange Assay. Parasites were extracted in TgGAP45 IP
buffer containing 15mM iodoacetamide and glideosomes were isolated from
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labeled parasites as above. Following immunoprecipitation, Sepharose beads were
incubated in 1M hydroxylamine, pH 7.4, for 60 minutes. Control samples were
incubated in 1M Tris pH 7.4. Beads were washed three times in 1XPBS and incubated
with 200µM iodoacyl-Biotin (Pierce) for 90 minutes in the dark. Beads were washed
three times in 1xPBS and once in 10mM Tris pH 7.4. Proteins were eluted from the
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beads with octyl buffer and resolved by 2D gel electrophoresis. Total protein was
visualized by audioradiography and biotinylated proteins were visualized by
streptavidin western blot.

2.4. Chapter 5 Methods
2.4.1. Actin co-sedimentation. After treatment with DMSO or 115556, parasites
were extracted in actin buffer containing 0.5% (v/v) TX-100 on ice for 10 minutes.
Insoluble proteins were removed by centrifugation at 100,000xg for 20 minutes at 4°C.
Soluble proteins were incubated with F-actin for 10 minutes at RT in the presence or
absence of 1mM ATP. F-actin was pelleted at 100,000xg for 20 minutes at 4°C.
Proteins in the supernatant and pellet were resolved on 12% SDS PAGE gels. Total
protein was visualized by silver stain, while TgMLC1 was visualized by anti-TgMLC1
western blot.
2.4.2. Cloning Flag-TgMLC1 WT and Flag-TgMLC1 K94A into the TgTUB
vector. Using myc-TgMLC1 WT and myc-TgMLC1 K94A expression vectors as
template Flag-TgMLC1WT and Flag-TgMLC1 K94A were amplified by PCR using
primers Flag-TgMLC1 5’ and TgMLC1 3’. PCR products were cloned into Vector T
(Promega), digested with AvrII and BglII and subcloned into TgTUB.
2.4.3. Isolation of glideosomes using Flag affinity resin. Aproximately 5x109
parasites were treated with DMSO or 115556 and extracted in 3mls Flag lysis buffer
(10mM imidazole pH 7, 300mM NaCl, 1mM EGTA, 5mM MgCl2, 1% (v/v) TX-100,
1mM ATP, 2mM DTT and 1:100 protease inhibitor cocktail) on ice for 10 minutes.
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Protein extracts were clarified at 12,000xg for 30 minutes. Before use, Flag resin
(Sigma) was equilibrated in 0.1M glycine pH 3.5 as per manufacturer’s instructions.
Protein extracts and approximately 400ul Flag resin were agitated for 2 hours at 4°C.
Resins were extensively washed with Flag wash buffer (10mM Imidazole pH 7,
300mM NaCl, 1mM EDTA, 1mM DTT, 1% (v/v) TX-100 and 1: 5,000 protease
inhibitors) to remove any unbound proteins and Flag-TgMLC1 was eluted from
columns using 100ul 0.1mg/ml Flag peptide (Sigma) agitated for 10 minutes.
Remaining protein bound to the beads was eluted with a second wash of 50ul of
0.1mg/ml Flag peptide. Elutions were combined before storage and use. Proteins were
stored on ice or diluted with 1/3 volume 100% (v/v) glycerol and stored at -20°C before
use in functional assays
2.4.4. In vitro motility and force assays. In-vitro motility assays were performed
as described in section 2.2.3. Force assays were performed as in Malmqvist et al., 2004.
Prior to performing the assays, lysophilised α-actinin (Cytoskeleon) was reconstituted
in ultra-pure water to a concentration of 1µg/µl. To perform force assays, glideosomes
were added to flow-cells and incubated for 4 minutes. Flow cells were washed 3 times
in actin buffer and then α-actinin (Cytoskeleton) diluted in actin buffer was infused into
the chamber. After 1 minute, the flow cells were blocked by washing three times with
0.5mg/ml BSA diluted in actin buffer. Slides were washed with actin buffer before the
addition of TRITC-labeled actin filaments with one repeat. Myosin activity was
analyzed in 1x actin buffer containing 0.5% (v/v) methylcellulose and 1mM ATP.
Filament velocities were analyzed as previously described (Work and Warshaw, 1992).
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2.5. Chapter 6 Methods
Differential Gel Electrophoresis (DIGE) 3x107 parasites were treated with either
DMSO or 115556 for 15 minutes at RT. Parasites were extracted in 25µl DIGE lysis
buffer (10mM Tris pH 7.4, 7M Urea, 2M Thiourea, 1% (w/v) ASB14 (Calbiochem)) at
RT for 10 minutes. Insoluble proteins were removed by centrifugation at 12,000xg for
10 minutes at RT. Soluble proteins were added to a clean tube with 200 or 400pmol of
CyDyes 2, 3 or 5 and incubated at RT in the dark for 30 minutes. The labeling reaction
was stopped by incubating with 1µl of 10mM L-lysine for 10 minutes in the dark.
Proteins samples were combined and brought to a total volume of 200ul with DIGE
rehydration buffer (7M Urea, 2M thiourea, 1% (w/v) ASB14 and 26mM DTT). IPG
strips were rehydrated overnight in the protein sample at 20°C and 2D gel protocol was
continued as above (section 2.1.4). Following SDS PAGE, gels were fixed for 10
minutes in 50% (v/v) methanol, 10% (v/v) acetic acid and washed twice in double
distilled H20. Proteins were visualized using the Biorad FX-Imager on the Cy2 and Cy3
channels at 200nm resolution. Images were exported as TIFFs and then pseudocoloured
red and green respectively in Adobe Photoshop X. When the images were merged,
proteins expressed at equal levels in the parasites appear yellow. Proteins expressed at
higher levels in DMSO-treated parasites are labeled red and proteins expressed at
higher levels in 115556-treated parasites appear green. For mass spectrometry
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identification of proteins, gels were Coomassie stained and the spots excised for trypsin
digestion.

Table 2. T. gondii lines
Parasite Line

Selectable
Marker

RH

Comments
Wildtype

Myc- TgMLC1

Chloramphenicol

TgMLC1-myc

Chloramphenicol

Myc-TgMLC1C8/11S

Chloramphenicol

Myc- TgMLC1C53S

Pyrimethamine

MycTgMLC1C58S

Pyrimethamine

Myc-TgMLC1K3/6/7R

Chloramphenicol

Myc-TgMLC1
K3A

Pyrimethamine

Myc-TgMLC1K6/7A

Chloramphenicol

Myc-TgMLC1E5A

Chloramphenicol

Myc-TgMLC1
K95A

Chloramphenicol

Flag-TgMLC1

Chloramphenicol

Flag-TgMLC1
K95A

Chloramphenicol

RH parasites
expressing Nterminally tagged
myc TgMLC1
RH parasites
expressing Cterminally tagged
myc TgMLC1
Myc- TgMLC1
with C8 and C11
mutated to serine
Myc- TgMLC1
with C53 mutated
to serine
Myc- TgMLC1
with C58S mutated
to serine
Myc- TgMLC1
with K3, K6 and
K7 mutated to
arginine
Myc- TgMLC1
with K3 mutated to
alanine
Myc- TgMLC1
with K6 and K7
mutated to alanine
MycTgMLC1with E5
mutated to alanine
Myc- TgMLC1
with K94 mutated
to alanine
RH parasites
expressing Nterminally tagged
Flag TgMLC1
Flag- TgMLC1
with K95 mutated
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Reference
Roos et al 1994

TgMLC11-79YFP

Pyrimethamine

TgMLC140-79YFP

Chloramphenicol

TgMLC160-79YFP

Chloramphenicol

Myc-TgMLC11-196

Chloramphenicol

Myc-TgMLC180-

Chloramphenicol

213

RH ΔHXGPRT
ΔUPRT

to alanine
aa1-79 of
TgMLC1tagged to
the N-terminus
YFP
aa40-79 of
TgMLC1 tagged to
the N-terminus
YFP
aa60-79 of
TgMLC1 tagged to
the N-terminus
YFP
Myc- TgMLC1
with aa 197-213
deleted
Myc- TgMLC1
with aa 1-79
deleted
Disrupted in both
HXGPRT and
UPRT loci
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Bohne and Roos,
1997

Table 3. Programs used to resolve proteins by 2D gel electrophoresis on 18 and
11cm strips

Step
1
2
3
4
5
6
7
1
2
3
4

18cm Strip program
Voltage
Duration
500V
30 minutes
1000V
30 minutes
3000V
1 hour
6000V
1 hour
8000V
1 hour
10000V
40,000 V hrs
500V
Hold
11cm Strip program
250V
30 minutes
8000V
2.5 hrs
8000V
3500 V hrs
500V
Hold

Table 4. Volumes of buffers used for protein solubilisation by octylglucoside method

Buffer
Lysis
SDS
Octylglucoside
Ampholytes
# of parasites

11cm
Volume (µl)
24
16
160
1
2x107
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18cm
Volume (µl)
42
27
262
1.65
3x107

Table 5. Summary of antibodies used for western blotting (WB), immunofluoresence
assays (IFA) and immunoprecipitation (IP)

Antibody
Rabbit antiTgMLC1
Rabbit antiTgGAP45
Mouse IgM antiactin
Mouse anti-myc
Clone 9E10
Mouse antiTgAMA1 B3-90
Mouse antiTgIMC1
Mouse anti-Flag
Rabbit anti-GFP

Source
C. Beckers

Dilution for WB
1:2,000

Dilution for IFA
1:500

Dilution for IP
1:500

C. Beckers

1:1,000

1:1,000

1:1,000

Oncogene

1:1,000

-

-

Green Mountain
Antibodies
Green Mountain
Antibodies
Green Mountain
Antibodies
Sigma
Invitrogen

1:2,000

1:1,000

1:2,000

1: 1,000

1:1,000

-

-

1:1000

-

1:7,500
1:1000

1:500
1:500

-
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Table 6. Primers used to produce TgMLC1 and TgMyoA expression construct
Name
TgMLC1 5’
B
TgMLC1 5’
E
TgMLC1 3’
A
TgMLC1 3’
B
MycTgMLC1 5’

Sequence
GGAAGATCTATGAGCAAGGTCGAGAAG

6

TgMLC1
myc 3’

CCTCCTAGGTTACAGGTCCTCCTCGGAGATG
AGCTTCTGCTCCTCCCTTCGCTCGAGC

7

Flag
TgMLC1 5’

AGATCTATGGATTACAAGGATGACGACGATAA
GATGAGCAAGGTCGAGAAC

8

TgMLC1
79 3’
TgMLC1
K3/6/7R 5’

CCTCCTAGGCTCCACCATCTCCTCGAGAG

10

TgMLC1
K3/6/7R 3’

CACCGGGCATCTTCTCTCGACTCTGCTCAT

11

TgMLC1
K3A 5’

ATGAGCGCGGTCGAGAAGAAATGCCCGGTG

12

TgMLC1
K3A 3’

CACCGGGCATTTCTTCTCGACCGCGCTCAT

13

TgMLC1
K6/7A 5’

ATGAGCAAGGTCGAGGCGGCATGCCCGGTG

14

TgMLC1
K6/7A 3’

CACCGGGCATGCCGCCTCGACCTTGCTCAT

15

TgMLC1
E5A 5’

ATGAGCAAGGTCGCGAAGAAATGCCCGGTG

16

TgMLC1
E5A 3’

CACCGGGCATTTCTTCGCGACCTTGCTCAT

17

TgMLC1
C8/11S 5’

TCGAGAAGAAAAGCCCGGTGAGCTACCA

18

TgMLC1
8/11S 3’

TGGTAGCTCACCGGGCTTTTCTTCTCGA

1
2
3
4
5

9

CATGGAATTCATGAGCAAGGTCGAGAAGA
CCTCCTAGGTTACTCCCTTCGCTCG
CATGAGATCTTGATTACTCCCTTCGCTCGAG
GGAAGATCTATGGAGCAGAAGCTCATCTC
CGAGGAGGACCTGAGCAAGGTCGAGAAG

ATGAGCAGAGTCGAGAGAAGATGCCCGGTG
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Target
5’ coding region of
TgMLC1 with BglII site
5’ coding region of
TgMLC1 with EcoRI site
3’ coding region of
TgMLC1 with AvrII site
3’ coding region of
TgMLC1 with BglII site
5’ coding region of
TgMLC1 with 5’ myc tag
coding sequence
3’ coding region of
TgMLC1 with 3’ myc tag
coding sequence
5’ coding region of
TgMLC1 with 5’ Flag tag
coding sequence
TgMLC1 coding region
binding from codon 79
Site directed mutagenesis
for primer for mutation of
aa 3, 6, 7
Site directed mutagenesis
rev primer for mutation
of aa 3, 6, 7
Site directed mutagenesis
for primer for mutation of
aa 3
Site directed mutagenesis
rev primer for mutation
of aa 3, 6, 7
Site directed mutagenesis
for primer for mutation of
aa 6, 7
Site directed mutagenesis
rev primer for mutation
of aa 6, 7
Site directed mutagenesis
for primer for mutation of
aa 5
Site directed mutagenesis
rev primer for mutation
of aa 5
Site directed mutagenesis
for primer for mutation of
aa 8, 11
Site directed mutagenesis
rev primer for mutation

19

TgMLC1
C53S 5’

ATGGTGCCAGCGAGTCGCCCT

20

TgMLC1
C53S 3’

AGGGCGACTCGCTGGCACCAT

21

TgMLC1
C58S 5’

CCTGTGAGTCGCCCTCTAGCCGCGAGG

22

TgMLC1
C58S 3’

CCTCGCGGCTAGAGGGCGACTCACAGG

23

TgMLC1
K94A 5’

TTCCGGAGGAGCGGTATCCACGGGA

24

TgMLC1
K94A 3’

TCCCGTGGATACCGCTCCTCCGGAA

25

TgMLC1
UTR 5’

AACGAAATTGTCCAGCCTT

26

TgMLC1
UTR 3’

AAACAGCTGTCCACACACAAA

27

Myc
TgMLC1
aa80 5’

GGAAGATCTATGGAGCAGAAGCTCATCTCCGA
GGAGGACCTGGCCGACGAAATGTATGCGCG

28

TgMLC1
aa 193 3’

CCTCCTAAGTTAGAAGTACTCCGCAGCCAA

29

TgMLC1
aa 20 5’

AGATCTATGGTTCTGGGTCCGATGGACAAG

30

TgMLC1
aa 40 5’

AGATCTATGCGCCCGGAACCGAAGGTGGGGGA
GTA

31

TgMLC1
aa 60 5’

AGATCTATGGAGGGGGGGCGCCCTGCGGCAGA
CGAA

32

YFP DHFR
3’

TGGCGGCCGCTCTAGAACTAGTGGAT

33

TgMyoA 5’

CATGCCATGGCGAGCAAGACCACGTC

34

TgMyoA
motor 3’

CGCGGATCCAGAAAGGCATTCTCTCTGAATCTG
C

35

TgMyoA
full 3’

CGCGGATCCGAACGCCGGCTGAACAG
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of aa 8, 11
Site directed mutagenesis
for primer for mutation of
aa 53
Site directed mutagenesis
rev primer for mutation
of aa 53
Site directed mutagenesis
for primer for mutation of
aa 58
Site directed mutagenesis
rev primer for mutation
of aa 58
Site directed mutagenesis
for primer for mutation of
aa 94
Site directed mutagenesis
rev primer for mutation
of aa 94
Binds 28bp upstream of
TgMLC1 ATG start in 5’
UTR
Binds 34bp downstream
of TgMLC1 stop codon
in 3’ UTR
Binds to TgMLC1 coding
region starting at codon
80 with 5’ myc coding
sequence
Binds to TgMLC1 coding
region starting at codon
193
Binding to TgMLC1
coding region starting at
codon 20
Binding to TgMLC1
coding region starting at
codon 40
Binding to TgMLC1
coding region starting at
codon 60
Binds 3’ YFP coding
sequence in IMC1-YFP
plasmid
Binds to the 5’ coding
sequence of MyoA with
EcoRI site
Binds to the coding
sequence of MyoA
starting at aa 777
Binds to the 3’ coding
sequence of MyoA with

NcoI site
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Figure 8. Plasmid map of the T. gondii expression vector pTgTUB.
TgMLC1 (pink) is expressed under the control of the T. gondii tubulin promoter (blue).
The 3’ UTR of the DHFR gene (not shown) is present upstream of the NotI site.
Parasites containing the plasmid can be selected for due to the presence of a
chloramphenicol acetyltransferase gene (red).
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CHAPTER 3: IDENTIFICATION OF SMALL MOLECULES THAT AFFECT
THE T. GONDII GLIDEOSOME
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3.1. Introduction
T. gondii motility is essential for host cell invasion and therefore parasite
survival. A complex of four major proteins, termed the glideosome, drives motility.
TgMyoA is an unconventional class XIV myosin. Its associated light chain, TgMLC1,
binds to a degenerate IQ motif in the TgMyoA tail. TgMyoA, TgMLC1 and another
associated protein, TgGAP45, are anchored to the outer membrane of the IMC through
an interaction with the transmembrane protein TgGAP50 (Gaskins et al., 2004). While
the components of the glideosome and their functions have been characterized at a
rudimentary level, much is still unknown about the functioning and regulation of this
protein complex. For example what role does TgMLC1 play in regulating TgMyoA
activity? What is the role of TgGAP45 and how does TgGAP45 phosphorylation alter
the activity of the complex? How is the “proto-glideosome” (Gaskins et al 2004)
trafficked from the cytosol to the IMC? Are there other as of yet uncharacterized
glideosome components?
Since many of the small molecule inhibitors and enhancers of invasion also
affect parasite motility, we hypothesized that some of these molecules may exert their
effects by altering glideosome activity. By identifying the targets of these small
molecules we can gain a greater understanding of how motility is regulated in the
parasite.
Some of what we already know about motility and invasion has been learned
from experiments with small molecule inhibitors of these processes. Myosin and actin
were originally implicated in parasite motility and invasion by experiments showing
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that these processes could be inhibited by either cytochalasin D (an inhibitor of actin
polymerization) and BDM (an inhibitor of myosin ATPase activity) (Dobrowolski and
Sibley, 1996; Meissner et al., 2002).
Compound 1, a potent inhibitor of parasite cGMP-dependent protein kinase
(PKG), inhibits T. gondii and E. tenella invasion, motility and microneme secretion
(Wiersma et al., 2004). The identification of PKG as the target of compound 1 was an
important discovery since very little is known about the signaling pathways that
regulate parasite motility and invasion. Compound 1 has a high degree of selectivity for
parasite PKG compared to bovine or chicken PKG, making this protein an attractive
drug target (Wiersma et al., 2004).
KT5926, an inhibitor of calcium dependent protein kinase and myosin light
chain kinase in other systems, inhibits the activity of T. gondii calcium dependent
protein kinase, TgCDPK1 (Kieschnick et al., 2001). Treating T. gondii parasites with
this compound inhibits parasite motility and attachment to host cells, and inhibits
phosphorylation of three target proteins of TgCDPK1. Unfortunately the identity of
these proteins has not be elucidated and it is therefore not known if TgCDPK1 is
responsible for phosphorylating glideosome components either directly or indirectly
(Kieschnick et al., 2001). However, PfCDPK1 has recently been shown to
phosphorylate PfMTIP in vitro (Kato et al., 2008).
Identification of the targets of pharmacological inhibitors provides valuable
information about proteins involved in a given biological process. A second advantage
of the pharmacological approach is that once the compound’s target has been identified
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in one system it is relatively easy to determine if the compound affects another
biological system, immediately implicating the compound’s target in that process. It is
necessary to verify that the small molecule is active against the same protein in each
case, but these experiments provide a good “jumping-off point” for investigations into
novel biological processes. Several of the effectors of T. gondii invasion identified in
the lab show similar activity against other apicomplexan parasites (G. Ward,
unpublished data). Once the targets of these compounds are determined it will be
possible to identify similarities and differences that exist between the processes of
invasion in apicomplexan parasites.
In an effort to learn more about how the inhibitors and enhancers of parasite
motility exert their effects, we performed a number of assays to determine if any of the
small molecules affect components of the parasite glideosome.
Assay 1: Do any of the small molecules alter TgGAP45 phosphorylation?
TgGAP45 is a 27kDa protein but is so named because it resolves on SDS PAGE gels
with an apparent molecular weight of 45kDa (Gaskins et al., 2004). TgGAP45 is
phosphorylated on at least 4 residues that can be resolved by 2D gel electrophoresis.
Mass spectrometry analysis revealed that serine 163 and 167 are phosphorylated
residues (S. Gilk and G. Ward, unpublished data). The other phosphorylation sites have
not been identified. TgGAP45 is expressed in the parasite cytosol where it binds to both
TgMLC1 and TgMyoA. Deletion of the last 57 amino acids of the TgMyoA tail
abrogates TgGAP45 binding (Herm-Gotz et al., 2002), however it is not known if
TgGAP45 binds directly to TgMyoA or if this interaction is mediated by TgMLC1. The
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function of TgGAP45, the effect of phosphorylation on its function and the kinase
responsible for TgGAP45 phosphorylation are all unknown. In an effort to learn more
about this protein we sought to determine if any of the small molecules that affect
motility affect TgGAP45 phosphorylation.
Assay 2: Do any of the small molecule inhibitors or enhancers of motility affect
TgMyoA function in the in vitro motility assay? TgMyoA can displace actin filaments
in vitro with velocities of approximately 5µm/s (Herm-Gotz et al., 2002) a speed
similar to that of fast skeletal muscle myosin. Parasites deficient in TgMyoA cannot
move or invade host cells (Meissner et al 2002), therefore parasites where TgMyoA
function is chemically inhibited should display the same phenotype. In an effort to
determine if any of the small molecules inhibit myosin function, the activity of
glideosome-associated myosin in the presence of each of the small molecules was
assessed in an in vitro motility assay.
Assay 3: Identification of small molecules that inhibit recombinant TgMyoA.
The protein sequence of TgMyoA differs significantly from that of vertebrate myosins
with only 23-34% identity to the head domains of other myosins (Heintzelman and
Schwartzman, 1997). Therefore it may be possible to find a small molecule that inhibits
TgMyoA function without significantly affecting the function of other myosin types.
Since MyoA is likely to be an essential gene in a number of parasite species, such a
compound has the potential to be a good antiparasitic drug effective against not only T.
gondii but other apicomplexan parasites as well. New treatments for these infections
are urgently needed as current therapies have profound side effects and there is an
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increasing prevalence of resistance to current therapeutics. To identify a small molecule
inhibitor of TgMyoA many thousands of compounds would need to be screened in a
high throughput assay. This would require large amounts of protein, much more than
could be realistically isolated from intact parasites. Therefore we attempted to
recombinately express the TgMyoA motor domain and full length TgMyoA in the
presence or absence of TgMLC1 using the baculovirus system. In addition to
facilitating high throughput screening for TgMyoA inhibitors, production of large
amounts of recombinantly expressed TgMyoA would allow in depth biophysical
characterization of this protein, providing insight into the workings of this
unconventional myosin.
Assay 4: Do any of the small molecules affect the composition of the
glideosome? The glideosome consists of four proteins: TgMyoA; TgMLC1; TgGAP45;
and TgGAP50. The function of these proteins has not been characterized in detail and
the topology of interactions between the glideosome components is unknown.
Identification of inhibitors that affect the glideosome composition may shed light on
some of these questions.

3.2. Results
3.2.1.

Do

any

of

the

small

molecule

inhibitors

affect

TgGAP45

phosphorylation? When TgGAP45 is resolved by 2D gel electrophoresis, multiple
phosphorylated forms of the protein can be identified (Figure 9a top panel). Treatment
with alkaline phosphatase results in complete collapse of the TgGAP45
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phosphorylation train (Figure 9a, lower panel). To determine if any of the small
molecule inhibitors or enhancers affected TgGAP45 phosporylation, parasites were
treated with each of the small molecules, proteins were resolved by 2D gel
electrophoresis and the TgGAP45 phosphorylation train was visualized by anti-GAP45
western blot. None of the compounds significantly altered the phosphorylation train.
Three representative images are shown in Figure 9b. The abundance of the leftmost
spot varies from gel to gel in both DMSO-treated and compound-treated samples, most
likely due to slight variability in the amount of protein present and the resolution of the
gels.
3.2.2. Do any of the small molecule inhibitors affect TgMyoA function in the in
vitro motility assay? Parasite extract enriched for the glideosome was prepared by actin
co-sedimentation in the absence of ATP and then release of the glideosome from the
pelleted actin filaments with ATP. TgMyoA purified in this way can displace actin
filaments at velocities of approximately 5µm/s in an in vitro motility assay. Using this
assay each small molecule was tested for its ability to inhibit motility. Motility was
inhibited by only one of the compounds, 137846. The structure of 137846 and a
summary of its effects on the parasites are shown in Figure 13 and Table 7 respectively.
137846 completely inhibited movement of actin filaments at concentrations between
100µM and 25µM. Partial inhibition of motility was observed at 12.5µM. Motility was
restored to DMSO-treated levels at concentrations between 6.25 and 3.1µM. To
determine if the effect of 137846 was specific to myosin XIV we assessed the effect of
the compound on skeletal muscle myosin. At a myosin concentration of 50µg/ml,
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137846 inhibited motility at concentrations between 100 and 25µM. Partial inhibition
was seen at 12.5µM.
During the course of these experiments a number of other assays were
performed in an attempt to identify small molecules that were active against other
parasite proteins. 137846 inhibited the interaction between MIC2 and aldolase in vitro
(L. Starnes, G. Ward and D. Sibley, unpublished data). 137846 also inhibited protein
arginine methyltransferase activity in vitro (J. Haraldsen and G. Ward, unpublished
data). It was concluded that 137846 may be non-specifically affecting protein function.
Previous studies have revealed that up to 20% of hits in high-throughput screens can be
false positives due to the prevalence of promiscuous inhibitors in small molecule
collections (Feng et al., 2005). Promiscuous inhibitors are those that non-specifically
inhibit protein function by forming aggregates in aqueous solutions, sequestering
enzymes away from their substrates (Feng and Shoichet, 2006). These small molecule
aggregates are detergent sensitive, so promiscuous inhibitors can be identified by
determining whether they lose their inhibitor activity in the presence of 0.1% - 0.01%
TX-100 (Feng and Shoichet, 2006).
To determine if 137846 was non-specifically inhibiting myosin activity we
tested its effect on skeletal muscle myosin in the in vitro motility assay in the presence
or absence of 0.1% TX-100. At a concentration of 50µg/ml, the activity of skeletal
muscle myosin was only slightly decreased in the presence of 0.1% TX-100 compared
to detergent-free buffer. However, the presence of 0.1% TX-100 completely abrogated
the inhibitory effect of 137846 at concentrations of 100 and 50µM. A similar loss of
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inhibitory activity was seen in the MIC2-aldolase interaction assay in the presence of
TX-100 (L. Starnes, G. Ward, D. Sibley, unpublished data). 137846 is therefore likely
to be acting as a promiscuous inhibitor and no further work has been performed with
this compound.
3.2.3. Expression of TgMyoA in baculovirus. The motor domain (MD) of
TgMyoA (aa1-777) and full length (FL) TgMyoA were expressed with a C-terminal
Flag tag using the baculovirus system. When Sf9 cells expressing the TgMyoA-MD
were lysed by sonication, only a small percentage of the total TgMyoA-MD expressed
in the cells was soluble (Figure 10a). This soluble fraction was purified using a Flag
affinity resin and the protein’s activity was assessed by actin co-sedimentation and
ammonium ATPase assay. TgMyoA-MD was incubated with actin filaments in the
presence or absence of ATP and subsequently centrifuged at 100,000xg. TgMyoA
pelleted in the both presence and absence of ATP, suggesting the myosin was in a
rigor-like state, unable to bind ATP. This is in contrast to the smooth muscle myosin
MD that remained in the supernatant in the presence of ATP (Figure 10b). Soluble
TgMyoA-MD did not display any ATPase activity (data not shown).
When Sf9 cells expressing TgMyoA-FL were lysed by sonication, no soluble
TgMyoA could be isolated. In an attempt to determine why TgMyoA was insoluble, an
immunofluoresence assay was performed with an anti-Flag antibody. TgMyoA-FL
localized to the periphery of the Sf9 cells when expressed alone or in the presence of
TgMLC1 (Figure 11a). This is extremely surprising since protein expressed in

83

baculovirus usually yields large quantities of soluble protein expressed in the cytosol
(O'Reilly, 1992).
To determine if TgMyoA-FL was membrane associated, Sf9 cells were
extracted in the presence of various detergents (octylglucoside, NP-40 or Chaps) or by
sonication in a detergent free buffer. Insoluble proteins were removed by centrifugation
and the distribution of TgMyoA-FL and TgMLC1, in the soluble and insoluble
fractions, was analyzed by anti-Flag and anti-TgMLC1 western blot after resolution on
SDS PAGE gels. In all extraction conditions 100% of TgMyoA-FL was insoluble while
approximately 50% of TgMLC1 was insoluble (Figure 11b). It has therefore not been
possible to isolate functional, soluble TgMyoA from Sf9 cells.
3.2.4. Do any of the small molecules affect the composition of the glideosome?
To determine if any of the small molecules affect the composition of the glideosome,
parasites were treated with each small molecule at a concentration of 100µM and the
glideosome was subsequently isolated by anti-GAP45 IP. One inhibitor, 115556,
resulted in an extra 30kDa protein associating with the glideosome (Figure 12a; K.
Carey and G. Ward, unpublished data). To determine the pI of this 30kDa protein and
to gain more insight about the protein’s identity, 35S-labeled parasites were treated with
115556, the glideosome was isolated by anti-GAP45 IP and proteins were resolved by
2D gel electrophoresis (Figure 12b). TgMLC1 from DMSO-treated parasites, indicated
with a blue arrow, resolves into two spots. The extra protein associating with the
glideosome after 115556 treatment has a pI of 4.6, similar to the pI of the major
TgMLC1 spot (indicated with a red arrow). This protein is recognized by an anti-
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TgMLC1 antibody, showing that a modified form of myosin light chain associates with
glideosome after compound treatment. The TgGAP45 phosphorylation train (indicated
with a black arrow) is unaffected by the compound. The structure of 115556 and a
summary of its effects on T. gondii can be found in Figure 13 and Table 7, respectively.
3.2.5. Time course of the TgMLC1 modification. To determine how quickly
115556 can affect TgMLC1, parasites were treated with compound for times ranging
from 5 to 120 minutes. TgMLC1 becomes modified less than 5 minutes after compound
addition (Figure 14). Surprisingly, even after 2 hours of treatment and with the addition
of additional compound, not all of the TgMLC1 in the cell can be modified. At all time
points the ratio of modified to unmodified TgMLC1 is approximately 1:1.
3.2.6. Irreversibility of the TgMLC1 modification. To determine if the TgMLC1
modification is reversible, extracellular and intracellular parasites were treated with
115556 for 15 minutes. The compound was removed by washing, and parasites were
incubated in compound-free media for the times indicated (Figure 15). TgMLC1
remains modified for at least two hours after compound washout in extracellular
parasites (Figure 15a) and for at least 4 hours after washout in intracellular parasites
(Figure 15b) indicating that the TgMLC1 modification is essentially irreversible.
3.2.7. Effect of 115556 on isolated glideosomes. To determine if TgMLC1 can
be directly modified by the compound, the glideosome was isolated from

35

S-labeled

parasites and subsequently treated with DMSO or compound for 15 minutes at RT.
115556 cannot modify isolated TgMLC1, in contrast to samples where whole parasites
were treated with compound before glideosome isolation (Figure 16).
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3.2.8. Effect of 115556 structural analogs on T. gondii invasion and motility.
Over 100 small molecules with structural similarity to 115556 were synthesized by
Federica Catti and Nick Westwood (Catti, 2007). Each of these compounds was tested
for it ability to inhibit T. gondii invasion in order to provide structure activity
information for 115556. The main aim of these experiments was to identify the regions
of the molecule that are required for T. gondii invasion inhibition, so that tagged
derivates of 115556 could be synthesized and used to identify the direct target of
115556.
Based on their activity in the invasion assay, a subset of these compounds
(Figure 17) were used to determine if there is a correlation between the ability of a
particular derivative to modify TgMLC1 and the ability of that compound to inhibit
parasite invasion and motility. As shown in Table 8, 6 out of 17 compounds tested
consistently caused the modification to TgMLC1 and inhibition of invasion and
motility. 4 of the compounds inhibited both invasion and motility but did not cause
TgMLC1 to be modified. The remaining seven compounds showed inconsistent results.
3.2.9. The effect of DTT on TgMLC1 modification. To determine if the
electrophoretic mobility of the modified form of TgMLC1 is sensitive to DTT,
parasites were treated with DMSO or 115556 and subsequently extracted in 1xSB in
the presence or absence of 50mM DTT. In the presence of DTT, the modified form of
TgMLC1 is resolved from the unmodified form of the protein and appears as a clear
doublet on an SDS PAGE gel (Figure 18a). In the absence of DTT, the unmodified and
modified forms of the protein resolve as a single band. The electrophoretic mobility of
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unmodified TgMLC1 is not altered by DTT, suggesting that this form of TgMLC1 does
not contain any intramolecular disulfide bonds.
To determine if TgMLC1 is disulfide bonded to any of the other glideosome
components, parasites expressing myc-tagged TgMLC1 were extracted in 1% TX-100,
0.5% SDS +/- DTT or 2% SDS (Figure 18b). The composition of the glideosome was
assessed after isolation by anti-myc IP. All 4 glideosome components co-IP after
extraction in TX-100. Extraction in 0.5% SDS resulted in the co-immuoprecipitation of
myc-TgMLC1 and TgMyoA in the absence of TgGAP45 and TgGAP50. The protein
profile pulled down after extraction in 0.5% SDS was not altered by 100mM DTT,
indicating that TgMLC1 does not contain any intermolecular disulfide bonds. MycTgMLC1 is isolated in the absence of all other glideosome components after extraction
in 2% SDS.
3.2.10. Effect of 115556 on glideosome oligomerization. When parasites are
treated with 115556 approximately 50% of the TgMLC1 in the cell becomes modified.
Increasing the time of incubation with the compound (Figure 14) or increasing the
concentration of 115556 does not increase the amount of modified TgMLC1 present in
the parasite. To determine why only half of TgMLC1 can be modified, the effect of
115556

on

glideosome

oligomerization

was

investigated.

The

ratio

of

TgMyoA:TgMLC1:TgGAP45:TgGAP50 in the glideosome is thought to be 1:1:1:1
(Gaskins et al., 2004). However it is not known if individual glideosome complexes are
stably associated with one another. If this is the case it is possible that the putative
modifying agent has access to some but not all of the TgMLC1 in the cell. To address
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this question we determined whether wild type TgMLC1 could be coimmunoprecipitated with myc-tagged TgMLC1. The glideosome was isolated from 35Slabeled parasites by either anti-TgGAP45 or anti-myc IP and proteins were resolved by
2D gel electrophoresis. As predicted both WT TgMLC1 (green brackets) and mycTgMLC1 (blue brackets) were co-immunoprecipitated with TgGAP45 (Figure 19).
After the anti-myc IP only myc-TgMLC1 was isolated, regardless of whether parasites
were treated with DMSO or 115556. These results indicate that individual glideosome
complexes are not stably associated with one another under the extraction conditions
used.
3.2.11. Expression of TgMLC1 in bradyzoites. To determine if TgMLC1 is
expressed in bradyzoites, RH ΔHXGPRT ΔUPRT bradyzoites were obtained by
growing parasites in low CO2 conditions for 2-5 days. Bradyzoite cyst walls were
visualized with TRITC-Dolichos Lectin. Immunofluoresence assay with anti-TgMLC1
antibody shows that TgMLC1 is expressed in T. gondii bradyzoites (Figure 20a).
Although movement of bradyzoites between PVs has been observed,
bradyzoites are relatively quiescent (Dzierszinski et al., 2004). Therefore, we wanted to
determine if parasite motility is regulated in bradyzoites by modifying TgMLC1 and
thereby altering glideosome function. Proteins from 4 day old in vitro bradyzoites were
resolved by SDS PAGE electrophoresis and TgMLC1 was visualized by anti-TgMLC1
western blot. TgMLC1 from bradyzoites resolves as a single band of the same
molecular weight as TgMLC1 from untreated tachyzoites, indicating that TgMLC1
from bradyzoites is not modified.
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3.3. Discussion
In an effort to learn more about the process of invasion we attempted to
determine if any of the small molecule inhibitors or enhancers of invasion affected
known aspects of glideosome activity.
The function of TgGAP45 is currently unknown. It was thought that by
identifying small molecules that alter its phosphorylation, we could learn more about
the function of this protein. Unfortunately none of the small molecules affected
TgGAP45 phosphorylation. Determining the role of TgGAP45 phosphorylation is of
great interest and is worth further investigation using classical reverse genetic methods.
It is possible that TgGAP45 phosphorylation is required for proper interaction with the
other components of the glideosome or that TgGAP45 phosphorylation affects
TgGAP45 palmitoylation and/or myristylation.
Studies of TgMyoA are important for two main reasons. From a biophysical
view-point, many intriguing questions remain about how TgMyoA functions and how
this small molecular motor with a number of unusual features (Heintzelman and
Schwartzman, 1997; Herm-Gotz et al., 2002) generates the force required to propel the
parasites during gliding motility and invasion. Secondly, TgMyoA has the potential to
be an excellent drug target that may be effective against a number of parasitic
infections. For these reasons we attempted to identify small molecules that affect
glideosome-associated myosin activity.
None of the compounds specifically altered glideosome function in vitro.
However, these studies did alert us to the presence of at least one promiscuous inhibitor
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within our collection of invasion inhibitors. In the future, all studies with this
compound must be performed in the presence of detergent to differentiate between nonspecific and specific activities. A general assay for identification of promiscuous
inhibitors has been developed (Feng and Shoichet, 2006). This detergent-based assay
identifies compounds that inhibit β-lactamase activity in the absence but not the
presence of 0.1% TX-100. In the future it would advantageous to identify any
promiscuous inhibitors within high-throughput screen hit lists before target
identification work begins.
A more direct way to identify small molecule inhibitors of TgMyoA would be
to screen a large collection of small molecules for compounds that can alter TgMyoA
function. In an effort to generate the amount of material required for such a screen, we
attempted to express TgMyoA-MD and TgMyoA-FL in the baculovirus system.
TgMyoA-FL was insoluble after extraction by sonication and extraction with detergent.
The reasons for this insolubility are unknown. It is possible that the insolubility is due
to the basic charge of the myosin tail. However class I myosins tails also have a basic
charge and this protein has been successfully expressed in Sf9 cells (Inoue et al., 2002).
TgMyoA localizes to the periphery of the Sf9 cells in both the absence and presence of
co-expressed TgMLC1. Therefore the peripheral localization cannot be due to
TgMLC1 being trafficked to the membrane, a phenomenon observed when TgMLC1
truncation mutants are expressed in T. gondii (See Chapter 4, Figure 28). Since this
peripheral localization cannot be disrupted by detergent, it is likely that TgMyoA is
localized to the periphery of the cell through cytoskeletal associations. The TgMyoA-
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MD was also largely insoluble after extraction by sonication; the reasons for this
insolubility are even more difficult to explain. The small amounts of soluble protein
that could be purified did not have any ATPase activity. It is therefore possible that the
protein is misfolded, contributing to the protein’s insolubility.
Treatment with inhibitor 115556 results in a modified form of TgMLC1
associating with the glideosome. Since nothing is currently known about the role of
TgMLC1 in regulating myosin function, we would like to determine if the TgMLC1
modification is responsible for the motility defects seen in the parasite after compound
treatment.
Addition of 115556 to isolated glideosomes does not cause TgMLC1 to be
modified. This suggests that TgMLC1 is not the direct target of the compound but
rather the modification of TgMLC1 is a “down-stream” consequence of 115556
interacting with its target. A second possibility is that 115556 interacts directly with
TgMLC1 but another accessory protein, not pulled down with the glideosome, is
required for the TgMLC1 modification to occur. We cannot currently discriminate
between these two possibilities.
When 115556-treated parasites are extracted in the absence of DTT and
resolved by SDS PAGE, the electrophoretic mobility of the modified form of the
protein is altered such that it does not resolve away from the unmodified form of the
protein. The reasons for this altered mobility are unclear. TgMLC1 does not appear to
contain intramolecular disulfide bonds nor does it appear to be disulfide bonded to
other glideosome components.
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TgMLC1 contains 5 cysteine residues, 4 in the first 79 amino acids of the
protein and one at the C terminus of the protein. This is an unusually high number of
cysteine residues compared to other myosin light chain proteins. It is possible that the
modification occurs on a cysteine residue or that one of the cysteine residues contribute
to the ability of TgMLC1 to be modified. This idea is investigated further in sitedirected mutagenesis experiments described in chapter 5.
The TgMyoA/TgMLC1 interaction is extremely strong and can withstand
extraction in 0.5% SDS. TgMLC1 appears to be functionally more similar to ELCs than
to RLCs. It has previously been shown that dissociation of ELC and smooth muscle
myosin is difficult, requiring strong denaturing conditions (Lowey and Trybus, 1995),
whereas RLC can be dissociated from myosin by chemical methods such as treatment
with high salt, 5'-dithiobis-(2-nitrobenzoic acid) or trifluoperazine (Lowey and Trybus,
1995).
To determine whether the relative lack of motility in bradyzoites is correlated
with TgMLC1 modification, we analyzed TgMLC1 in bradyzoites. TgMLC1 is
expressed in in vitro bradyzoites 5 days after differentiation is induced. Analysis of this
protein by western blot shows that TgMLC1 from bradyzoites resolves as a single band
and does not appear to be present in the modified form. Since cysts produced in vitro
are likely different from mature cysts present in the tissues of chronically infected
animals, the possibility remains that TgMLC1 is modified in mature cysts. To date, in
vivo cysts have been unavailable for analysis.
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One of the main aims of this work is to determine if the TgMLC1 modification
is the cause of motility and invasion defects seen in the parasite after compound
treatment. Therefore, we sought to determine if there is a correlation between the
ability of derivatives of 115556 to modify TgMLC1 and inhibit motility. From this
analysis, no clear pattern emerged. Many of the compounds showed inconsistent
results. This was most likely due to the insolubility of the compounds in aqueous
solution and compound instability (Catti, 2007). For example, 20% of 115556 degrades
within two hours when in DMSO solution.
Four of the derivatives tested inhibited invasion and motility but did not cause
TgMLC1 to be modified. While this is somewhat troubling, there are a number of
possible explanations for this result. For example, these compounds were not analyzed
in a cytotoxicity assay and so it is plausible that these compounds were killing the
parasites rather than specifically inhibiting some aspect of the parasite’s biology.
Alternatively, it is possible that 115556 has multiple targets within the parasite and that
these derivatives affect some, but not all, of the proteins affected by 115556. Most
importantly, no compounds were identified that modified TgMLC1 but failed to inhibit
invasion. If such a compound had been found it would have disproven the hypothesis
that the modification to TgMLC1 is responsible for the inhibition of motility by
115556. Chapter 5 will examine this hypothesis in more detail.
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Figure 9. TgGAP45 is a multiply phosphorylated protein.
(A) TgGAP45 was isolated from 35S-labeled parasites by immunoprecipitation,
treated with alkaline phosphatase, resolved by 2D gel electrophoresis and visualized by
autoradiography.

Treatment

causes

a

complete

collapse

of

the

TgGAP45

phosphorylation train. The unphosphorylated form of TgGAP45 is indicated with a red
arrow (B) Parasite proteins were resolved by 2D gel electrophoresis after treatment
with each of the small molecule inhibitors and enhancers. Proteins were visualized by
anti-TgGAP45 western blot. None of the small molecules affected the TgGAP45
phosphorylation train. Three representative images are shown; the arrow indicates the
unphosphorylated form of TgGAP45.
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Figure 10. Functional TgMyoA cannot be isolated from Sf9 cells.
(A) Total protein, T, from Sf9 cells expressing TgMyoA-MD and the soluble
fraction, S, after sonication and centrifugation at 100,000xg were resolved by SDS
PAGE; TgMyoA-MD was visualized by anti-Flag western blot. Only a small fraction
of the total TgMyoA expressed in the cells could be solubilised. (B) The soluble
TgMyoA-MD was purified using a Flag affinity resin and its activity was analyzed
using an actin co-sedimentation assay. TgMyoA-MD pelleted with actin in both the
absence and presence of ATP indicating the TgMyoA-MD was not functional. In
comparison, the smooth muscle myosin-MD pelleted with actin in the absence of ATP
but remained in the supernatant in the present of ATP. Myosin is indicated with a red
arrowhead and actin is indicated with a blue arrowhead.

95

Figure 11. TgMyoA localized to the periphery of Sf9 cells.
(A) The localization of TgMyoA-FL in Sf9 cells was analyzed by
immunofluorescence microscopy using an anti-Flag antibody.

TgMyoA expressed

alone or in the presence of TgMLC1 localizes to the periphery of Sf9 cells. (B) To
determine if TgMyoA-FL is membrane associated, Sf9 cells were extracted either by
sonication or in the presence of various detergents as indicated. Soluble (s) and
insoluble (p) proteins were resolved by SDS PAGE and TgMyoA and TgMLC1
visualized by anti-Flag and anti-TgMLC1 western blot respectively. In all extraction
conditions, TgMyoA remained insoluble. Coexpression with TgMLC1 did not increase
the amount of soluble protein in the cells. Approximately half of the expressed
TgMLC1 is soluble, likely representing the portion of TgMLC1 that is not associated
with TgMyoA.
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Figure 12. Inhibitor 115556 alters the composition of the glideosome.
(A)

35

S-labeled parasites were treated with each of the small molecules, the

glideosome was isolated by anti-TgGAP45 immunoprecipitation and proteins were
resolved by SDS PAGE and visualized by autoradiography. Treatment with inhibitor
115556 results in an extra 30kDa protein associating with the glideosome (red arrow).
None of the other compounds tested had an effect on the composition of the
glideosome; two representative examples (compounds 128045 and 102656) are shown.
(B) Glideosomes were isolated from DMSO- and 115556-treated 35S-labeled parasites
by anti-TgGAP45 immunoprecipitation. Proteins were resolved by 2D gel
electrophoresis and visualized by autoradiography (upper panel) and anti-TgMLC1
western blot (lower panel). The 30kDa protein that associates with the glideosome after
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compound treatment is recognized by an anti-TgMLC1 antibody, indicating that a
modified form of TgMLC1 associates with the glideosome. TgGAP45 is indicated with
a black arrow, TgMLC1 is indicated with a blue arrow and the modified form of
TgMLC1 is indicated with a red arrow.
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Figure 13. Structures of inhibitors 115556 and 137846
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Figure 14. Time course of the TgMLC1 modification.
Extracellular parasites were treated with DMSO or 100µM 115556 for times
ranging between 5-120 minutes. Parasite extracts were resolved on 12% SDS PAGE
gels and visualized by anti-TgMLC1 western blot. The modified form of TgMLC1 is
indicated with a red arrow.
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Figure 15. Irreversibility of the TgMLC1 modification.
Extracellular (A) or intracellular (B) parasites were treated with DMSO or
100µM 115556 for 15 minutes. The compound was removed and parasites were
incubated in compound-free media for the times indicated. Extracellular parasites were
incubated at RT and intracellular parasites were incubated at 37°C in 5% CO2. Parasite
extracts were resolved by SDS PAGE and visualized by anti-TgMLC1 western blot. The
modified form of TgMLC1 is indicated by the arrow.
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Figure 16. Effect of 115556 on isolated glideosomes.
35

S-labeled parasites were treated with DMSO or 100µM 115556 for 20 minutes

at RT and glideosomes were isolated by anti-TgGAP45 immunoprecipitation (left
panel). Alternatively, glideosomes were isolated from 35S-labeled parasites and treated
with DMSO or 100µM 115556 for 20 minutes at RT (right panel). Proteins were
resolved by SDS PAGE and visualized by autoradiography. 115556 does not modify
the TgMLC1 in isolated glideosomes. The modified form of TgMLC1 present in the
left panel is indicated with a red arrow.
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Figure 17. 115556 structural analogs.
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Figure 18. Effect of DTT on the electrophoretic mobility of the modified TgMLC1.
(A) Parasites expressing N-terminally myc-tagged TgMLC1 were treated with
either DMSO or 100µM 115556 and resolved on 12% SDS PAGE gels in the absence
or presence of DTT. In the absence of DTT, the modified form of TgMLC1 does not
resolve from the unmodified form of the protein. In the presence of DTT, the two forms
of the protein are efficiently separated and the protein is present as a clear doublet. (B)
35

S-labeled parasites were extracted in varying concentrations of SDS with or without

DTT as indicated. Glideosomes were purified using an anti-myc antibody. TgMLC1 is
not disulfide bonded to other components of the glideosome.
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Figure 19. Glideosome complexes do not associate with one another.
The glideosomes from

35

S-labeled parasites expressing both WT and myc-

tagged TgMLC1 were immunoprecipitated using either anti-TgGAP45 or anti-myc.
WT TgMLC1 was not recovered after immunoprecipitation with anti-myc indicating
that under the extraction conditions used, the glideosome complexes do not stably
interact with one another. Green brackets indicate WT-TgMLC1. Blue brackets indicate
myc-TgMLC1.
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Figure 20. TgMLC1 is expressed in bradyzoites.
(A) TgMLC1 expressed in bradyzoites was visualized with anti-TgMLC1 IFA.
Bradyzoite cyst walls were stained with Dolichos lectin. (B) Proteins from DMSO- and
115556- treated tachyzoites (T) and 4-day-old in vitro bradyzoite cysts (B) were
resolved by SDS PAGE and TgMLC1 was visualized by anti-TgMLC1 western blot.
TgMLC1 from bradyzoites co-migrates with TgMLC1 from untreated tachyzoites. The
modified form of TgMLC1, seen after 115556 treatment, is indicated with a red arrow.
Asterisks indicates a protein that cross-reacts with the anti-TgMLC1 antibody.
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Table 7. Effects of inhibitors 115556 and 137846 on T. gondii

Invasion
Motility
Conoid extension
Microneme secretion –
Induced
Microneme secretion constitutive

115556
Inhibitor (100µM)
Inhibitor
No effect
Inhibitor

137846
Inhibitor (50µΜ)
Inhibitor
No effect
No effect

Inhibitor

Inhibitor
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Table 8. Effect of 115556 structural analogs on T. gondii invasion, motility and the
TgMLC1 modification
Compound
115556
5
6b
8
13
30a
31a
32a
40
46
47
57
61
64
75
82
101
105

Effect on
Invasion
Is
N
Is
Is
N
Is
No
Iw
C
N
Is
C
N
Iw
Is
N
Is
C

Effect on
Motility
Is
Is
Is
Im
Im
Im
Im
Is
C
C
Is
Is
Is
Im
Iw
N
Im
N

Effect on
TgMLC1
Yes
No
No
Yes
C
No
No
No
Yes
No
Yes
No
C
C
Yes
No
No
No

Correlation
Yes
No
No
Yes
No
No
No
No
No
No
Yes
No
No
No
Yes
Yes
No
Yes

Compounds where inhibition of invasion and motility correlate well with the TgMLC1
modification are highlighted in green. Compounds that inhibited invasion and motility
but did not modify TgMLC1 are highlighted in yellow. All other compounds showed
inconsistent results. Abbreviations: strong inhibitor, Is; medium inhibitor, Im; weak
inhibitor, Iw; no inhibition, N; inconsistent results, C. All compounds were tested at
100µM.

108

3.4. Acknowledgements
Experiments involving expression of TgMyoA in baculovirus were performed
in collaboration with the lab of Kathleen Trybus.
Federica Catti and Nick Westwood synthesized the 115556 derivatives.
Initial studies with inhibitor 115556 were performed by Kim Carey (Carey,
2004).
Promiscuous inhibitor studies were performed by Jacqueline Leung under the
supervision of Aoife Heaslip.
Studies of TgMLC1 expression in bradyzoites was performed by Heng Guo
under the supervision of Aoife Heaslip.

109

3.5. References
Catti, F. (2007) 4,5-Dihydropyrazoles: Novel chemistry and biological activity. In School
of Chemistry. Vol. Ph.D Fife: University of St.Andrews.
Dobrowolski, J.M., and Sibley, L.D. (1996) Toxoplasma invasion of mammalian cells is
powered by the actin cytoskeleton of the parasite. Cell 84: 933-939.
Dzierszinski, F., Nishi, M., Ouko, L., and Roos, D.S. (2004) Dynamics of Toxoplasma
gondii differentiation. Eukaryot Cell 3: 992-1003.
Feng, B.Y., Shelat, A., Doman, T.N., Guy, R.K., and Shoichet, B.K. (2005) Highthroughput assays for promiscuous inhibitors. Nat Chem Biol 1: 146-148.
Feng, B.Y., and Shoichet, B.K. (2006) A detergent-based assay for the detection of
promiscuous inhibitors. Nat Protoc 1: 550-553.
Gaskins, E., Gilk, S., DeVore, N., Mann, T., Ward, G., and Beckers, C. (2004)
Identification of the membrane receptor of a class XIV myosin in Toxoplasma
gondii. J Cell Biol 165: 383-393.
Heintzelman, M.B., and Schwartzman, J.D. (1997) A novel class of unconventional
myosins from Toxoplasma gondii. J Mol Biol 271: 139-146.
Herm-Gotz, A., Weiss, S., Stratmann, R., Fujita-Becker, S., Ruff, C., Meyhofer, E.,
Soldati, T., Manstein, D.J., Geeves, M.A., and Soldati, D. (2002) Toxoplasma
gondii myosin A and its light chain: a fast, single-headed, plus-end-directed
motor. EMBO J 21: 2149-2158.
Inoue, A., Saito, J., Ikebe, R., and Ikebe, M. (2002) Myosin IXb is a single-headed
minus-end-directed processive motor. Nat Cell Biol 4: 302-306.
Kato, N., Sakata, T., Breton, G., Le Roch, K.G., Nagle, A., Andersen, C., Bursulaya, B.,
Henson, K., Johnson, J., Kumar, K.A., Marr, F., Mason, D., McNamara, C.,
Plouffe, D., Ramachandran, V., Spooner, M., Tuntland, T., Zhou, Y., Peters, E.C.,
Chatterjee, A., Schultz, P.G., Ward, G.E., Gray, N., Harper, J., and Winzeler, E.A.
(2008) Gene expression signatures and small-molecule compounds link a protein
kinase to Plasmodium falciparum motility. Nat Chem Biol.
Kieschnick, H., Wakefield, T., Narducci, C.A., and Beckers, C. (2001) Toxoplasma
gondii attachment to host cells is regulated by a calmodulin-like domain protein
kinase. J Biol Chem 276: 12369-12377.
Lowey, S., and Trybus, K.M. (1995) Role of skeletal and smooth muscle myosin light
chains. Biophys J 68: 120S-126S; discussion 126S-127S.
Meissner, M., Schluter, D., and Soldati, D. (2002) Role of Toxoplasma gondii myosin A
in powering parasite gliding and host cell invasion. Science 298: 837-840.
O'Reilly, D.R. (1992) Baculovirus expression vectors: a laboratory manual. New York:
W.H Freeman.
Wiersma, H.I., Galuska, S.E., Tomley, F.M., Sibley, L.D., Liberator, P.A., and Donald,
R.G. (2004) A role for coccidian cGMP-dependent protein kinase in motility and
invasion. Int J Parasitol 34: 369-380.

110

CHAPTER 4: INVESTIGATING THE NATURE OF THE TgMLC1
MODIFICATION
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4.1. Introduction
Compound 115556 is a small molecule inhibitor of T. gondii motility.
Treatment with 115556 results in a modified form of TgMLC1 associating with the
glideosome. A comprehensive list, on the Association of Biomolecular Resource
Facilities website (http://www.abrf.org/index.cfm/dm.home), reveals that over 300 posttranslational modifications have been described to date. To determine the nature of the
modification, two general approaches were taken. Hypothesis-driven approaches
involve making educated guesses about the nature of the modification and then
designing experiments to directly test these hypotheses. We describe here three such
hypotheses that we have tested.
A second, more general approach to identifying the nature of the TgMLC1
modification was also undertaken using LC-MS/MS and genetic methods, to analyze
the different forms of TgMLC1.
4.2. Results
4.2.1. Does treatment with 115556 result in TgMLC1 dephosphorylation?
Phosphorylation is a well-characterized post-translational modification. In HeLa cells
over 6,000 proteins are phosphorylated (Olsen et al., 2006). Myosin light chain
phosphorylation has been shown to regulate myosin II function. Phosphorylation on
RLC serine 19 upregulates myosin II function, while phosphorylation of serine 2
negatively regulates myosin activity by decreasing the affinity of myosin for actin
(Satterwhite et al., 1992). TgMLC1 appears to be phosphorylated on a single site
(Carey, 2004). I wanted to determine if treatment with 115556 results in TgMLC1
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dephosphorylation. Glideosomes were isolated from

35

S-labeled parasites by anti-

TgGAP45 immunoprecipitation and treated with alkaline phosphatase for thirty
minutes. When untreated proteins were resolved by 2D gel electrophoresis, four
TgGAP45 isoforms and two TgMLC1 isoforms were evident (Figure 21, black and
blue arrows respectively). Upon treatment with alkaline phosphatase, the TgGAP45
phosphorylation train collapses into a single unphosphorylated form. Alkaline
phosphatase treatment was not able to reproduce the TgMLC1 electrophoretic mobility
shift seen after 115556 treatment. The expected location of the modified form of
TgMLC1 is indicated with a red arrow (Figure 21). This suggests that the compound
induced modification is not dephosphorylation. Additionally, upon treatment with
alkaline phosphatase, there is a decrease in the relative abundance of the left hand spot
suggesting that this is the phosphorylated form of TgMLC1 (indicated with a blue
arrowhead).
To verify that the left hand spot is the phosphorylated form of TgMLC1,
glideosomes were isolated from

32

P-labeled parasites by anti-TgGAP45 IP. Proteins

were resolved by 2D gel electrophoresis visualized using audioradiography. TgMLC1
is phosphorylated on a single site (Figure 22, blue arrowhead). In addition, multiple
phosphorylation forms of TgGAP45 were observed (black arrow).

Western blot

analysis reveals that TgMLC1 is predominantly unphosphorylated in vivo. After
115556 treatment, the modified form of TgMLC1 is also unphosphorylated (red arrow).
Therefore, it appears that only the unphosphorylated form of TgMLC1 becomes
modified following compound treatment.

113

4.2.2. Does treatment with 115556 result in TgMLC1 proteolysis?
The modified form of TgMLC1 has a higher electrophoretic mobility than the
unmodified form of the protein. To determine if treatment with 115556 results in
TgMLC1 proteolysis, N-terminally tagged myc-TgMLC1 and C-terminally tagged
TgMLC1-myc were expressed in parasites. Both proteins localized to the parasite
periphery, although TgMLC1-myc staining was more punctate than endogenous
TgMLC1 (TgMLC1-WT) (Figure 23). The levels of myc-TgMLC1 in the cytosol were
increased compared to TgMLC1-WT. This is most likely due to its strong expression
from the tubulin promoter.
Proteins from parasites stably expressing myc-TgMLC1 were resolved by 2D
gel electrophoresis and analyzed by anti-myc and anti-TgMLC1 western blot. The antiTgMLC1 western blot reveals that TgMLC1-WT (Figure 24, red arrowhead) and mycTgMLC1 (blue arrowhead) are both modified following treatment with 115556. Both
the modified and unmodified forms of myc-TgMLC1 are recognized by the anti-myc
antibody. This indicates that the N-terminus of TgMLC1 is still present after compound
treatment. Therefore, the TgMLC1 modification is not due to N-terminal proteolysis.
It has not been possible to isolate parasites stably expressing TgMLC1-myc.
Based on analysis performed on PfMyoA and PfMTIP (Bosch et al., 2006), it is likely
that the C-terminus of TgMLC1 binds to the TgMyoA tail. The addition of the myc-tag
is presumed to disrupt this interaction, resulting in a dominant negative phenotype. By
this method, it has therefore not been possible to determine if TgMLC1 is cleaved at the
C-terminus, following treatment with 115556.
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4.2.3. Does treatment with 115556 result in alternative splicing of TgMLC1?
The TgMLC1 gene contains 3 introns and 4 exons (www.toxodb.org, accession number
55.m0021). It is possible that the modified form of TgMLC1 is due to alternative
splicing rather than addition or removal of a post-translational modification. To test this
hypothesis, total parasite RNA was isolated from DMSO- and 115556-treated parasites.
TgMLC1 transcript was then amplified from the corresponding cDNA. The TgMLC1
sequences from DMSO- and compound-treated parasites were identical. Therefore,
treatment with 115556 does not result in alternative splicing of TgMLC1.
4.2.4. Isolation of TgMLC1 for mass spectrometry analysis. Since our previous
hypothesis-driven approaches failed to identify the TgMLC1 modification, we chose a
more general method, using mass spectrometry. TgMLC1 is not an abundant protein in
T. gondii and is not detectable by Coomassie stain when total parasite protein
(approximately 100µg) is resolved by 2D gel electrophoresis. Since 100µg of protein is
the capacity of our 2D gels, it is not possible to simply increase the amount of protein
loaded into the gel in order to visualize TgMLC1. Therefore, it was necessary to
develop a differential detergent fractionation protocol for isolating a parasite extract
enriched for TgMLC1 (Figure 25A).
Proteins of the IMC are not extracted with PBS containing 1% (v/v) TX-100
(Johnson et al 2007), however proteins of the IMC are efficiently extracted using 1%
(w/v) DOC. Approximately 1.5x109 parasites were extracted in 1% (v/v) TX-100 and
clarified by centrifugation. Resolution of the soluble and insoluble proteins on SDS
PAGE reveals that approximately half of the TgMLC1 in the parasite is soluble in this
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step (Figure 25b). This was not unexpected since it had previously been shown that
there is a pool of TgMLC1 not associated with the IMC (Gaskins et al., 2004).
Insoluble proteins were extracted in 1% DOC and clarified by centrifugation. Most of
the proteins that were insoluble in TX-100 were also insoluble in DOC (Figure 25B).
However, approximately half of the TgMLC1 is soluble in 1% DOC. While
approximately 75% of the total TgMLC1 is lost during this procedure, TgMLC1 is
enriched in the extract. When DOC-soluble proteins are resolved by 2D gel
electrophoresis it is possible to visualize TgMLC1 by silver stain (Figure 25C) and
Coomassie stain. The upper and lower forms of TgMLC1 were excised from a
Coomassie stained gel and analyzed by mass spectrometry.
4.2.5. Analysis of TgMLC1 by LC-MS/MS. The protein sequence of TgMLC1
is shown in Figure 26. Tryptic peptides identified by LC-MS/MS are highlighted in
blue, and extensions of the tryptic peptide sequence seen after chymotrypsin digestion
are highlighted in green. Coverage of the TgMLC1 sequence for each of the TgMLC1
forms is approximately 75%.
Most of the peptides that were found in the upper form of the protein were also
found in the lower form of the protein suggesting that these peptides are unlikely to
contain the TgMLC1 modification. There are a number of peptides for which we have
not received spectra in either the upper or the lower form of the protein. There are also
a number of peptides found in one form of the protein but not in the other (Figure 23).
It is likely that one of these peptides contains the site of modification. It is difficult to
determine which peptide contains the modification since the mass of the modified
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peptide is unknown. In an attempt to identify the regions of TgMLC1 necessary for the
modification, twelve different TgMLC1 truncation mutants and point mutants were
expressed in the parasites.
4.2.6. TgMLC1 truncation mutants. To map the region of TgMLC1 that is
necessary for the modification to occur, five different TgMLC1 truncation mutants
were expressed in the parasites (Figure 27A). Immunofluoresence analysis of parasites
transiently expressing TgMLC1 truncated at either the N (myc-TgMLC180-213) or the C
(myc-TgMLC11-196) terminus reveals that myc-TgMLC11-196 localizes correctly to the
periphery of the parasite, however parasites expressing this protein exhibit
morphological defects. In addition, there is a decrease in the number of parasites per
vacuole (Figure 28). In contrast, myc-TgMLC180-213 is localized to the parasite cytosol
(Figure 28), indicating that the N-terminus of the protein may be important for
association of TgMLC1 with the IMC. Parasites stably expressing myc-TgMLC11-196
and myc-TgMLC180-213 could not be isolated, as expression of these proteins decreased
parasite viability. It was therefore not possible to determine by western blot if these
proteins become modified upon 115556 treatment.
The first 79 amino acids of TgMLC1 were expressed in parasites tagged to YFP
(TgMLC11-79YFP) to determine if the TgMLC1 modification occurs within this region.
TgMLC11-79YFP is localized at the parasite periphery (Figure 28) and co-localizes with
IMC1. These data show that amino acids 1-79 are sufficient for TgMLC1 peripheral
localization. Similar to the full length TgMLC1 staining pattern (Figure 38), TgMLC11-
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YFP staining is more concentrated at the apical end of the parasites, adjacent to

micronemes as visualized with microneme protein marker, TgAMA1 (Figure 28).
To determine if TgMLC11-79YFP is modified upon treatment with 115556,
parasites were treated with DMSO or compound. Proteins were resolved by SDS PAGE
and TgMLC11-79YFP was visualized by anti-GFP western blot. In DMSO-treated
samples, TgMLC11-79YFP resolves as a doublet, while after 115556 treatment,
TgMLC11-79-YFP resolves primarily as a single band of lower molecular weight
(Figure 29, red arrowheads). This indicates that the compound induced modification
occurs in the first 79 amino acids of this protein.
In an attempt to narrow down the region that is required for the modification to
occur, amino acids 40 to 79 (TgMLC140-79YFP) and 60 to 79 (TgMLC160-79YFP) were
expressed in the parasites tagged to YFP. These proteins are not modified after 115556
treatment (Figure 29, green arrowheads) and are not localized to the parasite periphery
(Figure 28).
4.2.7. TgMLC1 point mutants. There are 4 amino acids in the first 79 amino
acids of TgMLC1 for which we have no MS spectra, V4, E5, K6 and K7 . To determine
if any of these amino acids are modified, we expressed a number of TgMLC1 point
mutants (Figure 26B). Parasites expressing myc-TgMLC1-K3A, myc-TgMLC1-K6/7A,
myc-TgMLC1-K3/6/7R, myc-TgMLC1-E5A or myc-TgMLC1-WT were treated with
DMSO or 115556 and analyzed by SDS PAGE and anti-myc western blot. All proteins
are modified after treatment with 115556 (Figure 31), indicating that these amino acids
are not modified following treatment with 115556. Myc-TgMLC1-K3/6/7A, Myc-
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TgMLC1-C8/11S and myc-TgMLC1-K3A all localize predominately at the periphery
of the parasite similar to myc-TgMLC1. In contrast, myc-TgMLC1-K6/7A, MycTgMLC1-E5A, Myc-TgMLC1-C53S and myc-TgMLC1-C58S localize primarily to the
cytoplasm (Figure 30).
Since the electrophoretic mobility of the modified form of TgMLC1 is altered
by DTT (Figure 17) it is possible that TgMLC1 is modified on a cysteine residue.
Therefore, myc-TgMLC1-C8/11S, myc-TgMLC1-C53S and myc-TgMLC1-C58S were
expressed in the parasites. myc-TgMLC1-C8/11S is modified after 115556 treatment,
however myc-TgMLC1-C53S and myc-TgMLC1-C58S are not modified by 115556
and resolve as a single band on SDS PAGE (Figure 31). These data suggest that C53
and/or C58 are the modified amino acids or are essential for the TgMLC1 modification
to occur.
4.2.8. Palmitoylation of TgMLC1. The first 79 amino acids of TgMLC1 are
important for localization to the IMC and C58 appears to be important for TgMLC1
peripheral localization (Figure 30). Since C53 and C58 are important for the compound
induced modification, I wanted to determine if TgMLC1 is palmitoylated and if protein
palmitoylation is altered after 115556 treatment. Labeling cells with 3H-palmitate is
extremely inefficient. Therefore, a fatty-acyl exchange assay was used to assay protein
palmitoylation (Drisdel et al., 2006).
35

S-labeled parasites were extracted in the presence of iodoacetamide.

Glideosomes were isolated from these extracts by anti-TgGAP45 IP and subsequently
treated with hydroxylamine. Hydroxylamine mediates the cleavage of the palmitoyl-

119

thioester bond, leaving palmitoylated cysteine with a free sulhydryl that is reacted with
Iodoacyl-Biotin (Drisdel et al., 2006). Total protein was visualized by autoradiography
and palmitoylated proteins were visualized by streptavidin western blot.
In the absence of hydroxylamine treatment there is little or no biotinylation of
TgGAP45 and TgMLC1 (Figure 32). This indicates that iodoacetamide efficiently
blocked free-sulfhydryls in the protein extract.

TgGAP45 is biotinylated after

hydroxylamine treatment, suggesting that TgGAP45 is palmitoylated. After
hydroxylamine treatment both the upper and lower form of TgMLC1 are also
biotinylated indicating that TgMLC1 is palmitoylated. Therefore, palmitoylation is not
the 115556-induced modification.
4.2.9. Dimethylation of TgMLC1. The LC-MS/MS analysis of TgMLC1 reveled
that TgMLC1 is dimethylated on lysine 95 (Figure 33). There is a total mass difference
of 158 Da between y ion 12 (1305Da: K-V-S-T-G-D-A-M-I-L-A-R) and y ion 11
(1149Da: V-S-T-G-D-A-M-I-L-A-R). There is also a total mass difference of 158
between b ion 4 (273Da: A-S-G-G) and b ion 5 (429Da: A-S-G-G-K). There is a 28 Da
difference between the predicted mass of lysine and the measured mass of the lysine
K95 of TgMLC1, indicating that lysine 95 is dimethylated.
The peptide ASFQK/FVGTSTHPEDNIEDLVEAF is predicted to be cleaved
once, after lysine 95, upon trypsin digestion (indicated with / ). However, dimethylation
of TgMLC1 prevents cleavage after this lysine residue and the full peptide was found in
both of the TgMLC1 samples. Additionally, the upper sample contained the peptides
ASFQK and FVGTSTHPEDNIEDLVEAF and the lower sample contained the peptide
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FVGTSTHPEDNIEDLVEAF (Figure 23). This indicates that TgMLC1 is not 100%
dimethylated. Since dimethylation does not change the charge of the protein (Figure
34A), the methylated and non-methylated forms of the protein do not separate when
resolved by 2D gel electrophoresis. The dimethylated peptide has been found in both
the upper and the lower forms of the protein suggesting that this modification is not
induced by treatment with 115556. To show this conclusively, myc-TgMLC1-K95A
was expressed in the parasites. Myc-TgMLC1-K95A can be modified following
treatment with 115556 (Figure 34b).
Lysine residues can be methylated once, twice or three times and each reaction
involves the transfer of CH3 from S-adenosylmethionine to the nitrogen group of lysine
(Figure 34a). The biological significance of TgMLC1 dimethylation will be
investigated in chapter 6.

4.3. Discussion
4.3.1. Hypothesis-driven approaches to identifying the TgMLC1 modification.
The first approach to identifying the modification involved making educated guesses
about the nature of the modification and designing experiments to test these
hypotheses. Like many other myosin light chains, TgMLC1 is phosphorylated on a
single site. Therefore, we tested the hypothesis that 115556 treatment results in
TgMLC1 dephosphorylation. Experiments with alkaline phosphatase showed that this
is not the case. Additionally, experiments allowed us to rule out TgMLC1 N-terminal
proteolysis and TgMLC1 alternative splicing. These results suggest that the
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modification induced by 115556 is novel and has not been described for other myosin
light chains.
4.3.2. TgMLC1 is modified in the first 79 amino acids. Experiments with
MLC1-79YFP show that TgMLC1 is modified near the N-terminus of the protein.
MLC1-79YFP from DMSO-treated parasites resolves as a doublet, while after 115556
treatment, the protein resolves as a single band of lower molecular weight. It is unclear
why MLC1-79YFP from DMSO-treated parasites resolves as a doublet. We hypothesize
that the compound-induced modification can occur naturally, in the absence of
compound. However, due to the secondary structure of full length TgMLC1, the Nterminus may be protected from modification by the C-terminus of the protein. When
the N-terminus of the protein is expressed, the protein is no longer protected and is
available to the putative modifying agent, causing a portion of the protein in the cell to
be modified.
4.3.3. C53 and C58 are essential for the TgMLC1 modification to occur. The
mutagenesis data show that myc-TgMLC1-C53S and myc-TgMLC1-C58S are not
modified after compound treatment. This indicates either that these amino acids are
modified following 115556 treatment or they are essential for the modification to occur
elsewhere. Contrary to the mutagenesis data, the mass spectrometry data suggest that
the C53/C58 peptide (46VGEYDGACESPSCR59) is not modified, since it is present in
both the upper and the lower forms of the protein. In order to resolve this, quantitative
mass spectrometry will be used to determine if the presence of this peptide in the lower
form is due to “contamination” from the upper form of TgMLC1 (or vice versa). This
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contamination may be due to incomplete resolution on our 2D gels. Briefly, the upper
and lower forms of TgMLC1 will be trypsinized and added to the LC column along
with a known amount of a synthetic C53/C58-containing heavy peptide (made with 15N
or

13

C, (Pan et al., 2008)). By comparing the intensity of the C53/C58 peptide signal

from our samples to the intensity of the heavy peptide signal it will be possible to
determine if the quantity of this peptide is the same in both samples. If the C53/C58
peptide is less abundant in the lower form, it is likely that this is the modified peptide
and is present in the samples due to contamination from the upper form of the protein
(or vice versa).
If the C53/C58 peptide is less abundant in one form of the protein, another
round of mass spectrometry will be carried out. This form of the protein will be
analyzed by LC-MS/MS, in an attempt to identify a peptide with partially overlapping
MS/MS spectra compared with the C53/C58 peptide from the other form. For example,
if C58 is the modified amino acid then the mass of the C53/C58 peptide will be 1705
Da + an unknown mass X (1705+X). Fragmentation of this peptide between C58 and
R59 will yield two fragments, the y ion of mass 174 Da and the b ion 1531+X. If the
peptide is fragmented between S57 and C58 then the b ion will have a mass of 1410
and the y ion will have a mass of 293+X (174+121+X). In essence, all the fragments
that contain C58 will not have the predicted mass, whereas all the fragments that do not
contain C58 will have the predicted mass, giving partially overlapping spectra. This
analysis will allow us to determine the modified peptide and the size of the TgMLC1
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posttranslational modification. Using this information, we may be able to determine the
nature of the TgMLC1 modification.
4.3.3. TgGAP45 and TgMLC1 are palmitoylated. A fatty actyl exchange assay
was used to show that TgMLC1 and TgGAP45 are likely palmitoylated. TgGAP45 is
predicted to palmitoylated and myristoylated on residues 3 and 2 respectively (Gaskins
et al 2004). Many palmitoylated proteins are modified in cysteine-rich regions where
two or more cysteine residues are in close proximity. TgMLC1 contains two cysteine
pairs on residues 8/11 and 53/58. Using the TgMLC1 cysteine-mutants in the fatty acyl
exchange assay, it will be possible to determine which of these residues is
palmitoylated.
4.3.4. TgMLC1 is dimethylated on lysine 95. The LC-MS/MS analysis of
TgMLC1 showed that TgMLC1 is dimethylated on lysine 95. Methylation is a common
modification of histone proteins but, to date, only a small number of non-nuclear
proteins have been shown to be methylated and the function of their methylation has
not been well characterized.
Almost 3 decades ago, calmodulin was shown to be methylated on lysine 115
by the enzyme calmodulin N-methyltranferase (Sitaramayya et al., 1980). Since then, it
has been shown that calmodulin from a wide variety of eukaryotes is trimethylated on
this residue (Takemori et al., 2007). Paramecium tetraurelia calmodulin is
dimethylated on lysine 13 suggesting that the site of modification may vary from
species to species (Schaefer et al., 1987). Expressing calmodulin with a K115R
mutation in tobacco plant alters the activity of calmodulin-dependent nicotinamide
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adenine dinucleotide (NAD) kinase and causes developmental defects (Roberts et al.,
1992). These data suggest that methylation plays a role in regulating calmodulin
activity. Ubiquitination of calmodulin on lysine 115 also leads to protein degradation
by the ubiquitin-dependent pathway. Therefore lysine dimethylation increases
calmodulin stability by preventing ubiquitination (Gregori et al., 1987).
The transcription factor p53 is methylated by the Set9 methylase. Methylation
of p53 restricts this protein to the nucleus and increases protein stability (Chuikov et
al., 2004). The Ezh2 methyltransferase complex has long been known to be involved in
histone methylation but recently has been shown to indirectly regulate actin
polymerization in the cytosol of lymphocyte and fibroblast cells (Su et al., 2005). These
studies suggest that protein methylation is important for signal transduction in these cell
types, leading to cell proliferation (Nolz et al., 2005).
TgMLC1 is the first myosin light chain protein shown to be methylated. The
effect of this modification on protein function will be investigated further in chapter 5.
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Figure 21. Effect of alkaline phosphatase on TgMLC1.
Glideosome proteins isolated from

35

S-labeled parasites were treated with or

without alkaline phosphatase, resolved by 2D gel electrophoresis and visualized by
audioradiography. The TgGAP45 phosphorylation train collapses upon alkaline
phosphatase treatment (black arrow). TgMLC1 is indicated with a blue arrow and a
blue arrowhead indicates the putative phosphorylated form of TgMLC1. The TgMLC1
modification is not replicated with alkaline phosphatase treatment; the expected
location of the modified form of TgMLC1 after 115556 treatment is indicated with a
red arrow.
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Figure 22. TgMLC1 is phosphorylated on a single site.
32

P-labeled parasites were treated with DMSO or 100µM 115556 and

glideosomes were isolated by anti-TgGAP45 IP. Proteins were resolved by 2D gel
electrophoresis and visualized by western blot (top panels) or autoradiography (bottom
panels). TgGAP45 (black arrow) is multiply phosphorylated. TgMLC1 (blue arrow) is
phosphorylated on a single site (blue arrowhead). The western blots reveal that
TgMLC1 is predominantly unphosphorylated in vivo.
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Figure 23. Localization of myc-TgMLC1 and TgMLC1-myc in intracellular
parasites.
Myc-TgMLC1 and TgMLC1-myc expressing parasites were processed for IFA
and costained with anti-myc and anti-TgGAP45. WT parasites were labeled with antiTgMLC1 and anti-TgIMC1.
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Figure 24. The effect of 115556 on N-terminally tagged myc-TgMLC1.
Extracts from myc-TgMLC1 expressing parasites were resolved by 2D gel
electrophoresis and analyzed by western blot. Myc-TgMLC1 (blue arrowheads) and
TgMLC1-WT (red arrowheads) are both modified by 115556. Since the modified form
of myc-TgMLC1 is detected by the anti-myc antibody, the modification induced by
115556 cannot correspond to cleavage at the N terminus.
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Figure 25. Isolation of TgMLC1 for mass spectrometry analysis by differential
detergent fractionation and 2D gel electrophoresis.
(A) Overview of the differential detergent fractionation procedure. Parasites are
extracted in 1% (v/v) TX-100 and clarified by centrifugation. Proteins in pellet 1 (P1)
are extracted in 1% (w/v) DOC. Insoluble proteins are removed by centrifugation and
soluble proteins in S2 are resolved by 2D gel electrophoresis. (B) Analysis of total
protein (bottom panel; silver stain) and TgMLC1 (upper panel; western blot) profiles
after differential fractionation. TgMLC1 is enriched in the S2 fraction compared with
most other parasite proteins. (C) Proteins in S2 were resolved by 2D gel electrophoresis
and visualized by silver stain. TgMLC1 is indicated with red arrows.
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Figure 26. Mass spectrometry analysis of TgMLC1.
Tryptic and chymotryptic peptides for which we received spectra are
highlighted in blue and green respectively. # indicates alkylated cysteine. * indicates
oxidized methionine. ^ indicates the end of the TgMLC1 N-terminal extension and the
beginning of the calmodulin-like portion of TgMLC1.
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Figure 27. Schematic of the TgMLC1 truncation mutants generated (A) and the
individual residues disrupted by site-directed mutagenesis (B).
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Figure 28. Localization of TgMLC1 truncation mutants
Dual labeling of myc-TgMLC1-WT, myc-TgMLC180-213 and myc-TgMLC11-196
expressing parasites with anti-myc and anti-TgGAP45 antibodies. myc-TgMLC180-213
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is localized in the cytosol and myc-TgMLC11-196 is localized at the parasite periphery.
(B)

Parasites

transiently

expressing

TgMLC11-79YFP,

TgMLC140-79YFP

and

TgMLC160-79YFP were dual labeled with anti-GFP antibody and either anti-TgIMC1
antibody or anti-TgAMA1. TgMLC11-79YFP co-localizes with IMC1 at the parasite
periphery while TgMLC140-79YFP and TgMLC160-79YFP are located in the cytosol.
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Figure 29. Effect of 115556 on the electrophoretic mobility of TgMLC11-79YFP,
TgMLC140-79YFP and TgMLC160-79YFP.
Parasites expressing TgMLC11-79YFP, TgMLC140-79YFP and TgMLC160-79YFP
were treated with DMSO or 100µM 115556. Proteins were resolved by SDS PAGE and
visualized by anti-GFP western blot. TgMLC11-79YFP is indicated with red arrowheads,
TgMLC140-79YFP and

TgMLC160-79YFP are indicated with green arrowheads. *

indicates degradation products of TgMLC11-79YFP and TgMLC160-79YFP.
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Figure 30. Localization of TgMLC1 point mutants.
Intracellular parasites expressing myc-TgMLC1-K3A, myc-TgMLC1-E5A,
myc-TgMLC1-K6/7A, myc-TgMLC1-K3/6/7R, myc-TgMLC1C8/11S, myc-TgMLC1-
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C53S or myc-TgMLC1-C58S were processed for IFA and co-stained with anti-myc and
anti-TgGAP45 antibodies.
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Figure 31. Effect of 115556 on the electrophoretic mobility of TgMLC1 point
mutants.
Parasites expressing myc-TgMLC1-K3A, myc-TgMLC1-E5A, myc-TgMLC1K6/7A, myc-TgMLC1-K3/6/7R, myc-TgMLC1C8/11S, myc-TgMLC1-C53S or mycTgMLC1-C58S were treated with DMSO or 100µM 115556. Proteins were resolved by
SDS PAGE and visualized by anti-myc western blot. 115556 treatment does not cause
myc-TgMLC1-C53S or myc-TgMLC1-C58S to be modified.
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Figure 32. TgMLC1 and TgGAP45 are palmitoylated.
35

S-labeled parasites were extracted in the presence of iodoacetamide and

glideosomes were isolated by anti-TgGAP45 IP. Proteins were treated with
hydroxylamine and labeled with iodoacyl-biotin. 35S-labeled proteins were visualized by
autoradiography and biotin-labeled proteins were visualized by streptavidin western blot.
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Figure 33. TgMLC1 is dimethylated on lysine 95.
MS/MS spectra of TgMLC1. There is a differential mass of 28 Da between the
measured and predicted masses of lysine 95, indicating that TgMLC1 is dimethylated.
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Figure 34. Effect of 115556 on the electrophoretic mobility of myc-TgMLC1-K95A
(A) Reaction mechanism of lysine methylation. Lysine residues can be
methylated once, twice or three times. Each reaction involves the addition of CH3 to the
guanidino nitrogen residue of lysine. (B) Following treatment with 100µM 115556, mycTgMLC1-K95A becomes modified indicating that K95 is not the site of the compoundinduced modification.
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CHAPTER 5: INVESTIGATING THE FUNCTIONAL CONSEQUENCES OF
THE TgMLC1 MODIFICATION
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5.1. Introduction
Treating T. gondii tachyzoites with 115556 causes a modified form of TgMLC1
to associate with the glideosome. If TgMLC1 plays a role in regulating TgMyoA
function, as is the case with other myosin/light chain complexes, then modifying
TgMLC1 function may lead to a decrease in TgMyoA activity and hence decrease
parasite motility. Therefore, we have focused on developing a number of assays for
assessing TgMyoA function in vitro.
Preliminary data discussed in chapter 4 suggests that TgMLC1 is palmitoylated
and the N-terminus of the protein is sufficient for TgMLC1 to associate with the IMC.
It is therefore also possible that TgMLC1 plays a role in trafficking the protoglideosome to the IMC or anchoring the glideosome in the IMC membrane. To address
this possibility, the localization of TgMLC1 in intracellular parasites, following
treatment with 115556, will be assessed.

5.2. Results
5.2.1. The effect of 115556 TgMyoA activity. Parasites treated with 115556 do
not display any form of gliding motility. This phenotype may be due to the TgMLC1
modification altering TgMyoA’s affinity for actin in the presence of ATP.

To

determine if this is the case, TgMyoA activity was assessed using an actin cosedimentation assay. Total parasite protein was incubated with rabbit F-actin in the
presence or absence of 1mM ATP for 10 minutes at RT. Proteins were centrifuged at
100,000xg for 20 minutes at 4°C. Proteins in the supernatant and pellet were then

147

resolved by SDS PAGE (Figure 35). Since no TgMyoA antibody was available,
TgMyoA binding was indirectly assessed by analyzing the fractionation profile of
TgMLC1. In the absence of ATP, TgMLC1 from both DMSO-treated and 115556treated parasites pelleted with actin, indicating that TgMyoA was bound to actin in both
cases. In the presence of ATP, TgMLC1 from both samples remained in the
supernatant. The actin co-sedimentation assay shows that the TgMLC1 modification
does not induce a rigor state between TgMyoA and actin and that TgMyoA retains the
ability to adopt a weak actin-binding state in the presence of ATP.
These data also confirm that all of the TgMLC1 in the cell interacts with
TgMyoA since no TgMLC1 remains in the supernatant after centrifugation in the
absence of ATP.
Although the TgMLC1 modification does not affect TgMyoA affinity for actin,
the possibility remains that the TgMLC1 modification may alter the velocity of
TgMyoA actin filament displacement. Therefore, TgMyoA activity was assessed using
an in vitro motility assay.
In the first series of assays, parasites were treated with DMSO or 115556 and a
parasite extract enriched for the glideosome was prepared by actin co-sedimentation.
There were no significant differences in actin filament velocities from DMSO- and
115556-treated samples (Figure 36, Table 9). However, there were a number of
problems with the design of these experiments. Firstly all the myosin proteins
expressed in T. gondii tachyzoites are isolated with this procedure. Since very little is
known about the other myosin isoforms in T. gondii, it is not possible to determine the

148

myosin composition of our samples and therefore we cannot assess the influence that
these other myosin isoforms have on our results. Secondly, given the crudeness of these
preparations and our lack of a TgMyoA antibody it is not possible to determine the
concentration of TgMyoA present in each sample. Thirdly, TgMyoA was enriched for
by binding and release from actin filaments. Therefore, if 115556-treated parasites
contain more non-functional myosin than DMSO-treated parasites, this non-functional
protein would be lost during the isolation process and potential differences between the
two samples may not be reflected in the in vitro motility assay results.
To circumvent these problems Flag-tagged TgMLC1 (Flag-TgMLC1-WT) was
expressed in parasites in the presence of the WT allele. Parasites were treated with
DMSO or 115556 and glideosomes were isolated from total protein extracts using a
Flag affinity resin. Using this procedure, Flag-TgMLC1-WT co-purified with TgMyoA
and TgGAP45 (Figure 37a). Glideosomes were resolved by SDS PAGE along with
protein standards of known concentration. The amount of TgMyoA in each sample was
determined by staining the gels with Sypro Ruby and imaging using the Bio-Rad FXimager (Figure 37b). By comparing the fluorescence intensity of the protein standards
to the fluorescence intensity of TgMyoA, the amount of myosin isolated from both
DMSO (TgMyoA-DMSO) and 115556 (TgMyoA-115556) treated parasites could be
determined.
TgMyoA-DMSO and TgMyoA-115556 were added to flow cells at a
concentration of 8µg/ml and 4µg/ml and the actin filament velocity was determined via
an in vitro motility assay. At each concentration, TgMyoA-DMSO displaced actin
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filaments with a higher velocity than TgMyoA-115556, while the percentage of
filaments moving was similar in each sample (Figure 37c, Table 9). Although these
results were obtained using protein isolated in a single preparation and need to be
repeated, they indicate that the TgMLC1 modification induced by 115556 negatively
affects TgMyoA function.
5.2.2. The effect of 115556 on TgMLC1 localization. To determine if 115556
treatment alters TgMLC1 localization, intracellular parasites were treated with DMSO
or 115556 for 60 and 120 minutes. Parasites were dual-labeled with anti-TgIMC1 and
anti-TgMLC1 antibodies (Figure 38). At both time points the TgMLC1 localization was
unaltered by treatment with 115556. TgMLC1 localizes to the parasite periphery and is
also seen as punctate spots in the cytosol. Unlike TgIMC1, TgMLC1 is not present in
the IMC of daughter parasites.
5.2.3. The effect of TgMLC1 dimethylation on glideosome composition and
protein localization. Methylation is a common post-translational modification of
histones and is important for both repressing and activating gene transcription,
depending on the site of methylation and type of methylation that occurs (Huang and
Berger, 2008). To date, only a few non-histone proteins are known to be methylated. It
is poorly understood how methylation alters protein function (Huang and Berger,
2008). Our mass spectrometry data show that TgMLC1 is dimethylated on lysine 95
(Figure 33). To investigate how dimethylation alters TgMLC1 function, myc-tagged
and Flag-tagged TgMLC1 mutated at lysine 95 to alanine (myc-TgMLC1-K95A and
Flag-TgMLC1-K95A) were expressed in parasites.
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To determine if lysine dimethylation alters TgMLC1 localization, myc-MLCWT and myc-MLC-K95A expressing parasites were dual-labeled with anti-TgGAP45
and anti-myc antibodies. No differences in protein localization were observed (Figure
39a).
To determine if TgMLC1 dimethylation is important for TgMLC1 proteinprotein interactions, glideosomes were isolated from
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S-labeled Flag-TgMLC1-WT

and Flag-MLC-K95A expressing parasites by anti-TgGAP45 IP (Figure 39b). Both WT
and mutant TgMLC1 co-purified with TgGAP45. Additionally TgMyoA co-purified
with Flag-TgMLC1-WT and Flag-TgMLC1-K95A following purification with Flag
affinity resin (Figure 40a).
5.2.4. The effect of TgMLC1 dimethylation on TgMyoA activity. To assess the
effect of TgMLC1 dimethylation on TgMyoA activity, glideosomes were isolated from
Flag-MLC-WT and Flag-MLC-K95A expressing parasites using Flag affinity resin.
Since TgMLC1-WT is not co-purified with tagged-TgMLC1 (Figure 19) the effect of
the TgMLC1 K95A mutation can be assessed in the absence of wildtype protein.
The amount of TgMyoA isolated from each parasite line was quantified as
described in section 5.2.1 (Figure 40a). TgMyoA activity was assessed in an in vitro
motility assay (Figure 40b). TgMyoA/Flag-MLC-WT displaced actin filaments at
4.5µm/s, similar to TgMyoA/Flag-MLC-K95A, which displaced actin filaments at
4.2µm/s. Therefore, preventing TgMLC1 dimethylation does not affect the velocity of
actin filament displacement in vitro (Figure 40b).
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5.2.5. The effect of TgMLC1 dimethylation on TgMLC1 phosphorylation.
There are numerous examples in the literature to show that protein methylation and
protein phosphorylation are co-regulated. For example, histone H3 methylation on
lysine 9 inhibits phosphorylation on serine 10. Conversely, phosphorylation on serine
10 prevents methylation on lysine 9 (Rea et al., 2000). In another instance, the
kinetochore protein Dam1 is methylated by Set1. Dam1 methylation prevents Dam1
phosphorylation on adjacent serine residues by aurora kinase Ipl (Zhang et al., 2005).
TgMLC1 is phosphorylated on a single residue (Figure 21), therefore we would
like to determine if TgMLC1 dimethylation affects TgMLC1 phosphorylation. Proteins
from Flag-TgMLC1-WT and Flag-TgMLC1-K95A expressing parasites were resolved
by 2D gel electrophoresis and TgMLC1 was visualized by anti-TgMLC1 western blot
(Figure 41). In Flag-TgMLC1-WT parasites, both TgMLC1-WT and Flag-TgMLC1WT are present in two forms, one phosphorylated and one unphosphorylated, as
indicated. In contrast, Flag-TgMLC1-K95A is present in the more basic isoform only,
indicating that the K95A mutation prevents TgMLC1 phosphorylation. Additionally,
there is an increase in the levels of TgMLC1-WT phosphorylation in these parasites
(Figure 41). It is likely that the levels of TgMLC1 phosphorylation are tightly
controlled. An increase in TgMLC1-WT phosphorylation may compensate for the
presence of an unphosphorylatable form of TgMLC1. These observation needs to be
more thoroughly investigated by analysis of the TgMLC1 phosphorylation patterns in
32

P-labeled parasites.
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5.3. Discussion
5.3.1. The effect of 115556 on TgMyoA activity in vitro. The in vitro motility
assay was performed using TgMyoA isolated in two different ways. Since myosin
isolated by actin co-sedimentation may not accurately reflect the functional differences
between TgMyoA from DMSO- vs. 115556- treated parasites, the following discussion
will focus on data obtained using TgMyoA purified using Flag affinity resin.
At the myosin concentrations tested, TgMyoA isolated from DMSO-treated
parasites (TgMyoA-DMSO), displaces actin filaments with a higher velocity than
TgMyoA isolated from 115556 treated parasite (TgMyoA-115556). This is the first
evidence showing that TgMLC1 plays a role in regulating TgMyoA activity. This
strongly suggests that the motility inhibition induced by 115556 is caused by the
TgMLC1 modification.
As will be discussed in greater detail in section 6.2, the effect of 115556 on
TgMyoA activity will be tested over a greater range of TgMyoA concentrations. If
TgMyoA from DMSO-treated parasites displaces actin filaments at higher velocities
than TgMyoA from 115556-treated parasites, at all TgMyoA concentrations, it will be
concluded that the TgMLC1 modification alters maximal actin filament displacement
velocities of TgMyoA. However, if TgMyoA from DMSO-treated parasites displaces
actin filaments at higher velocities than TgMyoA from 115556-treated parasites at low
TgMyoA concentration but at the same velocity at higher TgMyoA concentrations, it
will be concluded that the TgMLC1 modification affects the TgMyoA duty-ratio.
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5.3.2. Cross-talk between TgMLC1 phosphorylation and TgMLC1 methylation
We have shown that TgMLC1-K95A is not phosphorylated. This indicates that the
efficiency of TgMLC1 phosphorylation is altered by the protein’s methylation state. In
addition, we predict that dimethylation is necessary for recognition of TgMLC1 by
myosin light chain kinase. TgMLC1 is phosphorylated on serine 124.
The experiments described here provide the first evidence that TgMLC1 is
important for controlling parasite motility by regulating TgMyoA activity. Although
many questions remain about how TgMLC1 regulates TgMyoA activity these data
provide an excellent basis for the development of new hypotheses.
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Figure 35. The TgMLC1 modification does not affect TgMyoA binding to actin in
an actin co-sedimentation assay.
When extracts from DMSO- and 115556- treated parasites are centrifuged in the
presence of F-actin, TgMLC1 pellets with actin in the absence but not the presence of
ATP, indicating that the TgMLC1 modification does not alter TgMyoA’s affinity for
actin. Total protein profiles were visualized by silver stain. TgMLC1 was visualized by
anti-TgMLC1 western blot. S=supernatant, P=pellet
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Figure 36. 115556 does not appear to alter TgMyoA velocity when myosin is isolated
by actin co-sedimentation.
TgMyoA was isolated by actin co-sedimentation and its activity was assessed
using an in vitro motility assay. The TgMLC1 modification does not appear to affect
TgMyoA actin filament displacement velocities. Velocities from DMSO- and 115556treated samples are 4.69µm/s +/- 0.18 and 4.9µm/s +/-0.13 respectively. Results shown
are the average from three independent experiments.
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Figure 37. TgMyoA-DMSO and TgMyoA-115556 displace actin filaments
at different velocities.
(A) Flag purified glideosomes from DMSO- and 115556-treated parasites,
visualized by silver stain. Astricks indicates additional proteins that co-purify with
Flag-MLC-WT (B) Quantification of TgMyoA. Parasites expressing Flag-MLC-WT
were treated with DMSO or 115556 and glideosomes were isolated using a Flag
affinity resin. Proteins were resolved by SDS PAGE along with protein standards of
known concentration and visualized by Sypro Ruby staining. The concentration of
TgMyoA in each sample was determined to be 8ug/ml by quantative fluorescence
imaging. (C) TgMyoA isolated from 115556- treated parasites displaces actin filaments
at a slower velocity compared with TgMyoA isolated from DMSO-treated parasites.
Results shown from a single experiment.
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Figure 38. The effect of 115556 on TgMLC1 localization.
Intracellular parasites were treated with DMSO or 115556 for 60 or 120
minutes. An IFA assay was performed with anti-TgMLC1 (green) and anti-TgIMC1
(red). The localization of TgMLC1 is not detectably altered after 115556 treatment.
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Figure 39. The effect of dimethylation on TgMLC1 localization and TgMLC1
protein-protein interactions.
(A) Intracellular parasites expressing myc-TgMLC1 WT and myc-TgMLC1
K95A were dual-labeled for immunofluoresence with anti-myc and anti-TgGAP45. The
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mutant and WT TgMLC1 have the same localization pattern. (B) Glideosomes were
isolated from

35

S-labeled parasites expressing Flag-MLC-WT or Flag-MLC-K95A.

Both WT and mutant TgMLC1 co-immunoprecipitate with anti-TgGAP45, indicating
that TgMLC1 dimethylation is not required for TgMLC1 and TgGAP45 interaction.
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Figure 40. The effect of TgMLC1 K95A on TgMyoA actin filament displacement
velocities.
(A) The concentration of TgMyoA isolated from Flag-TgMLC1-WT and FlagTgMLC1-K95A expressing parasites was deermined by Sypro ruby staining. (B)
162

20µg/ml of TgMyoA isolated from Flag-MLC-WT and 12µg/ml of TgMyoA isolated
from Flag-MLC-K95A expressing parasites displaces actin filaments at similar
velocities, 4.47µm/s +/- 0.14 vs. 4.23µm/s +/- 0.2 respectively. Results shown from a
single experiment.
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Figure 41. Effect of TgMLC1 dimethylation on TgMLC1 phosphorylation
Proteins from Flag-TgMLC1-WT and Flag-TgMLC1-K95A expressing
parasites were resolved by 2D gel electrophoresis and analyzed by anti-TgMLC1
western blot. TgMLC1-K95A is not phosphorylated. TgMLC1-WT is indicated with a
red arrowhead. Flag-TgMLC1 is indicated with a blue arrowhead. Phosphorylated
forms are indicated with (P).
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Table 9. Summary of TgMyoA in vitro motility data
# AF=Total number of actin filaments analyzed. # Exp=Number of independent
experiments performed. Glideosomes containing Flag-TgMLC1-WT and FlagTgMLC1-K95A isolated using the Flag-affinity resin method. TgMyoA/TgMLC1-WT
were isolated by actin co-sedimentation.
Sample
TgMyoATgMLC1WT
TgMyoATgMLC1WT
TgMyoA/FlagTgMLC1-WT
TgMyoA/FlagTgMLC1-WT
TgMyoA/FlagTgMLC1-WT
TgMyoA/FlagTgMLC1-WT
TgMyoA/FlagTgMLC1-WT
TgMyoA/FlagTgMLC1-K95A

[TgMyoA]
ug/ml

Treatment

Velocity
µ m/s

SD

# AF
(#exp)

%
moving

-

DMSO

4.69

0.18

70(3)

-

-

115556

4.9

0.13

70(3)

-

4

DMSO

3.08

0.17

30(1)

73

4

115556

1.375

0.24

17(1)

60

8

DMSO

4.014

0.22

26(1)

71

8

115556

2.617

0.19

22(1)

75

20

-

4.474

0.14

25(1)

-

12

-

4.232

0.2

18(1)

-
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
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T. gondii motility is essential for host cell invasion. To date, very little is known
about the signal transduction pathways that control parasite motility. It is difficult to
identify proteins essential for motility by classic forward genetic screening since
mutations in these proteins are by definition lethal to the parasite. As an alternative
approach to studying parasite invasion and motility, our lab performed a highthroughput screen to identify small molecules that alter T. gondii invasion. 24 inhibitors
of invasion were identified and 21 of those also inhibited parasite motility. Treatment
with one of these inhibitors, 115556, results in a modified form of TgMLC1 associating
with the glideosome. We have shown that this modified form of TgMLC1 contributes
to the invasion and motility defects seen in the parasite by altering TgMyoA activity.

6.1 Nature of the TgMLC1 modification
Although an extensive characterization of the TgMLC1 modification was
carried out, the nature of the modification is currently unknown. Mutagenesis data
discussed in chapter 5 indicate that both C53 and C58 are important for the
modification to occur. We are currently using mass spectrometry methods to determine
if C53 and/or C58 are the modified amino acid(s). There are a number of PTMs that
occur on cysteine residues including nitrosylation, palmitoylation, glutathionylation and
prenylation. A fatty acyl exchange assay was used to show that palmitoylation is not
the compound induced modification. Glutathionylation can be ruled out since this
modification is sensitive to DTT and the compound induced modification is not.
Prenylation involves the addition of a C15 or C20 lipid groups to cysteine. Proteins are
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usually prenylated at the C-terminus at the consensus site CCXX or CaaXX where X is
usually a small amino acid such as serine or alanine. Since TgMLC1 is modified at its
N-terminus, the compound-induced modification is unlikely to be prenylation. Snitrosylation involves the addition of nitric oxide (NO) to the reactive thiol of cysteine
(Hess et al., 2005). Analysis by Stamler et al., 1997 revealed that in 14 out of 16
proteins known to be nitrosylated the modified cysteine is followed by an acidic amino
acid (D or E). Cysteine 53 of TgMLC1 precedes a glutamic acid (E). An S-nitrosylation
assay has been developed to identify S-nitrosylated proteins in vivo (Jaffrey and
Snyder, 2001). This assay could be used to determine if TgMLC1 is S-nitrosylated after
115556 treatment. Alternatively, the nitrosylation state of the protein could be
determined by mass spectrometry (Chen et al., 2007).
There is increasing evidence that post-translational modifications (PTM) can be
co-regulated. For example, phosphorylation and arginine methylation of Rho-GDI are
mutually exclusive modifications. Phosphorylation of this protein prevents it from
being methylated on adjacent residues (Guerrera et al., 2007). In other examples, the
presence of one PTM is required for the addition of a second PTM by acting as a
recognition signal for the binding of a protein carrying out the second modification
(reviewed in Hunter, 2007). Cysteine 53 and C58 of TgMLC1 are necessary for the
modification to occur. Additionally, only the unphosphorylated form of TgMLC1
appears to be modified. Therefore, I hypothesize that if neither C53 nor C58 are
themselves the modified amino acids then the modified residue lies between C53 and
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C58 and the phosphorylation site of TgMLC1, serine 124, since co-regulated PTMs are
usually in close proximity (Hunter, 2007).
This also provides a rationale for why only half of TgMLC1 is modified. It is
likely that the efficiency of TgMLC1 modification in response to 115556 depends on
post-translational modifications already present on the protein. For example,
phosphorylated TgMLC1 appears to be less likely to be modified than the
unphosphorylated form of the protein. Our data has shown that there are at least 3
posttranslational modifications on TgMLC1: phosphorylation, methylation and
palmitoylation. Each of these modifications could impact how TgMLC1 becomes
modified following compound treatment.
Our data show that the modification of TgMLC1 contributes to the motility
inhibition seen after treatment with 115556. To strengthen this hypothesis, it would be
interesting to determine if parasites expressing an unmodifiable form of TgMLC1
(myc-TgMLC1-C53 or myc-TgMLC1-C58) are resistant to 115556. If these parasites
are resistant it will confirm our hypothesis that the TgMLC1 modification is
responsible for the motility defects seen in the parasite. However, a number of other
factors may contribute to the observed motility defects that may cause parasites
expressing unmodifiable TgMLC1 to remain sensitive to the compound. Additionally,
myc-TgMLC1-C53 and myc-TgMLC1-C58 are expressed on a WT background and so
TgMLC1-WT is present in the parasites and is modified after treatment with 115556.
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6.2. Functional consequences of the TgMLC1 modification.
At the TgMyoA concentrations tested, treatment with 115556 appears to alter
the activity of TgMyoA, resulting in a decrease in the velocity of actin filament
displacement. This is the first evidence that TgMLC1 plays a role in regulating
TgMyoA activity.
Actin filament displacement velocity increases with increasing myosin
concentration, until the myosin reaches its maximal velocity, VF, at which point actin
velocity does not increase further despite increasing protein concentration (Figure 42).
It would be interesting to determine if the maximal velocity of TgMyoA-DMSO is
different from that of TgMyoA-115556. This could be done by performing a doseresponse curve, correlating actin filament velocity with TgMyoA concentration. There
are two possible outcomes to this analysis, depicted in Figure 42. In the first case, the
maximal velocity of TgMyoA-DMSO and TgMyoA-115556 are the same. However,
the actin filament velocity in TgMyoA-115556 samples is lower at intermediate
concentrations compared to TgMyoA-DMSO samples (Figure 42, red line vs. blue
line). This could be explained as follows: Glideosomes isolated from 115556-treated
parasites are made up of two populations of myosin molecules. Half of the TgMyoA
molecules are bound to modified TgMLC1 and the maximal velocity of actin
displacement in this sample is decreased compared to TgMyoA-DMSO. The other half
of the myosin molecules are bound to unmodified TgMLC1, and the VF of these
samples should be equal to that of TgMyoA-DMSO. If 10ug/ml of TgMyoA is needed
to move filaments at their VF, then TgMyoA-115556 actin filament displacement
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velocities should be less than VF at this concentration, since the concentration of
unmodified-TgMyoA/TgMLC1 is equal to approximately 5ug/ml. However, at a total
TgMyoA concentration of 20ug/ml, the amount of unmodified-TgMyoA-TgMLC1 is
equal to approximately 10ug/ml and the average VF of the sample will be equal to the
VF of TgMyoA-DMSO. If this is the case, it suggests that the duty-ratio of TgMyoA is
affected by the TgMLC1 modification, Since the Vmax of the TgMyoA from 115556treated parasites is the same as that of TgMyoA from DMSO-treated parasites it is not
possible to determine if modified TgMyoA/TgMLC1 has decreased velocity compared
with unmodified-TgMyoA/TgMLC1
In the second scenario, the VF of TgMyoA-115556 is less than the VF of
TgMyoA-DMSO (Figure 42, red line vs. green line). Most likely, the VF seen for
TgMyoA-115556 will be somewhere between the VF values for modifiedTgMyoA/TgMLC1 and unmodified-TgMyoA/TgMLC1.
Since it is not known how TgMLC1 regulates TgMyoA activity and actin
filament displacement, it will be informative to determine if the TgMLC1 modification
affects other aspects of TgMyoA function.
(1) Does 115556 affect TgMyoA ATPase activity? The TgMLC1 modification
may alter the velocity of actin filament displacement by either altering TgMyoA
ATPase activity or altering the mechanical properties of the enzyme. Since we now
have a robust method for isolating pure, active TgMyoA using Flag affinity resin it will
now be possible to determine if the TgMLC1 modification alters actin-activated
TgMyoA ATPase activity. Although the amount of TgMyoA purified from the
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parasites is relatively low, a small-scale myosin ATPase assay has already been
developed that requires only 0.5µg of myosin per sample. Briefly, 5µl of 0.1µg/µl of
myosin is incubated with F-actin and ATP until >95% of the ATP in control wells has
been hydrolyzed. The remaining ATP in the wells is determined by adding luciferin and
luciferase and measuring luminescence (Cheung et al., 2002).
(2) Does 115556 alter the force producing capacity of TgMyoA? Using a
modified in vitro motility assay we would like to determine if the TgMyoA force
production capacity is altered after 115556 treatment. In this assay, actin filament
velocity is assessed in the presence of varying concentrations of an actin binding
protein, α-actinin (Malmqvist et al., 2004). For a given myosin concentration the
amount of α-actinin needed to stop actin movement is determined. If myosin X has a
greater force producing capacity than myosin Y, more α-actinin will be needed to stop
myosin X actin filament displacement.
(3) Does TgMLC1 interact directly with actin? TgMLC1 is a calmodulin-like
protein with sequence similarity to other essential light chains (Herm-Gotz et al.,
2002), and contains a 79 amino acid N-terminal extension. Its function is not currently
understood. Using TgMLC1 truncation mutants it seems that this N-terminal extension
is important for trafficking the glideosome to the IMC and/or anchoring the glideosome
to the IMC.
Sequence analysis of the ELC from skeletal muscle shows that isoform 1
contains a 41 amino acid N-terminal extension compared to isoform 3. This N-terminal
extension contains two lysine pairs that are important for binding the negatively
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charged C-terminus of actin under rigor conditions (Andreev et al., 1999). Similarly,
cardiac ECL1v contains an N-terminal extension that interacts with actin. Deletion of
amino acids from this N-terminal region decreases isometric force production of
isolated cardiac tissue without affecting unloaded shortening velocities. This suggests
that the N-terminal extension of ECL1v plays an important role in cardiac function
(Miller et al., 2005).
We would like to determine if the N-terminal extension of TgMLC1 interacts
with actin through the positively charged lysines V3, V6 and V7. We will test whether a
direct interaction between TgMLC1 and actin occurs under rigor conditions using the
zero-length

cross-linker

1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide

hydrochloride (Andreev et al., 1999) to determine if this interaction is altered by
115556 treatment. Additionally, the myc-TgMLC1-K3/6/7/R parasites will be used to
determine if these lysine residues are important for TgMLC1/actin interaction.
(4) Do TgMLC1 point mutants alter TgMyoA activity? Since mutating C53 and
C58 to serine prevents TgMLC1 from being modified, it would be informative to
determine if these residues are important for regulating TgMyoA activity in the absence
of compound. To do this, parasites expressing Flag-TgMLC1-C53S and FlagTgMLC1-C58S will be constructed. TgMyoA will be isolated using a Flag affinity
resin as previously described and its activity assessed in the in vitro motility assay.
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6.3. Investigating the direct target of 115556
Treating parasites with 115556 causes TgMLC1 to become modified. However,
treating isolated glideosomes with 115556 does not cause TgMLC1 to become
modified, indicating that TgMLC1 is not the direct target of 115556. By identifying the
direct target of 115556 we can begin to elucidate the pathways in the parasite that
control motility.
(1) Synthesis of a biotinylated derivative of 115556. A collection of over 100
structural derivatives of 115556 has been produced by Federica Catti and Nick
Westwood (Catti, 2007). The inhibitor effect of each compound was determined using
the dual-fluorescence invasion assay, in order to provide structure activity information
for 115556. We would like to produce a biotinylated derivative of 115556 (115556biotin) that can be used to identify the direct target of the compound. This approach to
target identification has already been successfully used in our lab (J. Haraldsen, N.
Westwood, G. Ward, unpublished data).
(2) 2D Difference Gel Electrophoresis (DIGE). Identification of other proteins
that are differentially expressed or modified in the parasite after 115556 treatment may
provide insight into the signal transduction pathway that controls motility in T. gondii.
Proteins from DMSO- and 115556-treated parasites will be analyzed by 2D DIGE.
Preliminary data indicate that the most prominent difference between the two samples
is the presence of the modified form of TgMLC1 in 115556-treated parasites (Figure
43). The identity of this protein was confirmed by mass spectrometry. A number of
other, less abundant proteins were also differentially modified or expressed. Two
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examples are magnified in Figure 43. These preliminary data show that TgMLC1 is not
the only protein affected by 115556 treatment. Identifying these proteins is of great
interest since they may be part of a signal transduction pathway that controls T. gondii
motility or they may be involved in mediating the effect of the compound on
microneme secretion.

6.4. Additional proteins associated with the glideosome
When the glideosome is isolated from Flag-TgMLC1-WT parasites using a Flag
affinity resin, two previously unidentified high molecular weight (>150kDa) proteins
are co-purified. We would like to identify these proteins using mass spectroscopy. Once
the identity of these proteins is determined, a detailed characterization of the proteins
would be carried out to verify that they are specifically interacting with the glideosome.
Many questions about glideosome function remain to be answered such as how
the proto-glideosome is trafficked to the IMC, or how the glideosome is immobilized
within the membrane of the IMC. It is likely that additional proteins are required for
these events to take place. Characterizing the function of these proteins may provide a
more comprehensive understanding of the glideosome.

6.5. Topology of the glideosome
The topology of the proteins within the glideosome is poorly understood.
Identifying how the individual glideosome components interact with one another will
shed light on the functions of proteins within the complex.
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TgMLC1 contains a 79 amino acid N-terminal extension compared to
calmodulin (Herm-Gotz et al., 2002). To date, the role of this region in TgMLC1
function has not been understood. Expression and localization of TgMLC1 truncation
mutants TgMLC11-79-YFP and myc-TgMLC180-213 indicate that amino acids 1-79 of
the protein plays a role in trafficking the glideosome to the IMC or anchoring the
complex in the membrane. TgMLC11-79-YFP is localized to the parasite periphery
while myc-TgMLC180-213 is mislocalized to the parasite cytosol. It is not known if
TgMLC11-79YFP traffics to the IMC alone or if interaction with TgGAP45 is required. I
have attempted to determine if TgMLC11-79-YFP and TgGAP45 interact. However,
these experiments have been inconclusive since I have been unable to isolate parasites
stably expressing MLC1-79-YFP. Due to the apparent dominant negative effect of this
mutant protein I hypothesize that TgGAP45 and TgMLC11-79YFP interact.
Immunofluorescence analysis of myc-TgMLC180-213 expressing parasites shows that
TgGAP45 is correctly localized to the parasite periphery. This suggests that the
peripheral localization of TgGAP45 is not dependent on TgMLC1. It is likely that
TgMLC11-79YFP and TgMyoA do not interact since amino acids 1-80 of PfMTIP are
unnecessary for interaction with PfMyoA (Bergman et al., 2003; Jones et al., 2006).
If TgMLC11-79YFP interacts with TgGAP45 and myc-TgMLC180-213 interacts
with TgMyoA, but not TgGAP45, then the function of the glideosome could be further
investigated based on the following model: TgGAP45, in a complex with TgMyoA and
TgMLC1, becomes embedded in the IMC membrane after the protein is myristoylated.
TgGAP45 and TgMLC1 are subsequently palmitoylated and one or both of these
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proteins interacts with the transmembrane protein TgGAP50. TgMLC1 is a bridging
protein that binds TgGAP45 at its N-terminus and TgMyoA at its C-terminus, ensuring
that TgMyoA is correctly localized to the IMC. In addition, TgMLC1 likely plays a role
in regulating TgMyoA function. Co-crystallization studies of these proteins would
allow us to determine the palmitoylation sites of TgGAP45 and TgMLC1 are in close
proximity and provide insight into the orientation of the proteins within the membrane.

6.6 Methylation and phosphorylation of TgMLC1
Our data show that TgMLC1 dimethylation is not important for either TgMLC1
protein localization or TgMLC1 protein-protein interactions. The effect of TgMLC1
dimethylation on TgMyoA activity was tested in an in vitro motility assay. There is no
difference in the velocity that TgMyoA/TgMLC1-WT and TgMyoA/TgMLC1-K95A
can displace actin filaments. This indicates that dimethylation is not required for
TgMyoA activity in vitro and is unlikely to play a role in directly regulating TgMyoA
activity in vivo. Our data suggest that TgMLC1 dimethylation and TgMLC1
phosphorylation are co-regulated. It is likely that TgMLC1 dimethylation is necessary
for recognition of the TgMLC1 by myosin light chain kinase.
These results raise an important question about the effect of TgMLC1
phosphorylation on TgMyoA activity. Myosin light chain phosphorylation regulates
myosin activity in a number of other systems (Lowey and Trybus, 1995). TgMLC1
phosphorylation could act as a switch turning TgMyoA activity on and off.
Alternatively, TgMLC1 phosphorylation could enhance TgMyoA activity. We have
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determined that TgMLC1-K95A is not phosphorylated, yet TgMyoA activity is
unaffected by this mutation, suggesting that TgMLC1 phosphorylation does not turn
TgMyoA activity on or off. To directly test if TgMLC1 phosphorylation enhances
TgMyoA activity parasites expressed Flag-TgMLC1-S124A and Flag-TgMLC1-S124D
will be produced. The activity of TgMyoA with these light chains will be tested in an in
vitro motility assay.
Approximately 20% of TgMLC1 is phosphorylated, suggesting that TgMLC1
phosphorylation may be regulated spatially and/or temporally within the parasite. Once
the TgMLC1 phosphorylation site is identified, a TgMLC1 phospho-specific antibody
can be produced. Using this antibody, an immunofluorescence assay could be
performed on the parasites to determine where the phosphorylated form of TgMLC1 is
localized. These results may provide insight into how the glideosome is regulated. In
general, myosin activity is activated by actin. T. gondii actin filaments are extremely
short and present at the moving junction during invasion (Figure 6). Thus it is likely
that TgMyoA activity is upregulated at the moving junction. It would be of great
interest to determine if TgMLC1 is phosphorylated at the moving junction. This would
suggest that TgMLC1 phosphorylation provides an additional level of regulation to
TgMyoA.

6.7. Concluding Remarks
The studies described herein show, for the first time, that an apicomplexan
myosin light chain plays a role in regulating activity of a class XIV myosin. As
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summarized in Figure 44, we have shown that TgMLC1 contains a number of posttranslational modifications that likely regulate its activity. These data have allowed us
to generate many new hypotheses about the function of this unconventional myosin
motor complex and provide a basis for future studies.
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Figure 42. Theoretical actin filament velocity curves for TgMyoA-DMSO and
TgMyoA-115556.
In scenario 1, the maximal velocities of TgMyoA-DMSO and TgMyoA-115556
are the same. However, the velocity that TgMyoA-115556 displaces actin filaments is
lower at intermediate protein concentrations compared with TgMyoA-DMSO,
indicating that the TgMyoA duty ratio is affect by the TgMLC1 modification. In
scenario 2, the maximal velocities of TgMyoA-DMSO and TgMyoA-115556 are
different.
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Figure 43. Analysis of T. gondii proteins by 2D DIGE
Proteins from DMSO- and 115556-treated parasites were labeled with CyDye2
(green) and CyDye3 (red) respectively. Samples were combined and resolved by 2D
gel electrophoresis. Proteins labeled with each dye were visualized using the Biorad
FX-Imager. Proteins that are expressed at the same level in each sample appear yellow
in the merged image shown. Proteins that are differentially expressed or modified in
DMSO- and 115556-treated samples appear green and red, respectively. TgMLC1 is
highlighted with a white circle and two other proteins whose expression or modification
is altered by 115556 are highlighted with white squares and magnified in the insets.
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Double asterisks indicate a protein that is present in equal amounts in the two samples
but is differentially labeled by CyDye3 compared with CyDye2 (Q. Tang, G. Ward,
unpublished data). Single asterisks indicates background fluorescence on the imager.
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Figure 44. Post-tranlational modifications of TgMLC1.
Cysteines 53 and 58 (orange) are essential for the 115556 induced modification
to occur. TgMLC1 could be modified on one or both of these residues upon compound
treatment. Since the TgMLC1 modification affects TgMyoA activity in vitro, these
residues are likely important for TgMLC1’s ability to regulate TgMyoA function.
TgMLC1 is dimethylated on lysine 95 (pink). Dimethylation does affect TgMyoA
activity in an in vitro motility assay at the TgMyoA concentration tested. FlagTgMLC1-K95A is not phosphorylated suggested TgMLC1 dimethylation is necessary
for TgMLC1 phosphorylation. TgMLC1 is phosphorylated on serine 124 (green). The
role of TgMLC1 phosphorylation in regulating TgMLC1 function has not yet been
determined. Amino acids 1-79 of TgMLC1 (underlined) are important for TgMLC1
peripheral localization.
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APPENDIX: INVESTIGATING THE EFFECT OF 115556 ON REACTIVE
OXYGEN SPECIES IN TOXOPLASMA GONDII
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A1. Introduction
There are a number of reasons to believe that TgMLC1 is not the direct target of
115556 but rather TgMLC1 becomes modified as a downstream consequence of the
compound interacting with its target. 115556 cannot directly modify TgMLC1 in vitro
(Figure 16), suggesting that additional components are required for the TgMLC1
modification to occur. TgMLC1 modification decreases the velocity that TgMyoA can
displace actin filaments. This could account for the invasion and motility defects seen
in the parasites after compound treatment since TgMyoA is essential for both of these
processes. However, after compound treatment both constitutive and ionophoreinduced microneme secretion are also inhibited (Carey et al., 2004) and TgMyoA does
not play role in microneme secretion (Meissner et al., 2002). By identifying the direct
target of 115556, we can begin to uncover signal transduction pathways in the parasite
that control motility and possibly microneme secretion.
Compounds with structural similarity to 115556 (Figure A1) have been shown
to act as anti-oxidants and can scavenge free-radicals in both a cell free assay and in a
cell-based colorimetric assay. In the cell-based assay, the compounds were tested for
their ability to scavenge oxygen free radicals produced by neutrophil cells in response
to Phorbol-12-myristate-13-acetate (PMA) (Youssef et al., 2004). PMA has been
shown to activate PKC and cause an increase in reactive oxygen species (ROS)
production by the mitochondria (Wang et al., 2006).
ROS are by-products of enzymatic reactions and high levels of ROS are
damaging to cells (Droge, 2002). ROS also act as second messengers and are important
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in signal transduction (Droge, 2002). Nitric oxide (Le Moan et al. 2006) and other ROS
play an important role in regulating smooth muscle contraction. A simplified schematic
diagram of the signal transduction pathway controlling vascular smooth muscle
contraction is depicted in Figure A2. Superoxide ion and NO are produced by
Nicotinamide adenine dinucleotide phosphase oxidase (Nox) and nitric oxide synthase
(NOS) respectively (Droge, 2002). NO binds to and activates guanylate cyclase (GC)
resulting in an increase in intracellular cGMP. cGMP binds and actives cGMP
dependent protein kinase (PKG). PKG phosphorylates MLC phosphatase, leading to a
decrease in MLC phosphorylation and smooth muscle cell relaxation (reviewed in
Surks, 2007). The signal transduction pathway that regulates glideosome activity is
unknown, but it is plausible that a similar pathway may exist in parasites. It has already
been shown that PKG is necessary for T. gondii motility (Wiersma et al., 2004). If
115556 scavenges the ROS involved in this pathway, this may lead to the modification
of TgMLC1.
Using a variety of assays I sought to determine if 115556 is acting as an antioxidant in T. gondii.

A2. Materials and Methods
A2.1. Effect of nitric oxide inhibitors on MLC. Nicotinamide adenine
dinuceoltide phosphatase oxidase (Nox) inhibitors brilliant green and gentian violent
were dissolved in 100% ethanol and diluted to concentrations of 5-20µM in Hanks
buffered salt solution (Invitrogen). 2x107 parasites were treated with Nox inhibitors at
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concentrations between 5 and 20µM for 20 minutes at RT. 2x107 parasites were treated
with 1-Chloro-2,4-dinitrobenzene (DNCB) at RT at concentrations from 2.5 to 20µM
for 10 minutes. Cells were pelleted at 6500xg for 4 minutes and resuspended in Hanks
buffer containing DMSO or 100µM 115556 and incubated at RT for 15 minutes. 2x107
parasites were treated with curcumin ranging in concentration from 0.625 to 100µM for
20 minutes at RT. Following compound treatment all parasites were lysed with 1xSB
containing 1.25% (v/v) βME and resolved on 12% SDS PAGE gels. TgMLC1 was
visualized by anti-TgMLC1 western blot.
A2.2.

Analysis

of

levels

of

ROS

in

the

parasite

with

2',7'-

Dichlorodihydrofluorescein diacetate (H2DCFDA). Fresh extracellular parasites were
allowed to settle on Cell tak treated coverslips for 30 minutes at RT and then treated
with 5µM H2DCFDA (Invitrogen) for 30 minutes at 37°C followed by DMSO or
115556 for 10 minutes. Parasites were imaged by fluorescence microscopy in the
presence of compound.
A2.3. Analysis of reduced protein profile in the parasites with EZ-Link BiotinHPDP (N-(6-(Biotinamido)hexyl)-3'-(2'-pyridyldithio)-propionamide. 1x108 parasites
were treated with DMSO or 115556 for 20 minutes at RT. Parasites were lysed with
12.5% (v/v) trichloroacetic acid (TCA) at RT for 10 minutes. Proteins were pelleted by
centrifugation for 10 minutes at RT, washed once in acetone and solubilised with
HPDP rehydration buffer (10mM Tris pH 7.4, 7M urea, 2M thiourea and 2% (w/v)
ASB14) in the presence of 0.25mM EZ-link biotin-HPDP (Pierce) at 30°C in the dark
for 45 minutes (Leichert and Jakob, 2004). Proteins were precipitated with 1/4 volume
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of 100% TCA, pelleted 12,000xg at 4°C, washed once in acetone and repelleted.
Proteins were solubilised using the ASB14 method and resolved by 2D gel
electrophoresis. Labeled proteins were visualized by probing the blot with streptavidin
conjugated to HRP.

A3. Results
A3.1. Does 115556 scavenge ROS in T. gondii? To determine if 115556
scavenges ROS, the ROS reporter H2DCFDA was used to detect ROS in the parasites.
This compound is cell permeable and non-fluorescent when ROS are at low
concentrations but increases in fluorescence with increasing ROS. The levels of ROS
involved in signal transduction are low and typically not detectable using this
fluorescent probe. Therefore, we sought to determine if 115556 could protect the
parasites against oxidative stress induced by juglone (Akerman and Muller, 2005).
Parasites were treated with juglone for 15 minutes and then treated with DMSO or
115556 for an additional 15 minutes. Parasites were then labeled with H2DCFDA for
15 minutes at 37°C, and visualized by fluorescence microscopy.
In samples where treatment with juglone was omitted, parasites were nonfluorescent when initially visualized. To our surprise, the fluorescence of the parasites
increased with increasing exposure to light, and were strongly fluorescent after
approximately 20 seconds. 115556 treatment appears to decrease the number of
fluorescent parasites compared to DMSO controls (Figure A3). After treatment with
juglone, parasites treated with DMSO or 115556 fluoresced brightly. These results
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suggest that 115556 may play a role in scavenging ROS produced by UV light but not
ROS produced by juglone.
A3.2. The effect of 115556 on the redox state of proteins in the parasite. Since
115556 may play a role in scavenging ROS in the parasite, we sought to determine if
115556 alters the redox state of proteins in the parasite. Cysteine oxidation plays an
important role in redox signaling as the oxidation state of proteins is altered in response
to changes in the level of ROS. Deletion of the thioredoxin and GSH in S. cerevisae
alters the extent of protein oxidation in the cell (Le Moan et al., 2006).
Parasites were treated with DMSO or 115556. Proteins were precipitated with
trichloroacetic acid, solubilized and labeled with EZ-link biotin-HPDP, which reacts
with the free-sulhydryls present on reduced cysteine residues (Leichert and Jakob,
2004). Proteins containing reduced cysteines can be visualized by 2D gel
electrophoresis and streptavidin western blot.
115556 does not appear to alter the redox state of proteins compared to DMSOtreated samples (Figure A4). In each sample, a large number of biotin-labeled proteins
are detected. Minor differences in the samples are observed. These differences were not
reproducible and are likely due to gel-gel variation often observed with 2D gel
electrophoresis.
A3.3. The effect of Nox inhibitors brilliant green and gentian violent on
TgMLC1 electrophoretic mobility. If 115556 scavenges ROS in the parasites and alters
the signal transduction pathway that regulates parasite motility, then treating parasites
with inhibitors of Nox should also cause TgMLC1 to be modified. Parasites were
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treated with two NOX inhibitors gentian violet and brilliant green (Perry et al., 2006),
at concentrations between 5-20µM. Proteins were resolved by SDS PAGE and
TgMLC1 was visualized by anti-TgMLC1 western blot. Neither compound altered the
electrophoretic mobility of TgMLC1 (Figure A5).

A4. Discussion
A4.1. The effect of 115556 on ROS. Data obtained using ROS detector
H2DCFDA suggests that 115556 may scavenge a subset of ROS in the parasite.
Treating parasites with 115556 did not decrease the levels of ROS induced by juglone.
Juglone produces ROS by two mechanisms, an enzymatic mechanism where H2O2 is
produced as a result of oxidation of GSH to GSSG (Inbaraj and Chignell, 2004) or the
non-enzymatic generation of superoxide anion (Akerman and Muller, 2005). Since
115556 failed to scavenge the ROS produced by juglone and the TgMLC1 is not
modified after treatment with gentian violet or brilliant green, it is reasonable to
conclude that 115556 does not alter these pathways within the parasite.
Treating parasites with 115556 causes a decrease in the UV-induced ROS in the
parasite. It is unclear why the ROS levels in the parasite are increased after exposure to
UV light and no other examples of this phenomenon can be found in the literature. Our
lab has previously shown that diphenyleneiodium Cl, an inhibitor of endothelial NOS
(eNOS), inhibits parasite invasion. It would be interesting to determine if
diphenyleneiodium Cl alters the levels of light-induced ROS in the parasite. This would
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provide evidence that NO levels in the parasite are increased upon exposure to UV
light.
NO has been shown to bind and activate GC causing an increased production of
cGMP. cGMP is important for invasion and motility in T. gondii (Wiersma et al.,
2004). In other systems, cGMP causes indirect activation of MLC phosphatase.
Therefore, it would be interesting to determine if diphenyleneiodium Cl can cause the
TgMLC1 modification in parasites. These preliminary data suggest that a signal
transduction pathway similar to that in smooth muscle cells may be present in the
parasite and controls T. gondii motility.
An alternative explanation for these results is that 115556 inhibits a protein
involved in the generation of ROS in the parasite after exposure to light. As described
in chapter 8, we will attempt to identify the direct target of 115556 using a biotinylated
version of 115556.
A4.2. The redox state of proteins in T. gondii after 115556 treatment. Proteins
containing a reduced cysteine were labeled with biotin-HPDP. Preliminary data shows
that there is not a global change in the redox state of proteins after 115556 treatment.
However, there may be changes in the redox state of a small subset of proteins that are
difficult to visualize due to the abundance of proteins on the gel whose redox state is
unaffected by compound treatment. It would be beneficial to repeat this experiment and
further resolve proteins using larger format gels.
Alternatively, it may be informative to analyze the oxidized proteome of the
parasite.

In such an analysis, reduced cysteines are blocked with iodoacetimide.
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Proteins are then reduced with DTT and labeled with either Biotin-HPDP or IodoacylBiotin. This experiment would be easier to interpret since there are fewer oxidized
proteins in the cell; thus, small changes may be more visible.
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Figure A 1. A simplified diagram of the signal transduction pathway that controls
smooth muscle contraction.
Adapted from (Surks, 2007) and (Droge, 2002). Abbreviations: NOX,
Nicotinamide adenine dinucleotide phosphase oxidase; NOS, nitric oxide synthase;
NO, nitric oxide; GC, guanylate cyclase; PKG, cGMP dependent protein kinase; MLCK, myosin light chain kinase; MLC-P, myosin light chain phosphatase. See text for
details.
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Figure A 2. Structure of 115556 and structural derivatives shown to scavenge ROS
in other systems (Youssef et al., 2004).
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Figure A 3. 115556 alters levels of light-induced ROS in T. gondii
Parasites were treated with juglone for 15 minutes and subsequently treated
with DMSO or 115556 for 15 minutes, followed by labeling with the ROS reporter
H2DCFDA. In the absence of H2DCFDA the parasites did not show detectable
fluorescence. Upon exposure to UV light, the levels of ROS in T. gondii increase. After
treatment with 115556, few parasites are fluorescent although a large number of
parasites are present in the field, suggesting that 115556 scavenges the light-induced
ROS in the cell. In contrast, 115556 does not appear to scavenge the ROS induced by
juglone.
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Figure A 4. Effect of 115556 on the redox state of proteins in T. gondii.
Parasites were treated with DMSO or 115556 and extracted with TCA. Proteins
were subsequently solubilized and labeled with Biotin-HPDP. Labeled proteins (i.e.
those containing reduced cysteines at the time of cell ysis) are visualized using
streptavidin-HRP.
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Figure A 5. Treatment of parasites with the Nox inhibitors gentian violet and
brilliant green does not cause the TgMLC1 modification.
Parasites were treated with concentrations of gentian violet and brilliant green
ranging from 5 to 20µM or with 100µM 115556. Proteins were resolved on SDS
PAGE gels and an anti-TgMLC1 western blot was performed.
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